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ABSTRACT 
Tetraspanins are a superfamily of four-transmembrane proteins. They associate laterally with 
one another and with other transmembrane proteins to form membrane microdomains, in 
which associated proteins are regulated. Tetraspanins regulate diverse processes such as cell 
signalling and fusion, intracellular trafficking, viral infection and cancer. 
The primary aim of this thesis was to study a previously uncharacterized tetraspanin, 
Tspan18. Unlike other tetraspanins, over-expression of Tspan18 in lymphocyte cell lines 
activated an NFAT/AP-1 reporter, which responds to calcium and MAPK signalling. In DT40 
B cell lines, Tspan18 signalling was independent of Lyn, Syk, PLC2 and IP3 receptors, 
which are essential for B cell receptor signalling. However, Tspan18 signalling did require 
extracellular calcium and the calcium-activated phosphatase calcineurin, which activates 
NFAT. Additional studies that included the Jurkat T cell line showed that Tspan18 could not 
activate the MAPK-responsive AP-1 promoter, but instead mimicked the effect of the calcium 
ionophore ionomycin. For the secondary thesis aim, over-expression of Tspan18 or other 
tetraspanins did not affect signalling by the platelet collagen receptor GPVI. 
Finally, Tspan18 mRNA was found to be relatively highly expressed in endothelial cells and 
peripheral blood leukocytes. Together these data suggest a role for Tspan18 in calcium 
signalling on these cell types. 
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1.1 TETRASPANINS 
1.1.1 Overview 
Tetraspanins are a large superfamily of evolutionarily conserved surface membrane 
proteins that have four transmembrane domains. A vast range of organisms, including 
plants, fungi and vertebrates, expresses tetraspanins. Humans have 33 tetraspanin 
members and studies have revealed that they are expressed in all cell types, each of 
which usually expresses multiple superfamily members. Some tetraspanin proteins are 
expressed in most cell types, such as CD9 and CD81, while others are expressed in 
only certain cell types, such as Tspan32 and CD37 in leucocytes.  
The most distinctive feature of tetraspanin proteins is that they can form lateral 
associations with multiple molecular partners and with each other, organizing the 
surface membrane proteins in dynamic microdomains, referred to as “tetraspanin 
microdomains” or the “tetraspanin web.” This membrane organization, which is 
distinct from “lipid rafts,” can regulate important cell functions, such as the immune 
response, cell adhesion, mammalian fertilization, fungal invasion of rice leaves, cell 
fusion, trafficking and signal transduction (Wright, Moseley et al. 2004; Hemler 
2005; Levy and Shoham 2005; Berditchevski and Odintsova 2007; Charrin, le Naour 
et al. 2009).  
 
1.1.2 Structure of tetraspanin proteins 
Tetraspanin proteins have four transmembrane domains, linked together by a small 
extracellular domain and a large second extracellular domain. Both the amino and the 
carboxy-termini are cytoplasmic and typically less that 10 amino acids in length 
(Figure 1.1). Tetraspanins are small transmembrane proteins, composed of 200-250 
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amino acids with a molecular weight of 25-50 kDa, and protrude only 4-5 nm above 
the membrane. Although several classes of molecules have four transmembrane 
domains they are not classified as members of the tetraspanin family unless they 
contain certain structural features. Tetraspanins have a number of conserved residues 
including one glycine and from four to eight cysteine residues in the large 
extracellular loop. Within this region, tetraspanin proteins contain a conserved CCG 
motif (where C is cysteine, G is glycine), that is characteristic of this superfamily, 
together with a PXSC motif (P is proline, X is any amino acid, S is serine and C is 
cysteine) and an EGC motif (E is glutamic acid, G is glycine, C is cysteine) (Levy and 
Shoham 2005).  
Tetraspanin proteins can undergo post-translational modification such as 
glycosylation and palmitoylation. N-glycosylation can increase the size of a 
tetraspanin protein by up to 35 kDa (Tarrant, Robb et al. 2003). Tetraspanin proteins 
contain several cysteine residues at the interface between the plasma membrane and 
cytoplasm, which are palmitoylation sites (Kovalenko, Yang et al. 2004). Site-
directed mutagenesis of all the juxtamembrane cysteine residues of CD9 and CD151 
resulted in the disruption of tetraspanin-tetraspanin interactions, suggesting that 
palmitoylation plays a central role in tetraspanin microdomain assembly (Yang, 
Kovalenko et al. 2004). 
In 2006, the Kong research group used cryo-electron microscopy to obtain structural 
information to 6 Angstroms of a complex composed of the uroplakin tetraspanins Ia 
and Ib and their molecular partners, the uroplakins II and IIIa. (Min, Wang et al. 
2006). The structure is a very packed conformation, and, interestingly, tetraspanins 
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Figure 1.1 Schematic representation of a tetraspanin protein. Tetraspanin proteins 
contain four transmembrane domains, a small extracellular loop, a large extracellular 
loop and short amino and carboxy termini, both cytoplasmic. In the large extracellular 
loop, tetraspanin proteins contain the characteristic conserved CCG motif (where C is 
cysteine, G is glycine) a conserved PXSC motif (P is proline, X is any amino acid, S 
is serine and C is cysteine) and a conserved EGC motif (E is glutamic acid, G is 
glycine, C is cysteine). Tetraspanin proteins contain three other conserved residues in 
the transmembrane domains: an asparagine (N), a glutamic acid (E) and a glutamine 
(Q). Tetraspanin proteins are usually glycosylated on between one and three N-linked 
sites (represented by a red filled circle), and cytoplasmic cysteine residues can be 
palmitoylated (in yellow).  
 
 
 
 
-4- 
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form interactions with the respective molecular partners both at the interface of the 
large extracellular loop and in the transmembrane region (Figure 1.2).  
Kitadokoro et al. solved the crystal structure of the soluble portion of the CD81 large 
extracellular domain (Kitadokoro, Bordo et al. 2001). CD81 extracellular domain is 
composed of five -helices arranged in “stalk” and “head” sub-domains. Two 
disulphide bridges stabilize the structure, involving the cysteine residues of the CCG 
motif and other conserved cysteine residues of the large extracellular loop (Figure 
1.3). 
Sequence alignment comparison performed by the Bolognesi group in 2001 suggest 
that the overall structural organization of the large extracellular loop might be largely 
conserved among tetraspanin proteins (Kitadokoro, Bordo et al. 2001). Moreover, 
ClustalW2 sequence alignment of all human tetraspanin proteins reveals that certain 
tetraspanins form subgroups that are particularly highly related, such as CD9, CD81 
and Tspan2 (Figure 1.4). 
The Seigneuret group, combining computational modelling and crystallographic data 
of the large extracellular loop of CD81, predicted the complete three-dimensional 
structure of CD81. The computational model shows an overall cylindrical mushroom-
like shape with a packed structure (Seigneuret 2006).  The transmembrane domains 
appear to be organized as a four-stranded left-handed coiled coil, organized as an 
approximately square bundle, giving a tight packing of the transmembrane domains. 
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Figure 1.2 Structure of the tetraspanin uroplakin Ia and its molecular partner, 
the uroplakin II. (A) The molecular model of the tetraspanin uroplakin Ia (orange) is 
fitted into the electron density map of its molecular partner, the uroplakin II (blue). 
(B) The density of the tetraspanin uroplakin Ia tetraspanin is removed to show the 
model's relation to the density of the single-spanning transmembrane protein partner. 
The model is coloured so that the colour spectra start with blue at the NH2 terminus 
and end with red at the COOH terminus of the tetraspanin protein. Taken from Min et 
al (Min, Wang et al. 2006). 
 
                             
Figure 1.3 Crystal structure of the human CD81 extracellular loop. The view 
highlights the head subdomain localization relative to the NH2- and COOH- terminal 
helices (α-helices A and E, respectively), and the labelling of secondary structure 
elements. The two disulfide bridges are shown in yellow. Taken from (Kitadokoro, 
Bordo et al. 2001). 
-6- 
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The small extracellular loop appears to be composed of a small -strand, while the 
amino and carboxy terminal regions of CD81, close to the intracellular membrane 
surface, appear to have a non-ordered structure. The large extracellular loop appears 
to accommodate the small extracellular loop in a hydrophobic conserved groove, 
giving the molecule an overall compact and cylindrical shape (Figure 1.5). The 
transmembrane region is mostly composed of hydrophobic amino acids, while the 
portion of the molecule exposed to the aqueous extracellular phase appears to be 
mostly hydrophilic, despite the presence of some hydrophobic regions. Combining 
these structural observations, it was hypothesized that the hydrophobic regions are 
involved in the interaction with other CD81 molecules, forming CD81 dimers, while 
the hydrophilic regions are involved in interactions with other partner proteins 
(Seigneuret 2006). 
 
1.1.3 Tetraspanin web hypothesis and classification of 
tetraspanin interactions 
Tetraspanin proteins have the capacity to interact with each other and with specific 
partner molecules. Most of the partner proteins play a receptor role, or couple 
receptors to signalling pathways. Specific partners include integrins, growth factor 
receptors, immunoglobulin superfamily proteins (IgSF) or signalling molecules.  This 
unique capability leads to the ability to create supra-molecular complexes, referred to 
as “tetraspanin microdomains” or “tetraspanin webs” (Rubinstein, Le Naour et al. 
1996). The tetraspanin microdomains provide a platform on which membrane and 
signalling proteins can perform their biological roles. 
Chapter 1 
 
Figure 1.4 ClustalW2 phylogram tree of all human tetraspanin proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Ribbon-and-stick representation of the CD81 tertiary structure and 
topology. Transmembrane domains are represented in blue, the small extracellular 
loop represented in red, and the large extracellular loop is represented in green and 
pink. Different transmembrane regions are indicated (TM1-4) as well as different 
large extracellular loop sub-domains (A-E). The red asterisks represent probable 
palmitoylation sites. Taken from (Seigneuret 2006; Charrin, le Naour et al. 2009).  
-8- 
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Combining the use of chemical cross-linkers and different detergents with 
immunoprecipitation techniques, the interactions that tetraspanin proteins establish 
with their molecular partners have been classified. Robust, direct interactions between 
tetraspanins and specific partner proteins are maintained in strong detergents, such as 
Triton X-100, in the absence of Ca2+ and Mg2+. Less robust interactions, such as those 
between individual tetraspanins, are disrupted by Triton X-100, but are preserved in 
milder detergents, such as Brij 96 or Brij 97. Weaker interactions are only detected in 
very mild detergents, such as CHAPS (Hemler 2005; Levy and Shoham 2005). The 
direct interactions of several tetraspanin proteins with different molecular partners are 
summarised in Table 1.1.  
In 2006, the Thali group demonstrated that CD63 and other tetraspanins, on the 
surface of HeLa cells, cluster at a large number of discrete sites, each of which 
extends over a few hundred nanometres. Interestingly, these clusters, or 
‘microdomains,’ do not necessarily contain all the tetraspanins that were tested for, 
suggesting heterogeneity between microdomains (Nydegger, Khurana et al. 2006). 
This observed punctiform organization of the tetraspanin microdomains is distinct 
from the previous “web” or network hypothesis of tetraspanin surface organization. 
The idea that tetraspanins form discrete microdomains is further confirmed by single-
molecule fluorescence microscopy, used to track a single CD9 molecule and to 
demonstrate that this molecule can dynamically enter and exit from a CD9 enriched 
microdomain, distinct from lipid rafts, at the cell surface (Espenel, Margeat et al. 
2008). Furthermore, the Sanchez-Madrid group showed that the adhesion proteins 
VCAM-1 and ICAM-1, the receptors for leukocyte integrins, are recruited by 
inclusion within specialized preformed tetraspanin-enriched microdomains at the 
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surface of endothelial cells, thus acting as adhesive platforms for circulating 
leukocytes (Barreiro, Zamai et al. 2008).   
A feature of tetraspanin proteins is that they can form distinct partnerships in different 
cell types. For example, in B cells CD81 associates with CD19, a member of the B 
cell receptor (BCR) co-receptor complex (Bradbury, Kansas et al. 1992), while in T 
cells, CD81 associates with CD4 and CD8 (Todd, Lipps et al. 1996). There is also 
variability in the stoichiometry of association. Some associations between tetraspanin 
proteins and relative partners are highly stoichiometric, such as the tetraspanins 
uroplakin Ia and Ib and their specific partners uroplakin II and uroplakin IIIa (Liang, 
Riedel et al. 2001), while immunoprecipitation studies conducted on other 
tetraspanins have demonstrated that not all tetraspanins have such a strong 
stoichiometry with their partner molecules (Hemler 2008). Tetraspanin proteins can 
also form associations with other tetraspanins, which are retained in mild detergents. 
At present, it is not known whether all tetraspanin proteins expressed in one cell type 
can associate with each other (Hemler 2008).  
 
1.1.4 Specific tetraspanin functions 
It has been proposed that tetraspanin proteins are involved in a variety of 
physiological and pathological processes in different cell types. Tetraspanins are 
reported to play a role in protein maturation and trafficking (Hu, Liang et al. 2005), in 
regulation of signalling (Lau, Wee et al. 2004; Goschnick, Lau et al. 2006), in sperm-
egg fusion (Rubinstein, Ziyyat et al. 2006), in cancer (Le Naour, Andre et al. 2006) 
and in virus infection (Bartosch, Vitelli et al. 2003). The tetraspanin proteins that are 
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best studied are those for which an antibody or a knockout mouse is available. The 
results of these studies are described in the following sections. 
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Table 1.1 Directly associated tetraspanin partner proteins. Adapted from Hemler 
2008. 
Tetraspanin Partner protein Function References 
CD9 CD9 CD9-CD9 dimer may be a basic 
structural unit 
(Kovalenko, Yang et al. 2004) 
  EWI-2 (IGSF8, 
CD316) 
Modulates integrin-dependent cell 
motility  and/or spreading 
     
(Charrin, Le Naour et al. 2003) 
(Stipp, Kolesnikova et al. 2003) 
  EWI-F (C9P-1, FPRP) Function unknown (Stipp, Kolesnikova et al. 2003) 
  Claudin 1  (Kovalenko, Yang et al. 2007) 
   
CD9 stabilizes expression of non  
junctional Claudin-1 
 
  HB-EGF CD9 upregulates both diphtheria 
toxin binding and mitogenic 
functions of HB-EGF 
(Iwamoto, Higashiyama et al. 1994) 
(Higashiyama, Iwamoto et al. 1995) 
CD81 CD81 CD81-CD81 dimer might be a basic 
structural unit 
(Stipp, Kolesnikova et al. 2001) 
  EWI-2 (Charrin, Le Naour et al. 2003) 
    (Stipp, Kolesnikova et al. 2001) 
    
Modulates integrin-dependent cell 
motility and/or spreading; also 
CD81 supports maturation and 
surface expression of EWI-2 
  
  CD19 (Shoham, Rajapaksa et al. 2006) 
    
CD81 supports maturation and 
surface expression of CD19 
(Horvath, Serru et al. 1998) 
  41 integrin CD81 supports a4b1 integrin 
adhesion and 
(Serru, Le Naour et al. 1999) 
    strengthening   
CD151 CD151 CD151-CD151 dimer may be a 
basic structural unit 
(Kovalenko, Yang et al. 2004) 
  31 integrin  CD151 affects integrin-dependent 
adhesion and motility 
(Zijlstra, Lewis et al. 2008) 
  61 integrin CD151 affects integrin-dependent 
adhesion  
(Lammerding, Kazarov et al. 2003) 
    and strengthening    
  64 integrin CD151 affects integrin-dependent 
adhesion and motility 
(Sterk, Geuijen et al. 2002) 
  71 integrin unknown function (Sterk, Geuijen et al. 2002) 
CD63 Syntenin-1 endocytosis regulation (Latysheva, Muratov et al. 2006) 
uroplakin Ia uroplakin II trafficking and ER exit (Hu, Liang et al. 2005) 
uroplakin Ib uroplakin IIIa trafficking and ER exit (Hu, Liang et al. 2005) 
ROM1 Peripherin/Rds photoreceptor viability and 
morphogenesis  
(Boesze-Battaglia et al. 2007) 
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Signalling: Several research groups have reported that tetraspanin proteins are 
involved in signalling processes. CD81 was shown to be an essential component of 
the CD9/CD21/CD81 co-receptor complex. Upon BCR stimulation, CD81 is found to 
be essential for the prolonged localization of the BCR/CD19/CD21 complex to lipid 
rafts and for sustained signalling. This appears to be due to an increase in CD81 
palmitoylation within the lipid raft microdomains (Cherukuri, Shoham et al. 2004). 
However, a recent study contradicts this observation, convincingly showing that B 
cell receptor-induced calcium mobilization, tyrosine phosphorylation and 
proliferation are enhanced in the absence of CD81, suggesting that this tetraspanin is 
a negative regulator of B cell receptor signalling (Sanyal, Fernandez et al. 2009). In 
antigen-presenting cells, the tetraspanin CD37, a specific immune cell tetraspanin, is 
reported to interact with and negatively regulate the C-type lectin dectin-1, the major 
-glucan receptor. CD37 appears to be important for dectin-1 stabilization at the 
plasma membrane and for the negative regulation of dectin-1 mediated interleukin 6 
(IL-6) production (Meyer-Wentrup, Figdor et al. 2007). Moreover, in a previous study 
conducted by the same research group, CD37 deficient mice show T cell 
hyperproliferation in response to T cell receptor cross-linking (van Spriel, Puls et al. 
2004). Mice deficient in CD151 and Tspan32 show a similar phenotype, suggesting 
that tetraspanin microdomains negatively regulate T cell receptor signaling (Tarrant, 
Groom et al. 2002; Tarrant, Robb et al. 2003; Wright, Moseley et al. 2004). Both the 
tetraspanins CD151 and Tspan32 have also been found to positively regulate the 
“outside-in” signaling of platelet integrin IIb3. Indeed, CD151 and Tspan32-
deficient platelets exhibit impaired kinetics of clot retraction, impaired platelet 
aggregation at low doses of various agonists, and impaired platelet spreading on 
fibrinogen (Lau, Wee et al. 2004; Goschnick, Lau et al. 2006). Moreover, CD151 and 
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Tspan32-deficient platelets show normal “inside-out” integrin IIb3 activation and 
normal platelet adhesion on fibrinogen (Lau, Wee et al. 2004; Goschnick, Lau et al. 
2006). These data suggest that CD151 and Tspan32 regulate IIb3 "outside-in" 
integrin signalling events in platelets. 
Other tetraspanins have been found to play a role in signalling. For example, CD82 is 
involved in the negative regulation of hepatocyte growth factor (HGF) receptor c-Met 
signalling (Takahashi, Sugiura et al. 2007). Moreover, the tetraspanin CD151 is able 
to modify the PI 3-K (phosphoinositide 3-kinase)/Atk pathway and the FAK (focal 
adhesion kinase)/Src kinase/p130 pathway (Takeda, Kazarov et al. 2007).  
Regulation of integrins: Tetraspanin regulation of integrins has been the subject of 
several studies, which have focused on the relatively strong and specific functional 
interaction between CD151 and laminin-binding integrins. In 3T3 cells, CD151 can 
strongly associate with and regulate the integrin 61, the major laminin-1 receptor at 
the cell surface, by selectively enhancing the adhesion strengthening of α6β1 binding 
to laminin-1 (Lammerding, Kazarov et al. 2003). The Hemler group additionally 
reported, in lung endothelial cells lacking CD151, a reduced level of AKt 
phosphorylation, and its downstream target eNOS (endothelial nitric oxide synthase) 
in response to adhesion on laminin. This is accompanied by impaired localisation of 
laminin-binding integrins to tetraspanin microdomains and impaired endothelial cell 
angiogenesis (Takeda, Kazarov et al. 2007). Moreover, the Hemler group 
demonstrated that elevated expression of CD151 is associated with almost one third 
of breast cancers, and that CD151-6 complexes promote tumour progression (Yang, 
Richardson et al. 2008). Finally, the Berditchevski group demonstrated that CD151 
can regulate α6β1 glycosylation, suggesting that CD151 plays an important role in 
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post-translation modification of this integrin (Baldwin, Novitskaya et al. 2008). Taken 
together, these data demonstrate that CD151 regulates adhesion strengthening, 
signalling and post-translational modification of laminin-binding integrins.  
Protein maturation and trafficking: The apical surface of mammal urothelium 
contains four major integral membrane proteins, uroplakins Ia, Ib, II and IIIa, which 
are specialized in providing the barrier function of the bladder.  Uroplakins Ia and Ib 
are tetraspanins which specifically associate with their molecular partners uroplakins 
II and IIIa, respectively. The Sun research group showed that the uroplakin 
tetraspanins can induce conformational changes in their partners, leading to ER-exit, 
protein stabilization and cell surface expression (Hu, Liang et al. 2005). In addition, 
the Levy group reported that in B cells the tetraspanin protein CD81, in addition to 
being part of the CD19/CD21/CD81 BCR co-receptor complex, associates with its 
molecular partner CD19 early in CD19 biosynthesis and is essential for normal CD19 
glycosylation and endoplasmic reticulum exit (Shoham, Rajapaksa et al. 2003).  
Furthermore, CD81 plays multiple roles in regulating CD19 intracellular trafficking, 
processing and membrane functions in B cells (Shoham, Rajapaksa et al. 2006). 
Taken together, these data support the hypothesis that tetraspanin proteins play 
multiple roles in processing, intracellular trafficking and membrane function of their 
molecular partners. 
Cancer: The Rubinstein group, using a CD9 immunoprecipiation strategy followed 
by proteomics, performed a comprehensive characterization of the tetraspanin web in 
human colon cancer cells (Le Naour, Andre et al. 2006). This work lead to the 
identification of 32 tetraspanin-associated proteins; these can be classified into 
adhesion molecules, membrane proteases, signaling proteins and tetraspanins. This 
work also established, using both tumor cell lines and patient samples, that several 
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components of the tetraspanin web are differentially expressed during tumor 
progression, suggesting a role in cancer. Indeed, a number of tetraspanin proteins are 
linked to tumor progression. For example, transfection of Tspan8 and CD151 
promotes metastasis formation (Zoller 2006). CD151 overexpression has been 
reported in several studies, as discussed previously, and has been observed in several 
tumor types, including breast, pancreatic and colorectal cancer. As already described, 
CD151 appears to accelerate breast cancer by regulating 6 integrin function, 
suggesting that CD151 could be a potential therapeutic cancer target (Yang, 
Richardson et al. 2008; Zoller 2009). Despite these data, not all tetraspanin proteins 
have been found to promote metastasis and tumor formation. For example, the 
tetraspanin Tspan13 inhibits tumor proliferation in MDA-MB-231 cells (Huang, 
Sossey-Alaoui et al. 2007); expression of CD9 in a colon cell line delays the 
appearance of detectable tumors; and CD82 is downregulated in advance stages of 
cancer, and impairs cell mobility (Zoller 2009). Despite these findings, the precise 
molecular mechanisms by which tetraspanins are involved in cancer are still largely 
unknown.  
Viral receptors: Tetraspanins play an important role in hepatitis C virus (HCV) entry 
and in human immunodeficiency virus (HIV) entry (Martin, Roth et al. 2005). In 1998 
it was found that the HCV envelope glycoprotein E2 binds the tetraspanin protein 
CD81, and CD81 was addressed as a first putative HCV receptor (Pileri, Uematsu et 
al. 1998). Following this initial observation, other studies have confirmed that HCV 
entry is CD81 dependent and anti-CD81 monoclonal antibodies inhibit HCV entry in 
a hepatoma cell line (Bartosch, Vitelli et al. 2003; Cormier, Tsamis et al. 2004; 
Zhang, Randall et al. 2004). Moreover, HCV binding to CD81 is necessary but not 
sufficient for HCV infection (Cocquerel, Voisset et al. 2006). Several research group 
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have identified other molecules that are necessary for HCV entry, including the 
scavenger receptor class B type I and the tight junction protein claudin-1 (Dubuisson, 
Helle et al. 2008). More recently, occludin, another tight junction protein, was 
identified as a fourth crucial HCV entry factor (Ploss, Evans et al. 2009). 
Furthermore, it has been suggested that HCV might use all of these four proteins as an 
entry route to hepatocytes (Pietschmann 2009). Altogether, these data demonstrate 
that CD81 plays a critical role, as part of a multi-step mechanism, in HCV entry, 
although precise mechanisms regulating HCV entry are still under active 
investigation.  
A physical link between tetraspanins and HIV-1 was first demonstrated through 
studies of viral trafficking in monocyte-derived dendritic cells (Garcia, Pion et al. 
2005). In particular, internalised virus did not traffic to lysosomes, but instead to a 
tetraspanin-enriched compartment that was distinct from late endosomes and 
multivesicular bodies. Moreover, upon engagement with a T cell, the virus re-
localised to the tetraspanin-containing infectious synapse (Garcia, Pion et al. 2005; 
Nydegger, Khurana et al. 2006; Jolly and Sattentau 2007). A functional link between 
tetraspanins and HIV-1 was then demonstrated when soluble forms of tetraspanin 
large extracellular loops were found to inhibit HIV-1 infection of macrophages (Ho, 
Martin et al. 2006), while tetraspanin knockdown increased infection of T cells 
(Gordon-Alonso, Yanez-Mo et al. 2006). In addition, CD63 over-expression was 
shown to inhibit viral infection of T cells by causing a loss of surface expression of 
the HIV-1 co-receptor CXCR4 (Yoshida, Kawano et al. 2008). Interestingly, the 
incorporation of tetraspanins into released viral particles reduced infectivity (Sato, 
Aoki et al. 2008) and infected T cells appeared to maximise infectivity by down-
regulating tetraspanin expression (Krementsov, Weng et al. 2009). However, in a 
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recent study, the Thali group proposed that HIV-1 has evolved to utilise tetraspanins 
at the virological synapse to prevent cell-cell fusion and resulting syncytia formation, 
which is thought to be detrimental to viral spread in vivo (Weng, Krementsov et al. 
2009). 
Cell fusion: Tetraspanins are involved in two distinct fusion processes, the sperm-egg 
fusion process and syncytium formation.  
A role for tetraspanins in sperm-egg fusion has been identified using a knockout 
mouse approach. The fertility of mice lacking CD9 appears to be severely reduced but 
not completely impaired. This is due to a defect in sperm-egg fusion and appears to be 
oocyte specific (Le Naour, Rubinstein et al. 2000). Mice lacking both CD9 and CD81 
are completely infertile, suggesting that CD9 and CD81 play complementary roles in 
the sperm–egg fusion process (Rubinstein, Ziyyat et al. 2006). Later experiments 
demonstrated that CD9 might regulate the distribution of some membrane proteins 
into clusters, including the laminin-binding integrin α6β1, which may play a role in 
gamete fusion (Ziyyat, Rubinstein et al. 2006). Moreover, CD9 is expressed on mouse 
oocyte microvilli, which are involved in the sperm-egg fusion processes. In wild type 
mice, microvilli appear long and thin, while in CD9 null mice microvilli appear 
uniform, short and thick. This altered morphology might explain why the CD9 null 
mice show impaired sperm-egg fusion (Runge, Evans et al. 2007). Despite these 
findings, the precise role of tetraspanin proteins in the sperm-egg fusion process has 
not been elucidated yet. 
The second cell fusion process that tetraspanins are involved in is the formation of a 
syncitium, which is defined as a cell-like structure with a large cytoplasmic mass 
containing multiple nuclei. Antibodies to CD82 block human T-cell lymphotropic 
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virus type 1 (HTLV-1) -induced syncytium formation in T lymphoblastoid cells 
(Fukudome, Furuse et al. 1992). Moreover, more recent data suggests that 
overexpression of CD82 inhibits syncytium formation, in addition to cell-to-cell virus 
transmission (Pique, Lagaudriere-Gesbert et al. 2000). CD9 and CD81 have been 
found to play a role in multinucleated giant cells (MGC). These cells form from the 
fusion of monocytes and macrophages as a response to external bodies. Antibodies 
against CD9 and CD81 enhance fusion of human monocytes and mouse macrophages 
in vitro (Takeda, Tachibana et al. 2003). Moreover, CD9 and CD81 knockout 
macrophages show enhanced MGC fusion, and the double CD9/CD81 knockout 
shows spontaneous MGC formation (Takeda, Tachibana et al. 2003). The Monk 
research group, in a more recent study aimed at identifying the precise role of 
tetraspanins in fusion processes, confirmed previous findings that CD9 and CD81 
antibodies enhance MGC formation. Moreover, using recombinant proteins 
corresponding to the large extracellular loop of tetraspanin proteins, this group 
demonstrated that CD63, CD9 and CD151 all appear to play a role in MGC formation 
(Parthasarathy, Martin et al. 2009). 
Tetraspanin proteins in lower organisms: Several studies have demonstrated the 
role of tetraspanin proteins in lower organisms, although the mechanisms behind the 
following data are not yet understood. 
In the nematode Caenorhabditis elegans, the lack of the tetraspanin protein TSP-15 
causes abnormalities of the hypodermis, including dissociation of the cuticles, 
indicating that TSP-15 functions in the maintenance of epithelial cell integrity 
(Moribe, Yochem et al. 2004).  
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In the plant Arabidopsis thaliana, deletion of the TORNADO2 gene, which encodes 
one of 17 tetraspanins in this species, leads to reduced complexity of the leaf venation 
network, asymmetric leaf growth and aberrant venation pattern (Cnops, Neyt et al. 
2006). In addition, TORNADO2 appears to be involved in the maintenance of the 
radial pattern of tissue differentiation in the root (Cnops, Wang et al. 2000).  
The genetic analysis of Drosophila melanogaster has revealed that this organism 
expresses 35 tetraspanin proteins (Todres, Nardi et al. 2000). Deletion of the neuronal 
tetraspanin late bloomer results in delayed motoneuron synapse formation with target 
muscles (Kopczynski, Davis et al. 1996). In contrast, a more recent study has 
demonstrated that the deletion of up to 25% of tetraspanin proteins does not perturb 
progression of the Drosophila life cycle, suggesting that molecular compensation 
exists for many tetraspanin proteins in this organism (Fradkin, Kamphorst et al. 
2002).  
In fungi, three tetraspanin families have been identified so far. These are Pls1 
tetraspanins, of which Pls1 is required for pathogenicity of the plant pathogenic 
ascomycetes, Magnaporthe grisea, Botrytis cinerea and Colletotrichum 
lindemuthianum; Tsp2 tetraspanins, whose function is unknown; and Tsp3 
tetraspanins, which are involved in the infection process of the plant pathogenic 
fungus M. grisea (Lambou, Tharreau et al. 2008). 
These specific examples demonstrate that tetraspanin proteins are expressed in a vast 
range of organisms and are implicated in the regulation of a variety of cell functions. 
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1.2 CALCIUM SIGNALLING 
Calcium is a very versatile second messenger, which modulates a variety of cellular 
processes (Berridge, Bootman et al. 2003) (Figure 1.6). Calcium signals are both 
responsible for short term cellular responses, such as secretion and contraction, and 
long term cellular responses, such as cell division, apoptosis and growth (Soboloff, 
Spassova et al. 2007). The plasma membrane and the membrane of many organelles 
separate compartments with different calcium concentrations: in the extracellular 
environment calcium concentration is around 2mM, in the ER (or in the 
sacroplasmatic reticulum in muscle cells) calcium concentration is around 100-700 
M, while in the cytoplasm it is in the order of 100 nM (Clapham 2007). Calcium 
signals are thus derived by fluxes of calcium across the membranes. Signals are a 
balance between “on” reactions, which are fluxes from internal stores or from the 
extracellular environment to the cytoplasm, and “off” reactions, which involve the 
activation of calcium pumps which transport calcium against the concentration 
gradient and restore basal conditions (Berridge, Bootman et al. 2003). Each cell type 
expresses a particular set (or “toolkit”) of calcium-related proteins, such as receptors, 
transducers, channels, effectors, buffers and pumps. The expression of the specific 
toolkit creates a different system with unique spatial and temporal characteristics, 
which dictates the cellular calcium response (Berridge, Bootman et al. 2003). 
Calcium entry mechanism: calcium can enter from the extracellular environment in 
the cytoplasm by various channels, which have different properties and different 
kinetics. Caclum entry involves voltage-dependent and voltage-independent calcium 
channels. Voltage-operated channels (VOCs) are found in excitable cells, and are 
responsible for fast calcium fluxes that regulate muscle contraction or exocytosis of 
neuronal cells. The mechanism that drives the aperture of the calcium channel is the 
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difference in electrical potential that exist between the intracellular and extracellular 
environments. The kinetic of the voltage-operated channels is extremely high, whth 
each channel transporting up to one million calcium ions per second (Clapham 2007). 
The channel is kept closed by a negative-charged helix-turn-helix paddle containing 
positive charged arginines, which opens upon change of membrane potential(Long, 
Campbell et al. 2005). 
As the name suggest, in the voltage-independent calcium channels the aperture of the 
channel is not regulated by voltage. This class of channels include several members, 
including the receptor-operated channels, the second messenger-operated channels 
and the store-operated calcium channels. The receptor-operated channels (ROCs) are 
opened upon direct binding of a specific molecule to the calcium channel. Examples 
of ROCs include the N-methyl-D-aspartate receptor (NMDAR), which responds to 
glutamate, the ATP receptor P2X7. Second-messenger-operated channels (SMOCs) 
respond to specific second messengers. Specific transduction pathways between 
receptors and calcium channels, which are physically separated, exist according to the 
type of the receptor and tissue. Store calcium depletion from the ER is responsible for 
the calcium-release activated current (CRAC), which allow a calcium flux from the 
extracellular environment into the cytoplasm. The CRAC current is activated only by 
a decline in ER calcium concentration and it is the major calcium entry mechanism in 
B and T cells  
Plasma membrane receptors:  calcium signaling can be triggered by the activation 
of specific plasma membrane receptors, such as G-protein-coupled receptors or the 
tyrosine kinase-coupled receptors (Clapham 2007). The activation of these receptors 
triggers calcium signals through the PLC protein family. Thirteen different PLC 
isoforms have been identified in mammals, and further complexity is provided by 
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alternative splicing variants for each (Suh, Park et al. 2008). PLC isoforms are tissue 
and cell specific, can mobilize calcium and are activated by different mechanisms. 
These includetyrosine kinase-coupled receptors which activate PLC, increase in 
calcium concentration which activates PLC, Ras which activates PLC, and G-
protein coupled receptors which activate PLC(Berridge, Bootman et al. 2003). 
Upon activation, PLC generates IP3 and DAG (see sections 1.2.5 and 1.2.6). 
Calcium release from internal stores: the IP3 receptors and the ryanodine receptors 
are the two calcium channels responsible for the release of calcium from the ER or the 
sarcoplasmic reticulum into the cytoplasm. These channels are expressed on the ER or 
sarcoplasmic membrane surface and release calcium from intracellular stores in 
response to the activation of intracellular signaling pathways (Kushnir, Betzenhauser 
et al. ; Berridge, Bootman et al. 2003; Taylor, Rahman et al. 2009). While IP3 
receptors are thought to be restricted to the ER and sarcoplamic reticulum, recent data 
suggests that ryanodine receptors can also be expressed on the plasma membrane, 
where they mediate calcium entry in certain cell types (Rosker, Meur et al. 2009; 
Taylor, Prole et al. 2009).   
Calcium-binding proteins: Only a small proportion of the calcium inside the 
cytoplasm remains free, as intracellular calcium is bound by a variety of cytoplasmic 
proteins, called “effectors” or “buffers,” which have different properties and different 
expression patterns. Calcium can bind calcium-binding proteins such as calmodulin, 
but also calcium-regulated enzymes, such as PKC, or transcription factors, such as 
calcineurin (Berridge, Bootman et al. 2003). Upon calcium binding, effectors become 
active, and can trigger their biological responses. 
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Pumps and exchangers: following the transient increase in cytoplasmic calcium 
concentration, pumps and exchanges have the role to restore and maintain the basal 
calcium concentration. Pumps have also the role of ensuring that the internal stores 
are fully loaded. The two major pumps that perform this function are the plasma 
membrane calcium ATP-ase (PMCA), which actively pumps calcium from the 
cytoplasm to the extracellular environment, and the sarco(endo)plasmic reticulum 
calcium ATP-ase (SERCA), which pumps the calcium into the ER or sarcoplasmic 
reticulum (Berridge, Bootman et al. 2003).  
Calcium in organelles: Calcium stores are not limited to the ER and the sarcoplasmic 
reticulum. Calcium is also present in other organelles, such as mitochondria and 
lysosomes. Mitochondria store mM of calcium, but calcium flux is regulated by a 
mechanism that is distinct from that which regulates calcium flux in the ER. (Guibert, 
Ducret et al. 2008). Calcium is pumped into the mitochondria by a calcium uniporter, 
named the mitochondrial calcium channel (MiCa), and is exported from the 
mitochondria by the sodium-calcium exchanger (NCX) (Berridge, Bootman et al. 
2003). Lysosomes may also store calcium in certain cell types, since in sea urchin 
eggs, nicotinic acid adenine dinucleotide phosphate (NAADP) can mobilize calcium 
from lysosome-related organelles (Churchill, Okada et al. 2002) . 
Spatial and temporal organization: Calcium is a widespread signaling mechanism 
and all cell types depend on calcium signals. These signals involve a combination of 
calcium release from intracellular stores and calcium influxes across the plasma 
membrane (Putney 2005).  
Many calcium signals are organized in multicomplexes, that can function as an 
autonomous unit or module, or sequential switches (Berridge, Bootman et al. 2003). 
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Moreover, as the cell cytosol is enriched in calcium buffers, this results in relatively 
low calcium motility inside the cytoplasm. This allows the creation of local “calcium 
clouds” with high local calcium concentration (Taylor, Prole et al. 2009).  
Calcium signals differ in the length of their responses, depending on the stimulus that 
generates the signal and the calcium “toolkit” employed by the cell. The response 
spans from milliseconds (synaptic transmission or cardiac contraction), seconds 
(metabolic reactions), or hours and days (transcription factor activation and egg 
fertilization) (Berridge, Bootman et al. 2003).  
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Figure 1.6: schematic representation of calcium fluxes.  Under basal conditions, the 
extracellular calcium concentration is 2 mM, the intracellular calcium concentration is 
100nM, while the endoplasmatic reticulum (ER) calcium concentration is 100-700M. These 
differences create gradients that are responsible for different calcium fluxes. Voltage-operated 
channels (VOCs), receptor-operated channels (ROCs) and second messenger-operated 
channels (SMOCs), store operated channels (SOCs) and the transient receptor potential (TRP) 
channels, allow the calcium to enter from the extracellular environment into the cell. IP3 
receptors (IP3Rs) and ryanodine receptors (RYRs) allow the calcium to flow from the ER (or 
the sacroplasmic reticulum) into the cytoplasm, and the mitochondrial calcium uniporter 
(MiCa) allows calcium movement from the cytoplasm to the mitochondria. Upon activation, 
calcium concentrations are restored by the plasma membrane calcium ATP-ase (PMCA), and 
the sarco(endo)plasmic reticulum calcium ATP-ase (SERCA) and the mitochondrial calcium 
potassium exchanger (NCX). 
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1.3 ITAM RECEPTOR SIGNALLING 
1.3.1 Overview 
A major function of cell surface receptors is to respond to appropriate stimuli and to generate 
intracellular signals. Such signals often lead to the nucleus where they are responsible for 
changes in gene expression and ultimately for generating different cellular behaviours. The B 
and T lymphocyte antigen receptors recognize different antigens and play different roles in 
immunity, but share a common signalling mechanism (Figure 1.7). Both of them contain a 
specific signalling motif in their cytoplasmic tails, known as the immunoreceptor tyrosine-
based activation motif (ITAM), which is essential for signal transduction (Grande, Bannish et 
al. 2007). Other immune recognition receptors, such as some Fc receptors, contain and signal 
through ITAM motifs. These immune receptors share some of the signalling proteins and 
propagate the receptor signal in a similar way (Samelson 2002). On platelets, for example, the 
FcRchain, which contains a single ITAM motif, is coupled to glycoprotein VI (GPVI), 
forming the platelet collagen receptor GPVI/FcRcomplex. 
 
1.3.2 ITAM motif 
The ITAM motif was first described by Reth in 1989 and consists of the sequence 
YXX(L/I)X6–12YXX(L/I) (in single-letter amino acid code, where Y is tyrosine, L is leucine, I 
is isoleucine and X represents any amino acid) (Reth 1989). The ITAM motif is expressed 
both by transmembrane proteins and cytoplasmic proteins, the latter of which are less 
common (Grande, Bannish et al. 2007). Transmembrane proteins containing ITAM motifs are 
expressed specifically in hematopoietic cells and are part of immunoreceptor complexes. 
These include Ig and Ig chains of the B cell receptor (BCR) complex, CD3 and ζ chains of 
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the T cell receptor (TCR) complex and the  and  chains of the FcRI complex (Grande, 
Bannish et al. 2007). Cytoplasmic proteins that contain an ITAM motif are expressed in both 
hematopoietic and non-hematopoietic cells and include the proteins ezrin and radixin. These 
cytoplasmic proteins require recruitment to the membrane in order to be able to generate a 
signal (Grande, Bannish et al. 2007).    
 
1.3.3 Proximal B and T cell receptor signalling 
Upon engagement of the BCR or TCR, Src family protein tyrosine kinases are activated by a 
mechanism that is not entirely understood. Their phosphorylation of ITAM motifs provides 
docking sites for downstream effector molecules and adapter proteins via their tandem Src 
homology 2 (SH2) domains (Grande, Bannish et al. 2007). SH2 domains contain a positively 
charged pocket that binds the phosphorylated ITAM tyrosine and a hydrophobic pocket that 
binds the non polar leucine or isoleucine (Grande, Bannish et al. 2007). Two major effectors 
of the B and T cell receptors are the protein tyrosine kinases Syk in most hematopoietic cells  
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Figure 1.7: Schematic representation of the B and T cell receptors. The yellow boxes 
represent ITAM motifs.   
Chapter 1 
and the related ZAP-70 in T cells, each of which possess tandem SH2 domains for ITAM 
binding. Such binding and activation of Syk/ZAP-70 is a fundamental step in ITAM-mediated 
signal transduction, as it amplifies signals, both by direct phosphorylation and activation of 
downstream signalling proteins and by recruiting other SH2-containing proteins to its own 
phosphorylated tyrosine-containing binding motifs.  
 
1.3.4 Activation of PLC
Upon activation, Syk or ZAP-70 are responsible for propagating the signalling cascade. Both 
Syk and ZAP-70 engage a similar strategy, which involves the assembly of a “signalosome” 
which is responsible for the activation of PLC. Syk phosphorylates the adaptor protein 
BLNK in B cells, while ZAP-70 phosphorylates both LAT and SPL-76 in T cells (Figure 1.8) 
(Koretzky, Abtahian et al. 2006).  
BLNK, LAT and SLP76 are adaptor proteins with no intrinsic enzymatic activity, but can 
assemble and activate multiple signalling molecules (Koretzky, Abtahian et al. 2006). They 
function as “scaffolds” for bridging signalling cascades, for activating signalling proteins and 
are key elements for signal amplification. BLNK and LAT/SLP76 contain multiple protein 
interaction domains and multiple phospho-tyrosines, that recruit SH2 domains, and proline 
motifs, that recruit SH3 domains (Myung, Boerthe et al. 2000). BLNK, LAT and SPL76 
function as the docking site for several BCR and TCR signalling proteins, such as Vav, Nck, 
Btk/Itk, Grb2/Gads and PLC family members (Figure 1.8), which are responsible for 
activation of different downstream effectors. For example, the tyrosine kinases Btk, in B cells, 
and Itk, in T cells, are essential for the phosphorylation and activation of PLC enzymes 
(Koretzky, Abtahian et al. 2006).  
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PLC is one of the key proteins of the ITAM-induced signalling pathway, and is responsible 
for the cleavage of phosphatidylinositol 4-5-bisphosphate molecules, present in the plasma 
membrane, into the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG). Structurally, PLC contains a split pleckstrin homology (PH) domain, for plasma 
membrane localization via binding to inositol phospholipids, surrounding a central SH2-SH2-
SH3 region (Wen, Yan et al. 2006). In the DT40 B cell line, the lack of PLC-2 resulted in the 
lack of downstream signalling and calcium mobilization, suggesting a key role for this protein 
in the BCR signalling pathway (Takata, Homma et al. 1995). Indeed, the two second 
messengers generated by PLC, IP3 and DAG, trigger two distinct signalling cascades, the 
calcium and mitogen-activated protein kinase (MAPK) pathways, respectively (Berridge 
1993). These two signalling cascades are the subjects of the following sections. 
 
1.3.5 Calcium mobilization leads to NFAT activation 
Calcium signals are essential in lymphocytes, as they regulate several cell functions, such as 
differentiation, effector function and gene transcription (Oh-hora and Rao 2008). IP3 is 
responsible for the initial calcium release from the endoplasmic reticulum (ER) stores, which 
is followed by calcium influx across the plasma membrane. This is achieved by IP3 engaging 
the IP3 receptor on the ER. This causes the IP3 receptor, which is a calcium channel, to open, 
resulting in a transient increase in intracellular calcium (Taylor, Rahman et al. 2009). This ER 
calcium store depletion is responsible for the opening of calcium release-activated calcium 
(ICRAC) channels in the plasma membrane, leading to a sustained increase of intracellular 
calcium, by a mechanism which will be described in the following section (Oh-hora and Rao 
2008).  
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Figure 1.8: B cell receptor (panel A) and T cell receptor (panel B) signalling pathways. 
Square yellow boxes represent ITAMs motifs and yellow circles represent ITAM-binding 
SH2 domains.  
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The stromal-interacting molecule (STIM1) has recently been shown to promote calcium entry 
via ICRAC channels following calcium release from ER stores (Liou, Kim et al. 2005; Roos, 
DiGregorio et al. 2005). STIM1 is a single-spanning transmembrane protein that is 
predominantly expressed on the ER membrane, and which functions as calcium “sensor” 
(Zhang, Yeromin et al. 2006). The EF-hand calcium-binding domain on the N-terminal 
luminal portion of STIM1 mediates this function (Liou, Kim et al. 2005). Upon depletion of 
calcium from the ER, bound calcium dissociates from the EF-hand motif of STIM1, and this 
elicits a conformational change in STIM1. STIM1 then moves laterally in the ER and forms 
punctuare accumulations, some in close proximity to the plasma membrane (Hogan and Rao 
2007). STIM1 can subsequently induce opening of the ICRAC channel (Hogan and Rao 2007).  
The ICRAC channel, responsible for outside-in calcium flux, is a multi-protein complex 
expressed on the plasma membrane (Figure 1.9). Although the precise protein complex has 
not been completely elucidated yet, a major subunit of the ICRAC channel has been recently 
identified as Orai1 (Vig, Peinelt et al. 2006). Orai1 has four transmembrane domains and 
intracellular amino and carboxyl-terminus, and appears to form a functional ICRAC channel 
following tetramerisation (Penna, Demuro et al. 2008). Moreover, a recent study by the Lewis 
research group demonstrated that STIM1 has a 107-residue ICRAC activation domain that 
forms tetramers. This domain interacts with the amino and carboxy termini of Orai1, so 
inducing Orai1 tetramers. This study has therefore established that the direct binding of 
STIM1 to Orai1 is necessary for both the redistribution and activation of ICRAC channels in 
response to calcium depletion (Park, Hoover et al. 2009).  
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The increase in cytoplasmic free calcium, generated by the calcium influx from the ICRAC 
channel, regulates the activity of a large number of calcium-sensitive proteins. Calcium 
elevation leads to the activation of both calmodulin-dependent protein kinase II and the 
calmodulin-activated serine/threonine phosphatase calcineurin. One of the targets regulated 
by calcineurin is the transcription factor nuclear factor of activated T cells (NFAT), whose 
nuclear translocation is facilitated by dephosphorylation following interaction with a 
conserved PxIxIT motif in calcineurin (Liu, Masuda et al. 1999). De-phosphorylation results 
in the unmasking of a nuclear localisation sequence, leading to nuclear translocation and 
activation of transcription of target genes (Macian 2005). In the presence of sustained calcium 
elevation, sustained calcineurin activation maintains NFAT in a predominantly de-
phosphorylated state in the nucleus. Once in the nucleus, NFAT can be re-phosphorylated by 
p38 MAPK, causing nuclear exit (Yang, Xiong et al. 2002). Five different members of the 
nuclear factor of activated T cells (NFAT) family have been identified: NFAT1, NFAT2, 
NFAT3, NFAT4 and NFAT5. NFAT1, NFAT2 and NFAT4 are expressed mainly in cells of 
the immune system where they regulate a large number of genes during the immune response 
(Macian, Lopez-Rodriguez et al. 2001). 
NFAT1-4 contain a conserved regulatory domain in the amino-terminal region, which 
controls both NFAT cellular distribution and transcriptional activation, followed by a DNA-
binding domain and a carboxy-terminal region (Macian, Lopez-Rodriguez et al. 2001; Macian 
2005). NFAT5 possesses specific features that differentiate it from the classical NFAT1-4 
members: NFAT-5 is the only non calcium-regulated NFAT protein. In lymphocytes, NFAT-
5 regulates the expression of osmotic stress-induced cytokines, including tumour necrosis 
factor (TNF) and lymphotoxin-(Macian 2005). 
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1.3.6 The MAP kinase pathway leads to AP-1 activation  
The second product of PLC is DAG, which is a membrane glyceride composed of two fatty 
acid chains covalently bonded to a glycerol molecule. DAG is responsible for the activation 
of protein kinase C (PKC) and the Ras exchange factor RasGRP, leading to downstream Ras 
activation. Ras is a monomeric GTP-binding molecular switch that is activated when bound to 
GTP, and inactive when bound to GDP. Ras is localized to the plasma membrane via a 
farnesyl anchor, and upon activation can recruit and activate the serine/threonine kinase Raf. 
Raf phosphorylates and activates MEK, a dual specificity kinase which phosphorylates and 
activates Erk. Active Erk then translocates to the nucleus where its targets include the 
transcription factors c-Fos and c-Jun, which subsequently dimerize to form the activator 
protein 1 (AP-1) transcription factor complex, leading to gene transcription (Buday and 
Downward 2008).  
 
1.3.7 NFAT/AP-1 promoter activation  
Cooperation between NFAT and AP-1 proteins on composite DNA elements, which contain 
adjacent NFAT (T/AGGAAA/T) and AP-1 (TGAGTCA) binding sites, regulates the 
expression of a diverse group of genes, including interleukin-2, that are essential for a 
productive immune response (Figure 1.9) (Macian, Lopez-Rodriguez et al. 2001).  
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Figure 1.9 Schematic representation of lymphocyte signalling pathways downstream of 
PLC The two PLC-induced second messengers, IP3 and DAG, trigger two different 
signalling pathways. IP3 binds to the IP3-gated calcium channel on the ER membrane, 
inducing calcium release from the ER. The ER-resident calcium sensor, STIM1, undergoes a 
conformational change and re-localises to ER-plasma membrane junctions where it interacts 
with and induces Orai1 tetramers, so creating an ICRAC channel which allows calcium entry 
across the plasma membrane. This increase in intracellular calcium is responsible for the 
activation of several calcium-sensitive proteins, including the phosphatase calcineurin which 
dephosphorylates NFAT. Upon de-phosphorylation, NFAT translocates into the nucleus. The 
second PLC product, DAG, activates protein kinase C (PKC) and RasGRP, leading to 
activation of Ras and the MAP kinase signalling pathway, the latter of which is responsible 
for the assembly of Fos and Jun heterodimers to form the AP-1 transcription factor. The co-
operation of the NFAT and AP-1 transcription factors is required for the active transcription 
of interleukin-2 and many other important lymphocyte genes.  
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1.4 PLATELET COLLAGEN RECEPTOR GPVI AND 
PLATELET TETRASPANINS 
1.4.1 Platelets 
Platelets are of major interest to our group because of their central roles in haemostasis and 
thrombosis. Platelets are small and anuclear blood cells that circulate in a quiescent state but 
undergo rapid activation following damage to the blood vessel wall, leading to formation of a 
vascular plug and cessation of bleeding. This rapid response is mediated by a large repertoire 
of cell surface molecules, including immunoglobulin superfamily proteins, integrins, leucine-
rich repeat and G-protein-coupled receptors. These receptors interact with a wide range of 
ligands such as extracellular matrix proteins, surface molecules on other cells and soluble 
agonists (Varga-Szabo, Pleines et al. 2008). 
Platelets also play a role in the disease process termed atherosclerosis. This is the progressive 
thickening and hardening of the arterial wall leading to plaque formation, due to the 
deposition of fatty deposits under the endothelium and recruitment of inflammatory 
leukocytes. Plaque rupture and subsequent blockage of the artery by activated platelets can 
result in heart attack or stroke. However, it has recently emerged that platelet interactions with 
endothelial cells are an initiating event in atherosclerosis, and such interactions play a role 
throughout disease progression (Langer and Gawaz 2008). Indeed, at sites of turbulent blood 
flow or under inflammatory conditions, platelets can adhere to endothelium via selectins, 
integrins and immunoglobulin superfamily molecules. Activated platelets release chemokines 
and inflammatory cytokines, which stimulate endothelial cells to upregulate adhesion 
molecules and release further chemokines, which together recruit leukocytes and exacerbate 
inflammation (Langer and Gawaz 2008). 
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1.4.2 Platelet collagen receptor GPVI 
Platelet glycoprotein VI (GPVI) is the major signalling receptor for collagen, the most 
thrombogenic component of the subendothelial matrix and atherosclerotic plaque. GPVI is 
composed of two Ig domains, an O-glycosylated stalk, a transmembrane region and a 
cytosolic sequence of 51 amino acids in human or 27 amino acids in mouse (Figrue 1.10) 
(Moroi and Jung 2004). GPVI is coupled to a disulphide-linked Fc receptor (FcR) -chain 
homodimer in the membrane via a salt-bridge between charged amino acids in the 
transmembrane regions (Feng, Garrity et al. 2005). FcR contains an ITAM motif, which 
couples GPVI activation to the activation of Syk in a similar manner to the antigen receptors 
for B and T cells (Figure 1.10) (Watson, Auger et al. 2005). The GPVI signalling pathway 
culminates in inside-out activation of integrins and platelet secretion (Nieswandt and Watson 
2003). Critical to the understanding of platelet function are the way in which receptors such as 
GPVI are organised on the platelet surface and the manner whereby GPVI signals interact 
with those of other receptors to promote activation. 
 
1.4.3 Regulation of platelet function by tetraspanins 
Identification of platelet tetraspanins is difficult due to the lack of antibodies to most 
tetraspanins and the relatively low amount of mRNA in the anucleate platelet. However, using 
serial analysis of gene expression (SAGE) and DNA microarrays, 19 tetraspanins were 
identified in megakaryocytes, the platelet progenitors (Protty, Watkins et al. 2009). Using 
antibodies, five tetraspanin proteins have been reported to be expressed on platelets: CD9  
 
 
  -38-
Chapter 1 
  -39-
 
Figure 1.10 Schematic representation of the GPVI/FcR complex.  The GPVI/FcR 
complex is the platelet collagen receptor. Structurally, GPVI it is composed of two Ig 
domains (one of which is N-glycosilated, in red), an O-glycosylated stalk (in yellow), a 
transmembrane region and a short cytosolic sequence. GPVI is coupled to a disulphide-linked 
Fc receptor (FcR) -chain which contain an ITAM motif (in yellow). 
Chapter 1 
(Boucheix, Soria et al. 1983), CD63 (Nieuwenhuis, van Oosterhout et al. 1987), CD151 
(Ashman, Aylett et al. 1991), Tspan32 (Robb, Tarrant et al. 2001) and Tspan9 (Protty, 
Watkins et al. 2008). Several other tetraspanins, including Tspan18, have been identified in 
platelets by proteomics (Lewandrowski, Wortelkamp et al. 2009), although confirmation 
awaits the generation of antibodies (Tomlinson 2009). 
The roles of CD151 and Tspan32 were evaluated in platelets by the Jackson group using mice 
deficient in either of these tetraspanins. The two strains of mice had similar phenotypes, 
notably a mild bleeding defect detected by the tail bleeding assay, partially defective platelet 
aggregation to a variety of agonists, delayed clot retraction, impaired platelet spreading and 
partially defective in vivo thrombus formation. The authors also presented evidence that 
CD151 and Tspan32 each associate with IIb3 and, as outlined in Section 1.1.4, speculated 
that these tetraspanins regulate “outside-in” IIb3 signalling (Lau, Wee et al. 2004; 
Goschnick, Lau et al. 2006). However, our group have been unable to detect an interaction 
between IIb3 and tetraspanins in human platelets (Protty, Watkins et al. 2008). 
In contrast to CD151 and Tspan32, deletion of CD9 or CD63 has relatively minor effects on 
platelet function. CD9 is expressed at a level of approximately 49,000 copies per platelet 
(Protty, Watkins et al. 2008), which makes this tetraspanin the second most highly expressed 
protein at the platelet cell surface, behind IIb3. Using CD9-deficient mice it has been 
demonstrated that CD9 negatively regulates the activation of the integrin IIb3, although the 
phenotype is weak and leads to only marginally larger thrombi in an in vivo model (Mangin, 
Kleitz et al. 2009). The recent generation of the CD63-deficient mouse did not reveal a major 
role for this tetraspanin in platelets. Indeed, the only demonstrable phenotype was marginally 
enhanced platelet aggregation in vitro, in response to stimulation with collagen, ADP or a 
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thromboxane mimetic, but this was not accompanied by an effect on thrombus formation in 
vivo (Schroder, Lullmann-Rauch et al. 2009). Our group recently identified Tspan9 as the 
fifth platelet tetraspanin and showed it to be relatively specific to the megakaryocyte/platelet 
lineage, although its function is unknown (Protty, Watkins et al. 2008). In the same study, 
GPVI was found to be a component of tetraspanin microdomains on platelets (Protty, Watkins 
et al. 2008). 
 
1.5 THESIS AIM 
The initial aim of this thesis was to determine whether any platelet tetraspanins play a role in 
signal transduction. This was done by over-expressing tetraspanins in the DT40 model B cell 
line with an NFAT/AP-1 transcriptional reporter. NFAT/AP-1 reporter assays are a sensitive 
method to measure calcium and MAPK signal transduction. Our group had previously 
developed this model system to study signalling of the platelet collagen receptor GPVI 
(Tomlinson, Calaminus et al. 2007). The major aim of the thesis was developed from these 
initial experiments, and became the characterization of a novel tetraspanin protein, Tspan18, 
which was found to have the unique capability to activate NFAT/AP-1. A final aim of the 
thesis was to test if Tspan18, or any other platelet tetraspanin, could affect GPVI signalling in 
response to collagen. 
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2.1 MATERIALS 
2.1.1 Antibodies and reagents 
The antibodies used are described in Table 2.1. Firefly luciferin was from LuxBiotech 
(Edinburgh, UK). All general laboratory materials were purchased from Sigma (Poole, UK), 
and all tissue culture reagents and materials were purchased from PAA Laboratories 
(Somerset, UK). 
 
Table 2.1 Details of antibodies. Legend: IP: immunoprecipitation, WB: western blotting, 
FC: flow cytometry  
Antibody Source Experimental 
concentrations 
Mouse anti-FLAG epitope 
(clone M2) 
Sigma IP: 5 g/ml 
WB: 10 g/ml 
Mouse anti-human GPVI 
(clone 204-11) 
Dr. Masaaki Moroi FC: 10g/ml 
Mouse anti-Myc epitope 
(clone 9B11) 
Cell signalling technology WB: 1 g/ml 
 
Donkey anti--rabbit IgG, 
HRP-conjugated 
Amersham Pharmacia 
Biotech 
WB: 1 g/ml  
 
 
Sheep anti-mouse IgG, 
FITC-conjugated 
Sigma FC: 15 g/ml 
Sheep anti-mouse IgG, 
HRP-conjugated 
Amersham Pharmacia 
Biotech 
WB 1 g/ml 
Rabbit anti-flag  Sigma WB: 0.5 g/ml 
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2.1.2 Plasmids and constructs 
The vector used for tetraspanin cloning was pEF6/Myc-His (Invitrogen) (Figure 2.1). 
Human GPVI and FcR expression constructs were as described (Tomlinson, Calaminus et al. 
2007).  
The NFAT luciferase reporter construct contains three copies of the distal NFAT site from the 
IL-2 promoter (Shapiro et al., 1996) and was a gift from Prof. A. Weiss. The pEF6-lacZ 
construct was obtained from Invitrogen.  
 
2.1.3 Inhibitors and agonists used in luciferase assays 
EGTA: EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid) is a high 
affinity calcium chelating agent. EGTA was used at a concentration of 4 mM. 
Cyclosporin A: Cyclosporin A is a drug currently used after transplantation, and it is a 
selective calcineurin inhibitor. The cyclosporin A mechanism of action involves the formation 
of a complex with its binding protein, cyclophilin (Iano Ikuko, 2003). Subsequently, the 
cyclosporin A-cyclophilin complex binds to and inhibits the activity of the protein 
phosphatase calcineurin, which is responsible for the dephosphorylation and subsequent 
nuclear translocation of NFAT proteins. Cyclosporin A was used at a concentration of 2mM.  
PMA: PMA (Phorbol 12-myristate 13-acetate) is a powerful tumour promoter and a potent 
activator of protein kinase C (PKC) and RasGRP, which activate the MAP kinase pathway. 
PMA was used at a concentration of 50 ng/ml. 
Ionomycin: Ionomycin is an ionophoric antibiotic that binds calcium and serves as an 
effective mobile carrier of this cation (Chao-min Liu and Theron E. Hermann, 1978). 
Ionomycin has become a useful tool over other ionophores for studies of calcium transport  
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Figure 2.1 Map of the pEF6/Myc-His vector (Invitrogen). 
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across membranes. Ionomycin induces a rise in intracellular free calcium, although the precise 
molecular mechanism of action is still unknown. Ionomycin was used at 1 M. 
 
2.1.4 Cells and tissues 
Wild type DT40 chicken B cells and DT40 deficient in Lyn/Syk (Takata et al., 1996), PLC2 
(Takata et al., 1995) and IP3R (Sugawara, Kurosaki et al. 1997) were kindly provided by Dr. 
T. Kurosaki (Kansai Medical University, Moriguchi, Japan).  
Jurkat human T cells (clone E6.1) were a gift from Dr. A. Weiss (University of California, 
San Francisco, USA) and were previously characterized (Strauss et al, 1992).  
Human aortic smooth muscle cells were a gift from Prof. R. Bicknell (Institute of Biomedical 
Research, University of Birmingham). 
Human peripheral blood leucocytes were collected at the interface of red cells and plasma 
after centrifugation of citrated whole blood at 200 xg for 20 minutes.  
DAMI cells are a human megakaryocyte-like cell line (Greenberg, Rosenthal et al. 1988) and 
were obtained from Prof. J. Frampton (Institute of Biomedical Research, University of 
Birmingham). 
DG75 cells are an Epstein-Barr virus-negative human B-cell line that were obtained from Dr 
M. Rowe (Institute for Cancer Studies, University of Birmingham). 
Primary human fibroblasts were a gift from Prof. R. Bicknell (Institute of Biomedical 
Research, University of Birmingham). 
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Human K562 are a myelogenous leukaemia cell line (Lozzio and Lozzio 1975) that was a gift 
from Dr Padma-Sheela Jayaraman  (Institute of Biomedical Research, University of 
Birmingham). 
HPB-ALL are a human T-cell line that was provided by Prof. J. Gordon (Institute of 
Biomedical Research, University of Birmingham). 
The HEL human erythroleukaemia cell line was obtained from Prof. J. Frampton (Institute of 
Biomedical Research, University of Birmingham). 
The HEK-293T human embryonic kidney cell line (Graham, Smiley et al. 1977) was obtained 
from Prof. J. Frampton (Institute of Biomedical Research, University of Birmingham). 
Primary human hepatocyte total mRNA was a gift from Dr Peter Balfe (Institute of 
Biomedical Research, University of Birmingham). 
Primary human umbilical vein endothelial cells (HUVECs) were obtained from Dr V. Heath 
(Institute of Biomedical Research, University of Birmingham).  
MDA-MB-231 are a human epithelial cell line (Young, Cailleau et al. 1974) that was a gift 
from Dr F. Berditchevski (Institute for Cancer Studies, University of Birmingham). 
HMEC-1 is a human microvascular endothelial cell line (Ades, Candal et al. 1992) that was a 
gift from Dr. V. Heath and Prof. R. Bicknell (Institute of Biomedical Research, University of 
Birmingham). 
The RAJI human B cell line was obtained from Prof. J. Gordon (Institute of Biomedical 
Research, University of Birmingham). 
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The U937 monocyte cell line was obtained from Prof. J. Frampton (Institute of Biomedical 
Research, University of Birmingham). 
The following mouse tissues were obtained by dissection of 6-8 week-old C57 BL/6 mice: 
brain, heart, kidney, liver, lung, muscle, spleen and thymus.  
For peripheral blood leucocytes (PBL), human blood was taken from healthy and drug-free 
volunteers using sterile 1:10 (v/v) sodium citrate and 1:9 (v/v) acidic citrate dextrose (ACD) 
(120 mM sodium citrate, 110 mM glucose, 80 mM citric acid) as anti-coagulants. Whole 
blood was centrifuged at 200xg for 20 minutes, platelet-rich plasma (PRP) was removed and 
PBL were collected from the erythrocyte-plasma interface. The PBL were then washed twice 
with Tyrode’s-Hepes buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM 
NaHCO3, 20 mM HEPES, 5mM glucose, 1 mM MgCl2, pH 7.3). 
 
2.2 CELL CULTURE 
HEK-293T were grown in DMEM medium, supplemented with 10% heat inactivated fetal 
bovine serum (FBS), 100 units/ml penicillin, 100 g/ml streptomycin, and 20 mM 
glutamine.DT40 cells were cultured in RPMI 1640 supplemented with 10% heat inactivated 
FBS, 1% chicken serum, 100 units/ml penicillin, 100 g/ml streptomycin 50 M -
mercaptoethanol and 20 mM glutamine. Jurkat cells were cultured in RPMI 1640 
supplemented with 10% heated inactivated FBS, 100 U/ml penicillin, 100 g/ml streptomycin 
and 20 mM glutamine.  
All cells were kept at an exponential phase of growth and kept in 5% CO2/95% air in a 
humidified incubator at 37°C.  
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2.3 FUNCTIONAL STUDIES 
2.3.1 Transient cell transfection 
DT40 and Jurkat cells were transfected by electroporation. 1 x 107 DT40 or Jurkat were used 
for each sample. 
DT40 cells were counted and washed once with cytomix buffer (mM KCl, 0.5 mM 
CaCl2, 10 mM K2HPO4, 10 mM KH2PO4, 25 mM HEPES, 2 mM EGTA, 5 mM MgCl2, pH 
7.6) supplemented on the day of the experiment with 5 mM glutathione and 40 M 
ATP.DT40 cells were resuspended in 400 l of cytomix buffer and placed into an 
electroporation cuvette, together with the appropriate DNA constructs. Cells were 
electroporated using a GenePulser II (Biorad) set at 350 V, 500 F, were left 5 minutes at 
room temperature, incubated 10 minutes on ice and resuspended in 8 ml of complete medium. 
Sixteen hours after transfection, cells were used for the experiment. 
Jurkat cells were counted and washed once with serum free RPMI 1640 medium and 
resuspended in 400 l of RPMI 1640 medium and placed into an electroporation cuvette, 
together with the appropriate DNA constructs. Cells were electroporated using a GenePulser 
II (Biorad) set 250 V and 950 F, left 5 minutes at room temperature, incubated 10 minutes 
on ice and resuspended in 8 ml of complete medium. Sixteen hours after transfection, cells 
were used for the experiment. 
HEK-293T cells were transfected by the calcium phosphate method. On the day before the 
transfection, 3 x 106 cells were seeded into 10 cm plates in 10 ml complete medium. For the 
transfection, 5 g of DNA was added to 450 l of sterile distilled water, followed by 63 l of 
2 M CaCl2. Then 500 l of 2X HEPES-buffered saline (280 mM NaCl, 10 mM KCl, 1.5 mM 
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Na2HPO4, 50 mM HEPES, 12 mM dextrose, pH 7.5) was added drop-wise to the solution 
containing the DNA, mixing between drops. The solution was left for 15 minutes at room 
temperature to allow the calcium phosphate-DNA precipitate to form, then added drop-wise to 
the cells. After 16 hours incubation, the supernatant was removed and fresh medium was 
added to the cells. Cells were incubated for an additional 24 hours, to allow the transfected 
proteins to be expressed, before harvesting by scraping.  
	
2.3.2 Luciferase assay 
DT40 or Jurkat cells were transfected with 20 g of NFAT/AP-1- or AP-1-luciferase reporter 
constructs, and 2 g of a -galactosidase construct under the control of the EF-1 promoter, 
to act as a control for transfection efficiency. Sixteen hours after transfection, live cells were 
counted using Trypan blue exclusion, and the concentration was adjusted to 2 x 106 cells/ml 
for each sample. An aliquot of 250 l was used for -galactosidase assay and a second aliquot 
of 250 l was used for flow cytometry (to determine GPVI surface expression, in GPVI 
experiments). The luciferase assay was performed in triplicate wells of a 96-well plate, using 
1 x 105 cells per well in a volume of 100 l. Cells were unstimulated or stimulated for a 
period of 6 hours with the following different stimuli and/or inhibitors: 50 ng/ml PMA, 1 M 
ionomycin, 4 mM EGTA and 2 mM cyclosporin A. The assay was harvested by first lysing 
the cells for 5 minutes at room temperature using 11 l of harvest buffer (200 mM potassium 
phosphate buffer, pH 7.8, 12.5% Triton X-100 and 4 mM DTT). Following lysis, 100 l of 
cell lysate was added to 100 l of assay buffer (200 mM phosphate buffer pH 7.8, 20 mM 
MgCl2 and 10 mM ATP) in a white, opaque 96-well plate. The luciferase activity was 
measured using a Centro LB 960 microplate luminometer (Berthold Technologies, Germany) 
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after injection of 50 l of 1 mM luciferin and measured over a 10 second period. Data were 
expressed as relative luciferase activation, following correction to control -galactosidase 
activity, using the geometric mean and standard error of at least two independent experiments.  
 
2.3.3 -galactosidase assay 
The -galactosidase assay was performed using an aliquot of 5 x 105 cells, using the Galacto-
LightTM -Galactosidase Reporter Gene Assay System (Applied Biosystems, Bedford, Mass, 
USA), following the manufacturer’s protocol. -galactosidase activity was measured in 
triplicate using a microplate luminometer (Centro LB 960, Berthold Technologies, 
Hertfortshire). All luciferase assay data were normalized to the relative -galactosidase value. 
 
2.3.4 Flow cytometry 
Flow cytometry was used to assess the surface expression of GPVI following transient 
transfection. Samples of 5 x 105 cells were collected and stained in a 50 l volume of FACS 
buffer (PBS, 0.2% (w/v) BSA, 0.02% (w/v) sodium azide) with 10 g/ml mouse anti-human 
GPVI mAb for 30 minutes at 4○C. Cells were then washed once in 1 ml FACS buffer, and 
incubated for 30 minutes with 15 g/ml FITC-conjugated anti-mouse IgG secondary 
antibody, in a 50 l volume at 40C. Cells were then resuspended in 250 l of FACS buffer 
containing propidium iodide at 2 g/ml to label and allow gating out of dead cells, and 
analyzed by flow cytometry using a FACScalibur (BD Biosciences). Data were collected and 
analyzed using CellQuest software.  
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2.4 PROTEIN STUDIES 
2.4.1 SDS polyacrylamide gel electrophoresis, western blotting 
and immunoblotting 
Cells were lysed in 1% Triton X-100 lysis buffer (1% (v/v) Triton X-100, 10 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA, 0.01% (w/v) sodium azide). The following inhibitors were 
added to the lysis buffer just before use: 200 g/ml AEBSF (4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride), 10 g/ml aprotinin, 10 g/ml leupeptin, 1g/ml 
pepstatin A, 10 mM NaF and 2 mM sodium orthovanadate. Following lysis for 30 minutes on 
ice, insoluble debris was removed by centrifugation for 10 minutes at 18,000 xg in a micro-
centrifuge at 4oC. Cell lysates were mixed with an equal volume of 2x Laemmli sample 
buffer. 
Proteins were separated using 12% sodium dodecyl-sulphate (SDS)-polyacrylamide gels. 
Prestained molecular weight markers (Bio-Rad, Hemel Hempstead, UK) were used in all gels. 
Separation was performed at room temperature using a constant voltage of 125 mV. Upon 
protein separation, polyvinylidene fluorite (PVDF) membranes were quickly soaked in 
blotting buffer (25 mM Tris, 250 mM glycine, 20% methanol) and proteins were transferred 
to membranes by a Trans-Blot SD semi-dry transfer apparatus (Biorad), using a current of 110 
mA for 25 minutes. Membranes were blocked for 1 hour at room temperature in TBS-T (20 
mM Tris, 137 mM NaCl, 0.1% (v/v) Tween-20, pH 7.4) containing 5% (w/v) milk powder. 
The blocked membrane was stained with primary antibody in TBS-T containing 10% (w/v) 
bovine serum albumin (BSA) and 0.1% (w/v) sodium azide for one hour at room temperature 
under constant agitation, and washed three times in high salt TBS-T (TBS-T containing 500 
mM NaCl) for 10 minutes each wash. The membrane was then incubated for one hour at room 
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temperature (or overnight at 4 oC) with HRP-conjugated secondary antibody, diluted in TBS-
T containing 3% (w/v) milk powder. Membranes were washed five times, for five minutes 
each wash, in high salt TBS-T and developed using an enhanced chemiluminescence (ECL) 
kit (Amersham Bioscience, Buckinghamshire, UK), following the manufacturer’s 
instructions, using Amersham Hyperfilm ECL (GE Healthcare) films and a Compact X4 film 
processor (Xograph Imaging Systems). 
 
2.4.2 Lipid raft separations  
A transfected 10 cm plate of HEK-293T cells was washed twice with 10 ml PBS and lysed for 
30 minutes in 1 ml of ice-cold GEM lysis buffer (1% (v/v) Triton X-100, 25 mM Tris pH 7.5, 
150 mM NaCl, 5 mM EDTA, 200 g/ml AEBSF, 10 g/ml aprotinin, 1 g/ml leupeptin, 1 
g/ml pepstatin A, 10 mM NaF and 2 mM sodium orthovanadate). The supernatant was 
mixed with 1 ml ice-cold 80% (w/v) sucrose in GEM lysis buffer and laid at the bottom of an 
ultracentrifuge tube. In order to create a sucrose step gradient in the tube, 2 ml of 30% (w/v) 
ice-cold sucrose in GEM buffer was laid on top of the sample. On top of that was laid 1 ml of 
ice-cold 5% (w/v) sucrose in GEM buffer.  
Samples were ultracentrifuged at 200,000 xg for 16 hours at 4 oC in a Beckman Coulter 
ultracentrifuge, using a Sw Ti 55 rotor (Beckman Coulter, High Wycombe). Following 
ultracentrifugation, 12 aliquots of 400 l were collected from the top of the tube for each 
sample. In order to dissolve the lipid rafts, 1% (w/v) of N-Octyl--D-gluco-maltoside was 
added to each aliquot. Each sample was analyzed both by dot-blot and by electrophoresis. 
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2.4.3 Dot-blot analysis 
100 l of each aliquot from the lipid raft preparation was analyzed by dot-blot, using a Bio-
dot microfiltration apparatus (Bio-Rad, Hertfortshire). Samples were immobilized on a 
nitrocellulose membrane and washed twice with TBS. The membrane was blocked with 5% 
(w/v) milk powder in TBS-T and probed with 0.33 g/ml cholera toxin B subunit conjugated 
to peroxidase. The membrane was incubated for one hour at room temperature, washed five 
times, for five minutes each wash, with TBS-T and developed using ECL and film.  
 
2.5 MOLECULAR BIOLOGY 
2.5.1 Generation of tetraspanin constructs 
Tetraspanin expression constructs were generated by Kate Fitzpatrick-Ellis and Dr Victoria 
Heath. In brief, tetraspanin cDNAs were generated by PCR and cloned into the pEF6/Myc-His 
A vector (Invitrogen), which had been modified to include an in-frame, upstream sequence for 
the FLAG epitope tag (amino acid sequence: MDYKDDDDK, M is methionine, D aspartic 
acid, Y tyrosine and K lysine) (Figure 2.1), between the Kpnl and BamH1 restriction enzyme 
sequences. The endogenous stop codons were retained for each tetraspanin construct to 
prevent translation of the Myc and His epitope tags.  
 
2.5.2 CD9/Tspan18 chimera and Tspan18 isoform 1 constructs 
The CD9/Tspan18 chimera construct was generated by a two-step PCR method (Higuchi et 
al., 1988). This construct contains cytoplasmic and transmembrane domains of human CD9 
and small and large extracellular regions of human Tspan18. Tspan18 isoform 1 was 
generated by PCR from the IMAGE clone 3357734.  
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The oligonucleotides used to generate PCR products are detailed in Table 2.2. 
Construct Vector Restric
tion 
sites 
Primers 
CD9/Tspa
n18 
chimera 
pEF6/ 
Myc-
His-A 
BamHI 
and 
EcoRV 
(vector)
, BglII 
and 
EcoRV 
(insert) 
Forward 
5’-
TAGTAGGGATCCCCGGTCAAAGGAGGCACCAAG-
3’ 
Reverse 
5’-
TAGTAGGATGATTTAGACCATCTCGCGGTTCCT-
3’ 
Tspan18 
isoform 1 
pEF6/ 
Myc-
His-A 
BamHI 
and 
XbaI 
(vector)
, BglII 
and 
XbaI 
(insert) 
Forward 5’-
TAGTAGGGATCCGAAGGCGACTGTCTGAGCTGC-
3’ 
Reverse 5’-
TAGTAGTCTAGAGGCTGTGGCTCCGCGTGT-3’ 
Table 2.2 Oligonucleotides used to generate the CD9/Tspan18 chimera and Tspan18 
isoform 1 constructs. 
 
2.5.3 DNA amplification by PCR 
Tetraspanin PCR products for cloning were generated in 100 l reaction volumes using 
PfuTurbo DNA polymerase (Stratagene) according to the manufacturer’s protocol. Forward 
and reverse primers were used at a concentration of 0.4 pmol/l, and dNTPs were used at a 
concentration of 0.2 mM each nucleotide. Standard PCR conditions were the following: 
denaturation at 93 oC for 5 minutes, annealing at 55 oC for 60 seconds, and elongation at 72 
oC for 60 seconds (30 cycles). PCR products were separated on 1.5% agarose gels (prepared 
in TBE buffer: 89 mM Tris, 89 mM boric acid, 20 mM EDTA, 0.005% ethidium bromide, pH 
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8) and purified using a QiaQuick column (Qiagen) and the column was eluted with 50 l of 
appropriate buffer according to the manufacturer’s protocol.   
 
2.5.4 Restriction enzyme digest 
Digestion of DNA with specific restriction enzymes was used for both analytical purposes 
and for the isolation of specific fragments. Digestions were performed at the temperature and 
in the appropriate salt buffer suggested by the manufacturer for at least 3 hours. Digestion was 
followed by gel purification, using a Qiaex Kit (Qiagen).  
 
2.5.5 Ligation of DNA into vectors 
DNA fragments were ligated into the pEF6/Myc-His A plasmid in a reaction volume of 10 l, 
containing 20 ng of linear vector, 3-6 times more insert in molar terms, and 1 unit of T4 DNA 
ligase (Roche) per reaction. Ligations were performed at room temperature for 5 minutes, 
employing a Quick Ligation Kit (Roche), and following the manufacturer’s instructions. 
 
2.5.6 Transformation of plasmid DNA into bacteria 
Following ligation, 1 l of the ligation mix was added to 50 l of competent DH5 bacteria 
(Invitrogen) and placed on ice for 30 minutes. The mixture was then heat shocked at 37 ○C for 
20 seconds, and placed again on ice for 2 minutes. After the addition of 200 l of SOC 
medium (Invitrogen), bacteria were incubated for one hour at 37 oC, to allow the ampicillin 
antibiotic-resistance gene to be expressed. Bacteria were then spread on Luria-Bertani (LB) 
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agar ampicillin plates (1% NaCl, 1% Tryptone, 0.5% yeast extract, 1.5% agar, 100g/ml 
ampicillin, pH 7 and incubated overnight at 37 ○C. 
Colonies were individually screened by PCR using one insert primer and one vector primer. 
Positive colonies were confirmed by electrophoresis gels. A positive colony was then 
inoculated in 250 ml of LB broth (1% NaCl, 1% Tryptone, 0.5% yeast extract, 100g/ml 
ampicillin, pH 7), and grown for 16 hours at 37 °C under constant agitation.  Plasmid DNA 
was purified according to the Plasmid Maxiprep Kit (QIAGEN, West Sussex, UK). The 
sequence of all the generated constructs was confirmed using a sABI Prism 3,700 DNA 
analyser (Functional Genomics Laboratory, The University of Birmingham, UK). 
 
2.5.7 RNA extraction and conversion to cDNA 
For cells and lines, 1x106 cells were resuspended in 1 ml of TRIzol® Reagent (Invitrogen, 
Paisley, UK). For tissues, 50-100 mg of mouse tissue were added to 1 ml of TRIzol® Reagent 
and rotor-homogenized. Total RNA was extracted using the TRIzol® Plus RNA Purification 
Kit (Invitrogen) according to the manufacturer’s instructions.Total RNA was quantified using 
a Nanodrop 1000 spectrophotometer (Thermo Scientific, Whaltman, USA). A 2 g quantity 
of total RNA was collected after quantification and converted into cDNA using the 
Transcriptor High Fidelity cDNA Synthesis Kit (Roche), following the manufacturer’s 
protocol.  
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2.5.8 Quantitative real time PCR (qRT-PCR) 
A volume of 15 l of the reaction mix containing the two specific gene primers (0.4 l each), 
12.5 l qRT-PCR master mix and 0.4 l of specific probe, were added to 10 l of cDNA 
diluted 1:20. The probe contains two labels in close proximity to each other: a fluorescent 
reporter dye at the 5’- end and a fluorescent quencher at the 3’- end. When the probe is intact, 
the quenching label suppresses the fluorescent signal. When the probe is hybridized to its 
target sequence, it can be cleaved by the 5´-3´ exonuclease activity of the Taq DNA 
polymerase, which "unquenches" the fluorescent reporter dye and release it into solution. 
During each PCR cycle, the released fluorescent dye accumulates, boosting the fluorescent 
signal. The fluorescent dye is detected using a SYBR green I filter. A representative qRT-
PCR experiment is presented in Figure 2.2. 
The conditions for qRT-PCR amplification were the following: initial denaturation at 95oC for 
10 minutes, followed by 30 cycles of denaturation at 95oC for 10 seconds, and elongation at 
60oC for 45 seconds. qRT-PCR was performed in a Rotor Gene 3000 qRT-PCR machine 
(Corbett Research), which performs the PCR amplification in a spinning rotor to generate a 
uniform distribution of the temperature across the samples. The primers and probes are shown 
in Table 2.3. Mouse and human data were normalized for the HPRT and actin housekeeping 
genes, respectively. 
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Gene Primers Probe 
Human 
Tspan18 
isoform 2 
Forward 
5’- GAAGGCGACTGTCTGAGCTGC-3’ 
Reverse 
5’-CTACTGGATGCCCCGGAAGCG-3’ 
Probe 53 
Human 
Tspan18 
isoform 1 
Forward 5’-GAAGGCGACTGTCTGAGCTGC-3’ 
Reverse5’- GGCTGTGGCTCCGAGTG-3’ 
Probe 11 
Mouse 
Tspan18 
Forward5’-GAGGGCGACTGTCTGAGCTG-3’ 
Reverse5’-CTACTGGATGCCCCGGAAGAG-3’ 
Probe 66 
Human actin Forward5’- GCACCCAGCACAATGAAGA-3’ 
Reverse5’- CGATCCACACGGAGTACTTG-3’ 
Probe 63 
Mouse HPRT Forward5’- GAAGCGGTAGCACTT-3’ 
Reverse 5’-GTTCATCATCGCTAATCACGAC-3’ 
Probe 69 
Table 2.3 qRT-PCR primers and probes. Probe numbers refer to the Human Roche 
Universal Probe Library.  
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Figure 2.2 Representative example of a qRT-PCR experiment. Following PCR 
amplification of 11 samples, each was displayed as a curve on a graph of fluorescence 
intensity, which is proportional to the amount of PCR product, versus number of PCR cycles 
The threshold value was automatically calculated at a position above the background noise, 
and on the linear range of the positive samples (A.). A standard curve was drawn using the 
three dilutions of the positive HUVEC sample (shown as blue diamonds in panel B), using the 
number of PCR cycles at the threshold fluorescence versus an arbitrary measure of the sample 
dilution, labelled ‘concentration’ of the original cDNA. The other samples (shown as red 
diamonds in panel B) were quantitated relative to HUVEC using the standard curve B.). 
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2.6 ANALYSIS OF THE DATA 
Western blotting and FACS data were representative of 2-5 experiments. qRT-PCR 
experiments were performed three times. 
Luciferase assays were preformed between two and eight times, as indicated. Each luciferase 
reading was normalised for transfection efficiency by dividing by the relative -gal value. 
These data failed to pass the D'Agostino-Pearson normality test, suggesting that they are not 
normally distributed. In order to employ parametric statistical tests, which are more robust 
than the equivalent non-parametric tests, data were and multiplied by the arbitrary value of 
100, in order to obtain positive logarithmic data. Data were transformed into a logarithmic 
scale. Logarithmic data passed the D'Agostino-Pearson normality test, indicating that this 
transformation resulted in a normally distribuited data set. The normality of the logarithmic 
data was verified for each experiment (data not shown) and the standard deviations among 
replicate samples were calculated. Logarithmic data was analyzed by the analysis of variance 
(ANOVA) test. Statistical significance was determined by employing Tukey-Kramer’s test, 
which compares all pairs of columns of normally distributed and independent data, and 
P<0.05 was taken as significant. Following statistical analysis, data were re-transformed into 
linear values for graphical representation.  
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3.1 INTRODUCTION 
3.1.1 DT40 as a cell line model to study PTK-based signalling 
pathways 
The DT40 chicken B cell line is an effective model to study receptors that signal via PTK-
based signalling pathways, such as the ITAM-containing B cell receptor. This cell line 
expresses surface B cell receptor, of the IgM isotype, which is activated upon cross-linking, 
leading to calcium mobilization and apoptosis (Kurosaki, Maeda et al. 2000). Furthermore, 
DT40 is unique amongst cell lines in exhibiting a high propensity for homologous 
recombination, which has allowed the deletion of signalling components, either individually 
or in combination (Kurosaki 1997). Such work has played a pioneering role in dissection of 
the role of signalling molecules along the BCR signalling pathway. 
In 1994, the Kurosaki group generated DT40 cells deficient in the Src family PTK Lyn and 
studied B cell receptor signalling in this mutant, reporting a weak, delayed but sustained 
signalling (Takata, Sabe et al. 1994). Similar BCR cross-linking on Syk-deficient DT40 
revealed a lack of tyrosine phosphorylation of PLCresulting in the loss of both IP3 
generation and calcium mobilization. Moreover, Lyn/Syk doubly-deficient DT40 cells 
exhibited a complete defect in induction of tyrosine phosphorylation of any protein upon BCR 
ligation (Takata and Kurosaki 1996). These data indicate that Lyn and Syk play an essential 
initiating role in BCR signalling. 
In 1996, the Kurosaki group characterized DT40 cells deficient in the PTK Btk (Takata and 
Kurosaki 1996) Following BCR cross-linking, Btk-deficient DT40 exhibited reduced PLC 
phosphorylation and a loss of IP3 production and calcium mobilization, indicating that Btk is 
required for PLC phosphorylation and activation. Moreover, the same group generated and 
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characterized DT40 cells lacking PLC(Takata, Homma et al. 1995), reporting that, upon 
BCR cross-linking, PLC mutant cells completely failed to mobilize calcium. PLC 
hydrolyses the membrane inositol phospholipid PIP2, resulting in generation of the second 
messengers DAG and IP3. DAG activates protein kinase C and RasGRP which activate the 
MAPK pathway leading to AP-1 transcriptional activation (Chang and Karin 2001). IP3 binds 
to the IP3 receptors (IP3Rs), which form the calcium channels located on the endoplasmic 
reticulum (ER), leading to calcium release from this internal store. Together these studies 
delineated a BCR-Lyn/Syk/Btk-PLC2-IP3R pathway for induction of calcium mobilization.  
More recent studies using DT40 cells deficient in the ER-resident STIM1 protein (Prakriya, 
Feske et al. 2006) and cells and mice deficient in STIM1 and the calcium channel Orai1 
(Park, Hoover et al. 2009), have demonstrated that STIM1 detects calcium depletion of the 
ER stores and binds to a tetramer of Orai1 in the plasma membrane, resulting in channel 
opening, calcium entry and activation of downstream transcriptional responses such as the 
calcineurin/NFAT pathway (Macian 2005; Oh-hora and Rao 2008). 
 
3.1.2 NFAT/AP-1 luciferase assay 
Our group has previously developed a cell line assay to measure GPVI/FcR signalling 
responses to collagen (Tomlinson, Calaminus et al. 2007) (Figure 3.1). The method involves 
the transfection of the DT40 chicken B cell line with the NFAT/AP-1-luciferase 
transcriptional reporter construct and expression constructs different receptors.  DT40 chicken 
B cell line is transfected with the NFAT/AP-1-luciferase transcriptional reporter construct and 
expression constructs for GPVI and FcR. Sixteen hours post-transfection, cells are stimulated 
for six hours with the GPVI agonist collagen, or the positive control agonists PMA and 
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ionomycin, which bypass receptor proximal signalling to activate downstream MAPK and 
calcium pathways, respectively. GPVI/FcR stimulation with collagen induces the activation 
of PLC2 leading to downstream activation of MAPK and calcium pathways, both of which 
are required for optimal activation of the composite NFAT/AP-1/ promoter. In this cell line 
model, this leads to the generation of luciferase protein, which is measured using a 
luminometer that detects light production following oxidation of the luciferase substrate 
luciferin in the presence of ATP. A -galactosidase construct is always included in each 
transfection, and -galactosidase activity is used to correct for transfection efficiency. This 
method has been successfully used to study the signalling pathways of other platelet 
receptors, such as the C-type lectin receptors CLEC-2 and Dectin-1 (Fuller, Williams et al. 
2007), and has been be employed in this chapter to evaluate if a tetraspanin protein can induce 
NFAT/AP-1 signalling.  
 
3.2 AIM 
The aim of this chapter was twofold. The first aim was to evaluate if any of the platelet-
expressed tetraspanin proteins (CD9, CD63, CD151, Tspan32, Tspan9 and Tspan18) could 
induce signalling leading to activation of the NFAT/AP-1 promoter. This was done using the 
DT40 B cell line NFAT/AP-1-luciferase assay previously developed by our group 
(Tomlinson, Calaminus et al. 2007). The second aim was to study the signalling pathway of 
the tetraspanin Tspan18, which has been found to be able to induce NFAT/AP1 signalling 
during the first aim. 
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Figure 3.1 Model of the NFAT/AP-1 transcriptional reporter assay in DT40 cells. DT40 
B cell line is transfected with the NFAT/AP-1-luciferase transcriptional reporter construct and 
expression constructs for GPVI and FcR. Cells are stimulated for six hours with the GPVI 
agonist collagen, or the positive control agonists PMA and ionomycin, which bypass receptor 
proximal signalling to activate downstream MAPK and calcium pathways, respectively. The 
activation of MAPK and calcium pathways are both required for the optimal activation of the  
NFAT/AP-1/ promoter.  
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3.3 RESULTS 
3.3.1 Tspan18, but not other platelets tetraspanin proteins, can 
induce NFAT/AP-1 signalling in the DT40 B cell line 
In order to study if any of the tetraspanin proteins expressed on human platelets has an effect 
on NFAT/AP-1 signalling, a panel of FLAG-tagged tetraspanin proteins was individually co-
transfected with the NFAT/AP-1 reporter in DT40 cells. The tetraspanins CD9, CD63, 
CD151, Tspan9 and Tspan32 were selected because they were known to be platelet-
expressed, and Tspan18 was selected as a likely sixth platelet tetraspanin due to positive RT-
PCR data from human platelets (V.L. Heath and M.G. Tomlinson, 2004, unpublished). The 
response of each tetraspanin protein was evaluated under basal conditions. Despite the 
Tukey’s statistical analysis revealed CD9 and Tspan18 both significally induce NFAT/AP-1, 
only Tspan18, among the panel of tested tetraspanins, was able to substantially induce 
NFAT/AP-1 activation (Figure 3.2A). As a positive control, all transfection conditions 
responded robustly to PMA and ionomycin, albeit with a relatively high degree of variability 
between these three experiments, as shown by the large error bars, as one of the trhee 
experiment reported a stronger PMA+I response than the other two (Figure 3.2B). An aliquot 
of each transfected cell sample was lysed in 1% Triton X-100, analyzed by SDS-PAGE and 
blotted using an anti-FLAG antibody, in order to check the expression level of the transfected 
tetraspanin proteins (Figure 3.2C). Tetraspanins CD9, CD151 and Tspan9 were highly 
expressed, while CD63 and Tspan32 showed an intermediate expression level. The Tspan18 
expression level was the lowest of the tested tetraspanin proteins, being barely detectable at 
this exposure (Figure 3.2C), which suggests that this tetraspanin is a powerful activator of 
NFAT/AP-1 signalling. 
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3.3.2 Tspan18 activates NFAT/AP-1 in a dose-dependent manner 
Following the observation that Tspan18 can independently induce NFAT/AP-1 activation, the 
relationship between Tspan18 expression level and its ability to activate NFAT/AP-1 was 
investigated. DT40 cells were transfected with the NFAT/AP-1 reporter and different amounts 
of Tspan18 expression construct (2.5, 5, 10 and 20 g for sample). Tspan18 induced 
NFAT/AP-1 activation in a dose-dependent manner (Figure 3.3A). Tukey’s test demonstrated 
a significant increase in signalling over basal when samples are transfected with high doses of 
Tspan18 (10 and 20 g), but despite the statistical analysis, previous experiments (Figure 3.2) 
showed 5g of Tspan18 could induce a significant response over basal. This suggests a high 
variability among different experiments. The positive control stimulations with PMA and 
ionomycin were similar for each transfection (Figure 3.3B). Samples were analyzed Tukey’s 
test, which did not show any significant difference. Taken together, these data strengthen the 
finding in this chapter that Tspan18 over-expression is sufficient to induce NFAT/AP-1 
activation. 
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Figure 3.2 Tspan18 induces NFAT/AP-1 activation. DT40 cells were transfected with 20 
g of the NFAT/AP-1-luciferase reporter construct, 2 g of -galactosidase expression 
construct and 5 g of the FLAG-tagged tetraspanin. Cells were unstimulated (A.) or were 
stimulated with PMA and ionomycin (B.). Data were normalized for -gal values and 
analyzed by ANOVA test. Statistical significance is indicated by Tukey’s test (*P<0.05). 
Error bars represent the standard deviation of three independent experiments. Whole cell 
lysates were separated by SDS-PAGE, western blotted with an anti-FLAG antibody, and a 
representative blot is shown (C). 
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Figure 3.3 Tspan18 induces NFAT/AP-1 signalling in a dose-dependent manner. DT40 
cells were transfected with the NFAT/AP-1-luciferase reporter, a -galactosidase construct 
and 2.5, 5, 10 or 20 g of Tspan18. Cells were left unstimulated (A.) or were stimulated with 
PMA and ionomycin (B.). Data were normalized for -gal values and analyzed by ANOVA 
test. Statistical significance is indicated by Tukey’s test (*P<0.05). Error bars represent the 
standard deviation of two independent experiments.  
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3.3.3 Tspan18 signalling is Lyn/Syk- and PLC-independent 
As tetraspanin proteins do not possess any enzymatic activity, it is likely that the observed 
NFAT/AP-1 activation is not directly due to Tspan18, but is instead a result of a Tspan18-
associated signalling protein that is activated as a result of Tspan18 over-expression. If this 
theory is correct, and if the putative Tspan18 partner signals via a tyrosine kinase-activated 
PLC2 pathway, similar to the BCR, one would predict that signalling would be impaired in 
the absence of PLC2 or the major DT40 cell PTKs, Lyn and Syk. To address this, DT40 cells 
lacking in both the PTKs Lyn and Syk (Lyn/Syk-) and PLC (PLC2-), which were 
generated by homologous recombination (Ishiai, Sugawara et al. 1999), were transfected with 
Tspan18 and with the NFAT/AP-1 reporter construct. Tspan18 induced substantial 
NFAT/AP-1 activation in mutant cells lacking Lyn/Syk or PLC2 (Figure 3.4A). However, in 
control stimulations these mutant lines failed to respond to B cell receptor stimulation (Figure 
3.4B), as has been observed previously (Tomlinson, Kane et al. 2004). In order to determine 
whether Tspan18 was expressed at similar levels in each cell type, whole cell lysates were 
analyzed by SDS-PAGE and blotted with a FLAG antibody. The result showed that Tspan18 
expression was comparable in each sample (Figure 3.4C). Tspan18 was more readily 
detectable in this experiment than observed previously (Figure 3.2C), because four times 
more DNA was used in the transfection. 
Taken together, these data indicate that Tspan18 does not activate NFAT/AP-1 in a manner 
similar to that of the BCR, which uses ITAMs, PTKs and PLC2. 
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Figure 3.4 Tspan18 signalling is independent of Lyn, Syk and PLCWild-type (WT) 
DT40 cells or cells deficient for Lyn and Syk or PLC2 were transfected with 20g of the 
vector control or FLAG-tagged Tspan18 and with the NFAT/AP-1 reporter and -gal control 
construct. Cells were left unstimulated (A.) or were stimulated with 4 g/ml of anti-BCR 
antibody (B.) Data were normalized for -gal values and analyzed by ANOVA test. Statistical 
significance is indicated by Tukey’s test (*P<0.05). Error bars represent the standard 
deviation of three independent experiments. An aliquot of whole cell lysate was analyzed by 
SDS-PAGE and blotted with the FLAG antibody (C.).  
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3.3.4 Tspan18 signalling mimics the calcium ionophore ionomycin 
The two second messengers generated by PLC, IP3 and DAG, trigger two distinct signalling 
cascades, the calcium and mitogen-activated protein kinase (MAPK) pathways, respectively. 
The optimal NFAT/AP-1 activation requires both calcium and MAPK pathways. To address 
whether Tspan18 is inducing calcium or MAPK signalling, or both, DT40 cells were 
transfected with either the NFAT/AP-1 or AP-1 reporter construct in the presence or absence 
of Tspan18, and cells were stimulated with PMA alone, ionomycin alone, or PMA in 
combination with ionomycin. For the NFAT/AP-1 reporter, in the absence of Tspan18, the 
agonists PMA, ionomycin and PMA plus ionomycin induced a robust activation (Figure 
3.5A). This is consistent with the idea that calcium and MAPK signalling are required for 
optimal NFAT/AP-1 activation, but further shows that calcium alone can induce substantial 
NFAT/AP-1 activation, whereas MAPK alone has a minimal effect. Tspan18 over-expression 
induced significant NFAT/AP-1 activation (Figure 3.5A), similar to the level observed 
previously. However, the combination of Tspan18 and PMA yielded a synergistic response, 
while in contrast the combination of Tspan18 and ionomycin was not significantly different to 
ionomycin alone (Figure 3.5A). These results demonstrate that Tspan18 over-expression 
mimics the effect of ionomycin stimulation, albeit at a weaker level. 
To determine whether Tspan18 over-expression can induce activation of the MAPK pathway, 
the AP-1-luciferase construct was used. Consistent with the idea that this is a MAPK-
responsive reporter, maximal activation was observed with PMA regardless of the presence of 
ionomycin (Figure 3.5B). Tspan18 induced significant but relatively weak AP-1 activation 
(approximately 2.5-fold), similar to that induced by ionomycin (Figure 3.5B). The latter  
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suggests that calcium signalling can induce weak AP-1 activation in this DT40 cell line, 
perhaps due to some cross-talk with the MAPK pathway. The similar effect of Tspan18 and 
ionomycin suggest the idea that Tspan18 primarily activates calcium signalling leading to 
NFAT activation.  
To determine whether Tspan18 activates NFAT/AP-1 in other cell types, the DT40 
experiment shown in Figure 3.5A was repeated for the Jurkat T cell line, a widely used model 
system to study T cell signalling. In contrast to DT40 cells, Tspan18 over-expression did not 
induce significant NFAT/AP-1 activation in Jurkat cells. However, ionomycin also failed to 
activate substantial NFAT/AP-1 (Figure 3.6) in contrast to the activation observed in DT40 
cells (Figure 3.5A). This suggests that in Jurkat cells, unlike DT40 cells, calcium signalling 
alone cannot induce substantial NFAT/AP-1 activation. However, a striking synergy was 
observed between PMA and Tspan18 and between PMA and ionomycin (Figure 3.6). These 
data support the conclusion from the DT40 data that Tspan18 over-expression activates 
NFAT by activating calcium signalling. 
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Figure 3.5 Tspan18 mimics ionomycin. DT40 cells were transfected with NFAT/AP-1 (A) 
or AP-1 (B) reporter constructs, and the -gal control construct, in the presence or absence of 
20 g of the FLAG-tagged Tspan18 construct. Transfected cells were left unstimulated or 
were stimulated with PMA or ionomycin or with a combination of PMA and ionomycin. Data 
were normalized for -gal values and analyzed by ANOVA test. Data were analyzed in pairs 
(with and without Tspan18 of unstim, PMA, iono and PMA+I) employing the Tukey’s test 
(*P<0.05). Error bars represent the standard deviation of three independent experiments.  
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Figure 3.6 Tspan18 synergises with PMA to activate NFAT/AP-1 in Jurkat cells. Jurkat 
cells were transfected with the NFAT/AP-1-luciferase reporter and -gal control constructs in 
the presence or absence of 5 g of the FLAG-tagged Tspan18 construct. Cells were left 
unstimulated or were stimulated with PMA, ionomycin or a combination of PMA and 
ionomycin. Data were normalized for -gal values and analyzed by ANOVA test. Data were 
analyzed in pairs (with and without Tspan18 of unstim, PMA, iono and PMA+I) employing 
the Tukey’s test (*P<0.05), but none of the analyzed samples pairs presented a significant 
difference. Error bars represent the standard deviation of three independent experiments. 
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3.3.5 Tspan18 signalling is IP3R independent 
The Tspan18-induced NFAT/AP-1 activation observed in Lyn/Syk- and PLC2-deficient 
DT40 cells suggests that Tspan18 exerts its effect downstream or independently of PLC2. In 
ITAM-based signalling pathways such as that used by the BCR, the activity of PLC2 
generates the second messengers diacylglycerol and IP3, the latter of which activates IP3 
receptors, which are IP3-gated calcium channels in the endoplasmic reticulum. To test 
whether Tspan18 can activate NFAT/AP-1 independently of IP3Rs, DT40 cells lacking in all 
three IP3Rs, generated previously by homologous recombination (Sugawara, Kurosaki et al. 
1997), were used. Tspan18-induced NFAT/AP-1 activation was reduced in the absence of the 
IP3 receptors, but only by approximately 50% (Figure 3.7A), demonstrating that the IP3 
receptors are not essential for Tspan18 signalling. Control stimulations with anti-BCR  
antibody did not activate NFAT/AP-1 in the IP3 receptor-deficient cells (Figure 3.7B), 
consistent with the idea that IP3 receptors are essential components of the BCR signalling 
pathway leading to calcium release (Kurosaki, Maeda et al. 2000) .  
In order to check Tspan18 expression, whole cell lysates of each sample were analyzed by 
SDS-PAGE and blotted with the FLAG antibody. The result showed a similar Tspan18 
expression in wild-type and IP3 receptor-deficient cells (Figure 3.7C). These results show that 
Tspan18-induced NFAT/AP-1 activation is partially dependent on the IP3 receptors, but that 
they are not essential. This suggests a signalling role for Tspan18 downstream of IP3 
receptors. 
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Figure 3.7 Tspan18 signalling is maintained in the absence of IP3 receptors. Wild-type 
(WT) DT40 cells or IP3 receptor-deficient DT40 cells were transfected with control vector or 
FLAG-tagged Tspan18, and with the NFAT/AP-1 reporter and the -gal construct. Cells were 
left unstimulated (A.) or were stimulated with 4 g/ml of BCR receptor antibody (B.). Data 
were normalized for -gal values and analyzed by ANOVA test. Statistical significance is 
indicated by Tukey’s test (*P<0.05). Error bars represent the standard deviation of three 
independent experiments. . An aliquot of whole cell lysate was analyzed by SDS-PAGE and 
blotted with the FLAG antibody (C). 
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3.3.6 Tspan18 signalling is independent of STIM1 
When IP3 receptors release calcium, so emptying ER stores, the calcium sensor STIM1 
induces clustering and opening of Orai1-containing plasma membrane ICRAC channels, to 
cause calcium entry and sustained calcium elevation, leading to NFAT activation (Hogan and 
Rao 2007). To determine whether Tspan18 requires STIM1 for its activation of NFAT 
signalling, DT40 cells rendered deficient in STIM1 by homologous recombination (Baba, 
Hayashi et al. 2006) were utilised. Tspan18-induced NFAT/AP-1 activation was reduced by 
60% in the absence of STIM1, but this reduction in signalling was not significant (Figure 
3.8A). Moreover, in the absence of STIM1, BCR-induced NFAT activation was similarly 
impaired, but not completely abrogated (Figure 3.8B). As observed for the other mutants, 
expression levels of FLAG-tagged Tspan18 were similar between wild-type and STIM1-
deficient cells (Figure 3.8C). Together these data suggest that either Tspan18 is acting 
downstream of STIM1, or that Tspan18 is upstream but there is some compensation for the 
lack of STIM1, such as by the other family member STIM2. The latter possibility is supported 
by the residual BCR signal in the absence of STIM1. Future experiments could be performed 
using STIM1/STIM2 doubly-deficient DT40 cells or using an RNAi knockdown approach. 
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Figure 3.8 Tspan18 signalling is independent of STIM1. Wild-type (WT) or STIM1-
deficient DT40 cells were transfected with the FLAG-tagged Tspan18 and with NFAT/AP-1 
reporter and -gal control construct. Cells were left unstimulated (A) or were stimulated with 
4 g/ml of BCR receptor antibody (B.) An aliquot of whole cell lysate was analyzed by SDS-
PAGE and blotted with the FLAG antibody (C). Data were normalized for -gal values and 
analyzed by ANOVA test. Statistical significance is indicated by Tukey’s test (*P<0.05). 
Error bars represent the standard deviation of three independent experiments.  
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3.3.7 Tspan18 signalling is dependent on extracellular calcium 
To distinguish the relative importance of calcium release from internal stores and extracellular 
calcium entry across the plasma membrane, Tspan18 signalling was investigated using the 
extracellular calcium chelator EGTA. DT40 cells were transfected with Tspan18 and with the 
NFAT/AP-1 reporter. Transfected cells were left untreated or were treated with 4 mM EGTA. 
The data demonstrated that Tspan18 signalling was completely blocked by the presence of 
EGTA (Figure 3.9A). Control stimulations with PMA and ionomycin also failed to induce 
NFAT/AP-1 activation in the presence of EGTA (Figure 3.9B). 
As EGTA completely blocked Tspan18 signalling, this could be due to a global inhibition of 
signalling. In order to address this, the previously used AP-1 reporter was employed. The 
results demonstrated that EGTA was not toxic to the cells, as they retained partial AP-1 
signalling capability (Figure 3.9C), and enforced the previous findings of Tspan18 
involvement in calcium signalling. Moreover, the partial reduction in AP-1 signalling 
suggests that AP-1 signalling pathways might be partially calcium dependent, indicating a 
possible pathway cross-talk.  
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Figure 3.9 EGTA can block Tspan18 signalling. DT40 cells were transfected with the 
NFAT/AP-1 reporter and the -gal construct, and with 20 g of the control vector or FLAG-
tagged Tspan18. Cells were left untreated or treated with 4mM EGTA (A). DT40 cells were 
transfected with the NFAT/AP-1 or AP-1 reporter, in the absence of Tspan18 (B and C, 
respectively). Cells were left unstimulated or stimulated with PMA and ionomycin (B) or 
PMA alone (C). EGTA was added immediately following the transfection. Data were 
normalized for -gal values and analyzed by ANOVA test. Statistical significance is indicated 
by Tukey’s test (*P<0.05). Error bars represent the standard deviation of two independent 
experiments.  
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3.3.8 Tspan18 signalling is dependent on calcineurin activity 
Calcineurin is a calcium-activated cytoplasmic phosphatase that can activate NFAT by 
dephosphorylation, resulting in its translocation into the nucleus. Calcineurin activity can be 
selectively blocked by the immunosuppressive drug cyclosporin A (Liu 2009). Therefore this 
drug was used to test whether Tspan18-induced NFAT/AP-1 activation was dependent on 
calcineurin activity. 
DT40 cells were transfected with the NFAT/AP-1-luciferase reporter construct and either 
vector control or the Tspan18 construct, and cells were left untreated or treated with 
cyclosporin A. The data demonstrated that cyclosporin A was able to completely block 
NFAT/AP-1 activation induced upon Tspan18 over-expression (Figure 3.10A). These data 
suggest Tspan18 signalling is calcineurin dependent. 
As a control for cyclosporin A treatment, the drug completely inhibited NFAT/AP-1 
activation induced by the combination of PMA and ionomycin (Figure 3.10B). However, it is 
possible to speculate from these data that cyclosporin A was not specifically inhibiting 
calcineurin, but was instead globally inhibiting signalling by killing the cells, for example. 
However, AP-1 activation was unaffected by cyclosporin A (Figure 3.10C), suggesting that 
the drug is not toxic to the cells and strengthening the finding that Tspan18 signalling is 
calcineurin dependent. 
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Figure 3.10 Tspan18 signalling is blocked by cyclosporin A. DT40 cells were transfected 
with -gal control construct, with 20 g of control vector or FLAG-tagged Tspan18, and with 
the NFAT/AP-1 (A and B) or the AP-1 reporter (C). Cells were left unstimulated or 
stimulated with PMA or PMA and ionomycin, in the presence or absence of 2 mM 
cyclosporin A, as indicated. Cyclosporin A was added to the medium immediately after 
transfection, while agonists were added 16 hours after the transfection. Data were normalized 
for -gal values and analyzed by ANOVA test. Statistical significance is indicated by Tukey’s 
test (*P<0.05). Error bars represent the standard deviation of two independent experiments. .  
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3.4 DISCUSSION 
In this chapter, the possibility that platelet-expressed tetraspanin proteins could induce 
NFAT/AP-1 signalling has been tested, and the mechanism by which Tspan18 over-
expression induces NFAT/AP-1 activation was investigated using DT40 cells lacking in 
proteins involved in the BCR signalling pathway (Syk, Lyn, PLC2, IP3Rs and STIM1), 
inhibitors (EGTA and cyclosporin A) and agonists (anti-BCR antibody, PMA and 
ionomycin). The results demonstrated that, among the tested platelet tetraspanin proteins, only 
Tspan18 is able to induce NFAT/AP-1 signalling. Tspan18-induced activation is independent 
of Syk, Lyn, PLC2, IP3Rs and STIM1 but dependent on extracellular calcium and 
calcineurin. Moreover, Tspan18 over-expression mimics the effect of ionomycin, both in 
DT40 and in Jurkat cells, suggesting that Tspan18 activates NFAT/AP-1 by inducing calcium 
signalling. 
A prediction of the original hypothesis was that Tspan18-induced NFAT/AP-1 activation 
would be abrogated in the absence of Lyn and Syk or PLC2, since BCR signalling is 
abrogated in cells lacking these signalling proteins. However, Tspan18 signalling was 
completely unaffected in these mutant DT40 cells. Moreover, the Tspan18 signal was not 
significantly affected in the absence of the three IP3 receptors, which are key players in store-
operated calcium entry leading to NFAT activation. These findings suggested that Tspan18 is 
exerting its effect downstream or independent of the IP3 receptors, perhaps at the level of 
calcium entry or through activation of NFAT itself. The latter possibility was ruled out by the 
finding that cyclosporin A, an immunosuppressive drug that inhibits the NFAT-activating, 
calcium-activated phosphatase calcineurin, completely inhibited Tspan18-induced NFAT/AP-
1 activation. This data further suggested that Tspan18 might be activating NFAT by inducing 
calcineurin activation or calcium signalling. The latter was supported by complete inhibition 
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of Tspan18 signalling by EGTA, which chelated extracellular calcium, so preventing store-
operated calcium entry. Taken together, these data support the possibility that Tspan18 
induces calcium signalling by activating a calcium channel or calcium channel regulator.  
In recent years extensive research has been performed in the field of calcium signalling 
following the discovery of two players in the store-operated calcium entry (SOCE) 
mechanism, STIM1 and ORAI1. STIM1 detects calcium release from the ER stores and 
induces clustering of the calcium channel Orai1 and channel opening (Barr, Bernot et al. 
2008). In this chapter it has been demonstrated that Tspan18-induced NFAT/AP-1 activation 
is only partially dependent on STIM1. It is possible to speculate that STIM2, whose role has 
not been fully elucidated yet, might play a role in calcium signalling, and might be able to 
partially compensate for the lack of STIM1. A possible strategy to test this hypothesis might 
be to evaluate Tspan18 signalling in DT40 cells lacking in both STIM1 and STIM2, that have 
been recently developed (Wang, Deng et al. 2009). A second interpretation of the result might 
be that Tspan18 function is located downstream of STIM1. However, the partial BCR-
induced signal in STIM1-deficient cells suggests that they can compensate for the lack of this 
protein, thus making the Tspan18 data difficult to interpret. Studies using the agonists PMA 
and ionomycin, in both DT40 B cells and Jurkat T cells, demonstrated that Tspan18 over-
expression mimics the effect of ionomycin. This was observed in a number of ways. Firstly, 
both ionomycin and Tspan18 induced substantial NFAT/AP-1 activation in DT40 cells. 
Secondly, both induced relatively weak NFAT/AP-1 activation in Jurkat, and similarly weak 
AP-1 activation in DT40 cells. Thirdly, in both cell types, Tspan18 and ionomycin each 
synergised with PMA to induce NFAT/AP-1 activation. In combination with the inhibition of 
Tspan18 signalling by calcineurin and EGTA, this strongly suggests that Tspan18 over-
expression induces calcium signalling. 
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Two findings in the previous paragraph are worthy of further discussion. The first is the fact 
that DT40 and Jurkat were different in their capacity to activate NFAT/AP-1 in response to 
ionomycin or Tspan18: relatively strong activation was observed in DT40 and very weak 
activation occurred in Jurkat. The reason for this is not clear, but it is possible that calcium 
elevation in DT40 can induce a low level of AP-1 activation. This signalling pathway ‘cross-
talk’ may not exist in Jurkat. A second related discussion point is the fact that ionomycin and 
Tspan18 can induce weak AP-1 activation in DT40 cells, supporting the idea of pathway 
cross-talk. A possible mechanism for this was presented in a recent study by the Parekh group 
(Ng, Nelson et al. 2009) In this study, calcium entry via ICRAC channels in the plasma 
membrane activated MAPK and c-fos, a component of the AP-1 complex, via a Syk-
dependent pathway (Ng, Nelson et al. 2009). Interestingly, DT40 cells express Syk but Jurkat 
do not, thus providing a potential explanation for observed differences between the two cell 
lines. 
 
3.5 SUMMARY 
In the present chapter it has been demonstrated that: 
 Tspan18 is the only tetraspanin, amongst those platelet tetraspanins tested, to be able 
to induce constitutive NFAT/AP-1 signalling 
 Tspan18 signalling is independent of Lyn/Syk and PLC2  
 Tspan18 mimics ionomycin in its capacity to activate NFAT/AP-1 in DT40 B and 
Jurkat T cells, and, in particular, synergises with PMA 
 Tspan18 signalling is partially impaired in the absence of IP3R receptors and STIM1 
 Constitutive Tspan18 signalling is dependent on calcineurin and extracellular calcium
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4.1 INTRODUCTION 
In the previous Chapter, Tspan18 was found to be the only tetraspanin protein, amongst a 
panel of platelet-expressed tetraspanins, to be able to induce NFAT/AP-1 signalling in the 
DT40 luminometry assay.  
Tspan18 was firstly identified in 1999 by Perron and Bixby in the chicken embryonic spinal 
cord (Perron and Bixby 1999). This study reported the presence of the tetraspanins Tspan4 
(previously called NAG-2) and CD9, and the presence of a third novel protein, neurospanin 
(later renamed Tspan18). Nothern blot experiments revealed that Tspan18 mRNA is highly 
expressed in the developing brain, suggesting that Tspan18 might play a role in nervous 
system development (Perron and Bixby 1999). The Ouwehand research group later identified 
Tspan18 mRNA in human megakaryocytes (Macaulay, Tijssen et al. 2007), while we reported 
Tspan18 mRNA expression in mouse megakaryocytes and CD4-positive helper T cells 
(Protty, Watkins et al. 2009). The Sickmann group, employing proteomic techniques, recently 
demonstrated the presence of Tspan18 in human platelets (Lewandrowski, Wortelkamp et al. 
2009). 
At present, a Tspan18 antibody is not available, and this limits the research work that can be 
performed to further study this protein. Tspan18 thus remains an uncharacterized tetraspanin 
protein. Before proceeding in further functional studies, this chapter aimed to perform a 
preliminary characterization of Tspan18 using bioinformatics and quantitative real-time 
polymerase chain reaction (qRT-PCR).   
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4.2 AIM 
The aims of this Chapter were twofold. The first was to perform a preliminary Tspan18 
characterization, based on the data already present in public bioinformatic databases. The 
second was to delineate the Tspan18 expression profile using qRT-PCR, employing both a 
panel of primary cells and cell lines and a panel of mouse tissues.  
 
4.3 RESULTS 
4.3.1 Tspan18 bioinformatic analysis 
Using the NCBI database, it was possible to perform a preliminary Tspan18 characterization. 
The human Tspan18 gene was found to be located on chromosome 11, specifically in position 
11p11.2. The gene was found to have 10 exons and a total length of 71,836 bp 
(NC_000011.8). The mRNA appeared to undergo an alternative splicing process to generate 
two different Tspan18 mRNAs (NM_130783 and NM_001031730). The two different 
mRNAs encode for proteins with distinct C-termini: Tspan18 isoform 1 (NP_001026900) and 
Tspan18 isoform 2 (NP_570139).  These two isoforms differ only in their use of different 
final exons (Figure 4.1).  
Tspan18 isoform 1 was found to consist of 267 amino acids with a predicted molecular 
weight of 29.4 KDa, whereas isoform 2 had 248 amino acids with a predicted molecular 
weight of 27.7 KDa. There were no cytoplasmic signalling motifs which might suggest how 
Tspan18 could activate the NFAT/AP-1 promoter. ClustalW2 analysis showed that the two 
proteins had 93% amino acid identity and differed only at the carboxy terminus (Figure 4.2).  
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Figure 4.1 Schematic representations of Tspan18 gene structure and protein isoforms. A 
schematic diagram of the human Tspan18 gene structure is shown in the top panel, with exons 
common to the two isoforms in dark blue, the two alternatively spliced exons in green and 
grey, and introns in pale blue.  
 
                       
Figure 4.2 Sequence alignments of human Tspan18 isoforms 1 and 2. The amino acid 
sequences of human Tspan18 isoforms 1 and 2 were aligned using the ClustalW2 program. The 
TMHMM program was used to predict the domain organization. Legend: TM transmembrane, SEL 
small extracellular loop, LEL large extracellular loop. In black are written Tspan18 isoform 1 and 2 
common domains, in red are highlighted the specific Tspan18 isoform 2 domains. The amino acids are 
colour coded red (small or hydrophobic), blue (acidic), magenta (basic), green (hydroxyl or amine or 
basic) or grey (other amino acid not previously classified). Asterisks under each letter correspond to 
identical amino acids, colons represent conserved substitutions, and dashes represent missing amino 
acids. 
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Using four different transmembrane protein prediction programs, (TMHMM, PredictProtein, 
MEMSAT and DAS) it was possible to predict the location of the transmembrane regions of 
Tspan18 isoforms 1 and 2. The TMHMM program (accessible at 
http://www.cbs.dtu.dk/services/TMHMM/) predicts the location of transmembrane domains 
based on the hidden Markov model (Sonnhammer, von Heijne et al. 1998). After sequence 
analysis, the program provides a bioinformatic prediction, expressed as a confidence value 
between 0 and 1. Tspan18 isoform 2 appeared to contain the four transmembrane domains 
that are characteristic of tetraspanins (Figure 4.3A). In contrast, isoform 1 appeared to be 
composed of only three transmembrane domains, with an extracellular carboxy terminus, 
although the confidence value of this prediction was just 0.4, indicating 40% probability 
(Figure 4.3A). The PredictProtein program (accessible at http://www.predictprotein.org/) 
predicts locations of transmembrane helices based on evolutionary profiles (Rost, Fariselli et 
al. 1996) .Using the PredictProtein program, and taking into consideration the “best model” 
output, both Tspan18 isoform 2 and Tspan18 isoform 1 appeared to contain four 
transmembrane domains. The overall reliability of the models, both for Tspan18 isoform 1 
and Tspan18 isoform 2, is 6 on a scale between 0 and 9, where 1 is the lowest value and 9 the 
highest value (Figure 4.3B). The MEMSAT3 program (accessible at 
http://bioinf4.cs.ucl.ac.uk:3000/psipred) is an improved version of the MEMSAT program, 
which is based on the recognition of topological models (Jones, Taylor et al. 1994; Jones 
2007). The analysis with this program suggested that Tspan18 isoform 2 and Tspan18 isoform 
1 consisted of four transmembrane domains (Figure 4.3C). The DAS-TMfilter program 
(accessible at http://www.enzim.hu/DAS/DAS.html) is based on the analysis of low-
stringency dot-plots of the amino acid sequence against a collection of non-homologous 
membrane proteins using a previously derived, special scoring matrix (Cserzo, Eisenhaber et 
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al. 2002). The DAS-TMfilter program generates a graphic, and presents two cutoff values: a 
loose cutoff value, used to predict the exact transmembrane domain from the inserted amino 
acid sequence, and a strict cutoff value, used to determine how many transmembrane domains 
are contained in the sequence. Tspan18 isoform 2 clearly presented four tranmembrane 
domains, with a clear hydrophobic region in the large extracellular loop, between the amino 
acids 160 and 220. Tspan18 isoform 1 presented four peaks, suggesting four transmembrane 
domains, despite the fourth peak appearing to be thinner and of lower intensity, suggesting a 
lower confidence value for this peak (Figure 4.3D). In conclusion, from the data collected 
with four different transmembrane prediction programs, it is highly likely that Tspan18 
isoform 2 has four transmembrane domains, in common with other tetraspanins. The data 
collected so far regarding Tspan18 isoform 1 is not so clear, but three of the four prediction 
programs indicate that this isoform has four transmembrane domains. Therefore Tspan18 
isoform 1 has two possible structures: a more probable structure with four transmembrane 
domains, or a less likely structure with three transmembrane domains (Figure 4.3E).  
 
 
 -99-
Chapter 4 
 
 -100-
Chapter 4 
 -101-
Chapter 4 
 
 
 -102-
Chapter 4 
 
 
 
 
 
 -103-
Chapter 4 
E. 
 
Figure 4.3 Bioinformatic prediction of Tspan18 isoform 2 and Tspan18 isoform 1 
transmembrane domains. Tspan18 isoform 2 and Tspan18 isoform 1 sequences have been 
analyzed with the TMHMM (A), PedictProtein (B), MEMSAT (C) and DAS (D) prediction 
programs to identify the trasmembrane domains. In panels A, B and C, the first column 
represents the amino acid sequence, the second column the domain prediction and the third 
the degree of confidence expressed between the values 0 and 1 (A and B), or as a score (C). 
The DAS program produces the results as a graphic representation. On the X axis is the amino 
acid posistion of the analyzed sequence, while on the Y axis the degree of confidence is 
expressed between values of 0 and 8. The loose cut off is indicated at a value of 1.8, and the 
strict cut off is indicated at a value of 2.2 (D). Schematic representation of hypothetical 
Tspan18 conformations, based on the TMHMM prediction. Tspan18 isoform 2 amino acid 
sequence is represented in blue. The two alternate possibilities for the Tspan18 isoform 1 
carboxy-terminus are represented in red (E).  
 
 
 
 
 -104-
Chapter 4 
In order to determine in which organisms the two Tspan18 isoforms are expressed, Tspan18 
isoform 1 and Tspan18 isoform 2 sequences were analyzed using the Basic Local Alignment 
Search Tool (BLAST) tool of the NCBI database, performing a search across all the 
organisms available in the protein sequences database. Tspan18 isoform 1 was found to be 
expressed in human, chimp (Pan troglodytes) and macaque monkey (Macaca mulatta) 
(Figure 4.4A), while Tspan18 isoform 2 was found to be expressed in mammals, birds, 
amphibians and fish (Figure 4.4B). Tspan18 isoform 2 appeared to be well conserved between 
species, with amino acid identities varying between 99% (Homo sapiens versus Pan 
troglodytes) and 69% (between Pan troglodytes and Danio rerio) (Figure 4.4C).  
In order to determine in which tissues Tspan18 is expressed, an analysis of human Tspan18 
(Unigene number Hs.385634) was conducted using the Expression Sequence Tags (ESTs) 
profile of the Unigene NCBI database. Based on these data, Tspan18 appears to be expressed 
in most body sites, health states and developmental stages (Figure 4.4D). However, the 
general expression level is relatively low. For example, as a comparison, CD9 and CD81 are 
commonly expressed at levels of 100-500 ESTs per million in different tissues (data not 
shown), whereas very few tissues express Tspan18 at a level greater than 50 ESTs per 
million, a number which is often derived from less than five total ESTs per EST library 
(Figure 4.4D). Due to this relatively low level of expression, it is not possible to accurately 
define the Tspan18 expression profile from EST data. 
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Figure 4.4 Tspan18 bioinformatics analysis. Amino acid lineup of Tspan18 isoform 1 from 
human (Homo sapiens), chimp (Pan troglodytes) and macaque (Macaca mulatta) (A.). Amino 
acid lineup of Tspan18 isoform 2 in primates and cow (Bos taurus), mouse (Mus musculus), 
rat (Rattus norvegicus), chicken (Gallus gallus), frog (Xenopus tropicalis) and zebrafish 
(Danio rerio) (B.). The amino acids are colour coded red (small or hydrophobic), blue 
(acidic), magenta (basic), green (hydroxyl or amine or basic) or grey (other amino acid not 
previously classified). Asterisks under each letter correspond to identical amino acids, colons 
represent conserved substitutions, full stops represent semi-conserved substitutions, and 
dashes represent missing amino acids. Tspan18 isoform 2 is highly conserved among species, 
with amino acid identities between 99% (Homo sapiens versus Pan troglodytes) and 69% 
(Pan troglodytes versus Daino rerio), as indicated in the final ‘Score’ column (C.). Human 
Tspan18 EST profile by body sites, health states and developmental stages. The first column 
represents the source, the second the transcripts per million (TPM), the third the predicted 
intensity of the spot based on TPM, and the fourth represents the number of Tspan18 ESTs 
compared to the total ESTs in the pool (D.). 
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4.3.2 Tspan18 qRT-PCR expression profile 
In order to determine the Tspan18 expression profile, the qRT-PCR technique was employed. 
For each sample of cells or tissue, total RNA was extracted, RNA was converted into cDNA, 
and cDNA was analyzed by qRT-PCR.  
Tspan18 isoform 2 expression was firstly assessed in a panel of human cell lines and primary 
cells. The result showed that Tspan18 isoform 2 was expressed most strongly in HMEC-1 and 
HUVEC endothelial cells and in peripheral blood leucocytes, more weakly in DG75 B cells, 
Jurkat T cells, hepatocytes and U937 monocytes, but not at all in the others tested (Figure 
4.5A). In contrast, isoform 1 was not detected at substantial levels in any cell type (Figure 
4.5B), suggesting that this isoform may not be expressed. However, this does not rule out the 
possibility that this isoform is expressed in a subpopulation of cells such as peripheral blood 
leukocytes, which appeared to have the highest level of those tested (Figure 4.5B). 
The expression profile of the mouse homologue of Tspan18 was further examined by qRT-
PCR from a panel of mouse tissues. The result showed that Tspan18 isoform 2 was relatively 
highly expressed in mouse lung, while expression in the other analyzed tissues was 
approximately 10-fold lower (Figure 4.6). This is consistent with the relatively strong 
endothelial cell expression observed for human Tspan18 (Figure 4.5), since lung tissue 
contains a relatively large proportion of endothelial cells. Indeed, qRT-PCR analysis of RhoJ, 
a bone fide endothelial-specific gene, yielded similar data to Tspan18 from this panel of 
tissues (S Kaur and V Heath, unpublished data). 
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Figure 4.5 Human Tspan18 qRT-PCR expression profile in different primary cells and 
cell lines. Each sample was normalized for the relative qRT-PCR actin value. Data were adjusted 
such that Tspan18 isoform 2 expression in HUVEC was 100 (A.). qRT-PCR expression profile of 
Tspan18 isoform 1 in different cell lines. Data were adjusted such that Tspan18 isoform 2 
expression in HUVEC was 100 (in red) (B.) Error bars represent the standard error of two independent 
experiments. The cell types were PBL (peripheral blood leukocytes), DAMI (megakaryocytic cell 
line), DG75 (B cell line), Jurkat (T cell line), K562 (erthythroleukaemia cell line), HBP-ALL (T cell 
line), HEL (erythroleukaemia cell line), HEK-293T (embryonic kidney cell line), HUVEC (umbilical 
vein endothelial cell)  MDA-MB-231 (epithelial cell line), HMEC-1 (microvascular endothelial cell 
line), RAJI (B cell line), U937 (monocyte cell line).  
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Figure 4.6 Mouse Tspan18 qRT-PCR expression profile in different mouse tissues. Each 
sample was normalized for the relative qRT-PCR HPRT (hypoxanthine phosphoribosyl 
transferase) value. Data were adjusted such that mouse Tspan18 isofom 2 expression in lung tissue 
was 100. Error bars represent the standard error of three independent experiments. 
 
 -113-
Chapter 4 
4.4 DISCUSSION 
In this Chapter, the Tspan18 gene and protein sequence were characterized using data in 
public sequence databases, and the Tspan18 expression profile was evaluated using the qRT-
PCR technique. The bioinformatics analysis revealed two Tspan18 protein isoforms expressed 
in humans, Pan troglodytes and Macaca mulatta, generated by the alternative splicing of the 
last exon. The qRT-PCR data suggested that only one of these isoforms was expressed at 
substantial levels (Tspan18 isoform 2), and further suggested relatively strong endothelial 
expression and weaker expression in leukocytes. 
The alternative Tspan18 splicing form, Tspan18 isoform 1, appears to be a relatively recent 
development in evolution, since this does not occur in more primitive mammals, chicken, frog 
or fish. While Tspan18 isoform 2 contains the canonical four transmembrane regions typical 
of tetraspanins, the bioinformatics domain prediction did not unequivocally reveal if the last 
exon of isoform 1 is a transmembrane domain or an extracellular domain, as three of the four 
employed programs to predict the location of the transembrane indicated that this isoform 
present four transmembrane domains. Nevertheless, it is possible that, this less likely and 
atypical isoform 1, may have a distinct function from the more classical isoform 2, or might 
regulate the function of isoform 2 by acting as a dominant negative. A key function of the 
carboxy-terminus of tetraspanins is not without precedent. For example, the carboxy-terminus 
of CD63 contains intracellular targetting motifs and PDZ-binding motifs (Berditchevski and 
Odintsova 2007). In addition, the carboxy-terminus of CD151 is essential for the regulation of 
integrin function (Lammerding, Kazarov et al. 2003). However, the qRT-PCR data suggested 
that this atypical isoform is either not expressed or is expressed at very low levels compared 
to isoform 2. It is nevertheless possible that isoform 1 is expressed in a subpopulation of cells 
such as leukocytes. The future generation of an isoform 1-specific antibody would address 
 -114-
Chapter 4 
this issue at the protein level. 
Bioinformatics of Tspan18 species homologues further revealed that Tspan18 protein 
sequence is relatively highly conserved and expressed in a broad range of healthy and 
pathological tiessues. However, Tspan18 sequence conservation, at least at the level of human 
versus mouse, is quite typical of other tetraspanins (Tomlinson, JTH, 2009). 
The qRT-PCR data revealed that Tspan18 has a restricted expression profile. The mouse 
homologue was relatively highly expressed in lung, which is suggestive of strong endothelial 
cell expression, since the endothelial-specific gene RhoJ showed the same expression pattern 
in mouse tissues (S Kaur and V Heath, unpublished data). Moreover, human Tspan18 isoform 
2 was relatively highly expressed in the endothelial cells tested. However, Tspan18 is clearly 
not restricted to this cell type. Expression was also detected in human peripheral blood 
leucocytes, consistent with our earlier identification of expression in CD4-positive helper T 
cells, with weak expression in some lymphocyte cell lines and hepatocytes. In addition, 
Tspan18 has been identified in human platelets using proteomics (Lewandrowski, 
Wortelkamp et al. 2009). The future generation of an antibody is essential to determine in 
precisely which cell types Tspan18 protein is expressed. 
The qRT-PCR technique is well established for the quantitation of gene expression 
(VanGuilder, Vrana et al. 2008). The qRT-PCR technique employed in this study uses a 
Corbett Rotorgene 6000 qRT-PCR machine, which has some technical advantages over a 
conventional block qRT-PCR. For instance, as the amplification reaction is performed on a 
spinning rotor, the samples are exposed to less thermal variation than the conventional qRT-
PCR, resulting in increased reproducibility (Kim, Yang et al. 2008). 
An intrinsic necessity of the qRT-PCR technique employed in this Chapter is tissue 
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homogenization. This step inevitably destroys the tissue morphology, and it is not possible to 
identify where in the organ the mRNA is expressed. A possible strategy that could 
complement the data collected so far is in situ hybridisation. This technique involves the 
hybridization of a labeled complementary nucleic acid to allow the visualization of a specific 
mRNA on a tissue section, so preserving the tissue morphology (Jin and Lloyd 1997). The 
employment of this technique in future would address whether Tspan18 is relatively highly 
expressed on endothelial cells, particularly if a mouse embryo was used, in which the 
vasculature can be readily detected. 
 
4.5 SUMMARY 
In the present Chapter it has been demonstrated that: 
 In humans, Tspan18 protein consists of two isoforms, Tspan18 isoform 1 and Tspan18 
isoform 2, deriving from the alternative splicing of the last gene exon. 
 Bioinformatic analysis revealed that it is lickely Tspan18 isoform 1 contains four 
transmembrane domains, and is expressed, in addition to humans, in Macaca mulatta 
and Pan troglodytes. 
 qRT-PCR analysis revealed that Tspan18 isoform 1 is expressed at 5- to 20-fold lower 
than isoform 2, if at all. isoform 2 appears to be relatively highly expressed in 
endothelial cells, with weaker expression in leukocytes and hepatocytes but not other 
cell types tested. 
 Tspan18 isoform 2 is highly expressed in mouse lung and is expressed 10-fold lower 
in the other tested tissues, consistent with strong endothelial cell expression.
Chapter 5 
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5.1 INTRODUCTION 
5.1.1 Overview 
In Chapter 3, Tspan18, a novel and previously uncharacterized tetraspanin protein, was found 
to be able to induce NFAT/AP-1 activation when over-expressed in the DT40 B cell line. 
Moreover, a preliminary bioinformatic characterization, performed in Chapter 4, revealed that 
in humans Tspan18 exists as two different isoforms, Tspan18 isoform 1 and Tspan18 isoform 
2. The qRT-PCR expression profile demonstrated that Tspan18 isoform 2 is expressed in both 
cell lines and primary cells (particularly HMEC-1 and HUVEC endothelial cells), while a 
mouse tissue analysis revealed that Tspan18 isoform 2 is highly expressed in mouse lung 
tissues, consistent with relatively strong endothelial expression. Tspan18 isoform 1, however, 
was not readily detectable in the cell types analyzed.  
At present, a Tspan18 antibody is not available, and it is not possible to study Tspan18 
protein in tissue sections or perform biochemical assays assessing expression levels of 
endogenous Tspan18. In order to overcome this technical problem and perform a preliminary 
Tspan18 characterization using biochemical approaches, a human FLAG-tagged Tspan18 
isoform 2 protein construct was employed in this chapter.  
 
5.1.2 Lipid rafts 
Lipid rafts are defined as “small (10–200 nm) heterogeneous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalize cellular processes. Small rafts can 
sometimes be stabilized to form larger platforms through protein–protein and protein–lipid 
interactions” (Pike 2009). Lipid raft membrane microdomains are enriched in 
glycosphingolipids, cholesterol, glycosylphosphatidylinositol-anchored proteins and Src 
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family kinases; they appear to play many roles, especially in immune-receptor signalling. 
Lipid rafts play a critical role in the recruitment and the formation of multi-protein signalling 
complexes. The concept of lipid rafts as signalling platforms was proposed in 1997 (Simons 
and Ikonen 1997).  
Tspan18 contains a conserved amino-terminal CXXC motif. Such a motif, in LAT family 
adapters and when palmitoylated, targets these proteins to lipid rafts (Lin, Weiss et al. 1999). 
In this chapter, the raft localization of Tspan18 will be investigated, alongside two other 
tetraspanins, Tspan9 and CD9, because of the presence and absence of CXXC motifs in these 
proteins, respectively. 
 
5.1.3 Glycosylation and palmitoylation 
Proteins can undergo several post-translational modifications, some of which include the 
addition of lipid molecules (Folch, Arsove et al. 1951). S-palmitoylation is the reversible 
addition of a fatty acid (palmitate) to proteins on cysteine residues via a thioester bond (Joyoti 
2004). This post-translational modification is reversible, in contrast to myristoylation. S-
palmitoylation can regulate several protein functions, including trafficking, localization, 
partitioning into microdomains, and protein-protein interactions (Joyoti 2004). 
Palmitoylation is a key protein modification that supports the assembly of tetraspanin 
complexes. Removal of palmitoylation sites from tetraspanin proteins does not disrupt 
primary tetraspanin associations, such as CD9-CD9, CD151-or CD151-
associations (Berditchevski, Odintsova et al. 2002; Kovalenko, Yang et al. 2004; Yang, 
Kovalenko et al. 2004), but does reduce secondary tetraspanin associations, resulting in 
impaired cell signalling and altered cell morphology (Hemler 2008). Moreover, CD81 
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palmitoylation is implicated in regulating the B cell receptor complex. The Pierce research 
group showed that CD81 palmitoylation is necessary for sustained localization of the 
CD19/CD21/CD81 B cell co-receptor complex to lipid rafts and for sustained BCR signalling 
(Cherukuri, Shoham et al. 2004), although this has recently been challenged (Sanyal, 
 mediating and modulating cell adhesion and cell 
D151, for example, regulates integrin glycosylation (Baldwin, Novitskaya et 
 and GFP-
ed into HEK-293T or DT40 cell lines.  
 
Fernandez et al. 2009). 
Glycosylation is the enzymatic process that links complex heteropolymeric sugars to proteins 
or lipids (Taylor and Drickamer 2006). Sugars can be attached to proteins either through a 
nitrogen atom (N-linked) or an oxygen atom (O-linked). The function of glycosylation can be 
categorized in the following five broad categories: providing structural components (cell 
walls and extracellular matrix), modifying protein properties (solubility and stability), 
directing trafficking of glycoconjugates,
signalling (Taylor and Drickamer 2006). 
Most tetraspanins contain at least one N-glycosylation site, while several contain two, three or 
even four sites (Tarrant, Robb et al. 2003). Although the precise role of tetraspanin 
glycosylation is not known, tetraspanins can affect the glycosylation of their molecular 
partners. C
al. 2008).  
 
5.2 AIM 
The aim of this chapter was to investigate the sub-cellular localisation and to perform a 
preliminary biochemical characterization of Tspan18 using amino-terminal FLAG-
tagged human Tspan18 constructs, transfect
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5.3 RESULTS 
5.3.1 Study of Tspan18 subcellular localization 
In order to determine the subcellular localization of Tspan18 in the absence of a Tspan18 
antibody, an amino-terminal GFP-tagged Tspan18 construct was generated, transfected into 
DT40 cells, HEK-293T cells, and C2C12, and analysed by confocal microscopy two days 
post-transfection. DT40 were chosen because of the observed Tspan18 signalling phenotype 
in these cells (Chapter 3). In DT40 cells, the non-receptor protein tyrosine kinase Btk was 
used as a cytoplasmic control, alongside Tspan18, while the platelet collagen receptor 
GPVI/FcR complex was employed as a cell surface control. DT40 cells have a relatively 
small amount of cytoplasm relative to the size of the nucleus (Figure 5.1A). HEK-293T cells 
were transfected with GFP, used as negative control or Tspan18-GFP tagged, but the result is 
inconclusive, and the cell morphology does not appear to be round and not spread (Figure 
5.2B). The mouse fibroblast C2C12 cells were transfected with GFP and Tspan18-GFP 
tagged. In this case, cells appeared to be speeded on the glass coverslip, and Tspan18 appears 
to localize in the plasma membrane and in the cytoplasm. In conclusion, the data collected so 
far are inconclusive and do not clearly distinguish if Tspan18 is localized to the plasma 
membrame or if Tspan18 is localised to intracellular membranes, such as the ER and golgi 
 
during biosynthesis. 
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Figure 5.1 Study of Tspan18 subcellular localization. DT40 cells were transfected with 
constructs encoding GFP-tagged Btk, GFP-tagged GPVI and FcR,or GFP-tagged Tspan18. 
This experiment was performed in collaboration with Majd Protty.(A). HEK-293T cells were 
transfected with constructs encoding GFP or GFP-tagged Tspan18 (B). C2C12 cells were 
transfected with constructs encoding GFP or GFP-tagged Tspan18 (C). Two days post-
transfection, cells were analysed by confocal microscopy. 
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5.3.1 Analysis of lipid rafts for Tspan18 
Tetraspanin microdomains are thought to be distinct from lipid rafts (Le Naour, Andre et al. 
2006). However, Tspan18 has an N-terminal CXXC motif, which, in LAT family adapters, 
directs these proteins to lipid rafts when palmitoylated (Lin, Weiss et al. 1999). This raises the 
possibility that Tspan18 is localised to lipid rafts, which could explain the unique capacity of 
this tetraspanin to activate a signalling pathway leading to NFAT activation (Chapter 3). 
In order to determine if Tspan18 is a lipid raft-associated protein, HEK-293T cells were 
transfected with FLAG-tagged human Tspan18. Tspan9 was also tested in parallel, as it 
contains a CXXC motif, while CD9 was tested as it lacks a CXXC motif. Following 
tetraspanin transfection, cells were lysed in 1% Triton lysis buffer and separated by 
ultracentrifugation over a sucrose gradient. After collection of 12 fractions, each fraction was 
analysed by dot-blot using the -cholera toxin, which interacts with the lipid raft-specific lipid 
GM1. The result showed that in all the tested samples the lipid rafts mostly localized in 
fractions 2, 3, 4 and 5 (Figure 5.2). This lipid raft localization was consistent with data 
already published in the literature (Canobbio, Trionfini et al. 2008). The fractions resulting 
from the separation of each sample were analyzed by SDS-PAGE electrophoresis and blotted 
using a FLAG antibody, to identify the transfected tetraspanin proteins. The result 
demonstrated that Tspan18 was not localised to lipid rafts, but was present in the soluble 
fractions (fractions 9, 10, 11 and 12) (Figure 5.2A-B). Moreover, the majority of both Tspan9 
and CD9 were similarly not present in the lipid rafts (Figure 5.2C and Figure 5.2D). As the 
isolation of lipid rafts is detergent-sensitive and the choice of the detergent is critical, the 
same approach was employed to evaluate Tspan18 presence in lipid rafts using the milder 
detergent Brij 58. The data were comparable to samples lysed with Triton X-100 (data not 
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shown), suggesting that Tspan18, Tspan9 and CD9 are not lipid-raft associated tetraspanin 
proteins.  
 
5.3.2 Analyses of Tspan18 glycosylation and palmitoylation 
mutants 
In order to determine whether glycosylation or palmitoylation are required for Tspan18-
induced NFAT/AP-1 activation, two Tspan18 isoform 2 mutants were generated: a 
glycosylation site mutant for which the two key asparagine residues were mutated to alanine 
(Tspan18 GLY), and a palmitoylation mutant in which the six putative cysteine 
palmitoylation sites were mutated to serine (Tspan18 CS). The capacity of the two mutants to 
activate NFAT/AP-1 was tested using the luciferase reporter assay described in Chapter 3. 
Over-expression of the glycosylation-deficient mutant activated NFAT/AP-1 to a degree 
comparable to the wild-type Tspan18 form, while the palmitoylation-deficient mutant induced 
only 50% of the wild type signal (Figure 5.3A). Interpretation of these data was complicated 
by the fact that the mutant-transfected cells responded to positive control PMA plus 
ionomycin stimulation at only 50% of the level of wild-type transfectants (Figure 5.3B), and 
that the expression levels of the proteins were different (Figure 5.3C). Indeed, the 
palmitoylation mutant expressed at a higher level than wild-type, and the glycosylation 
mutant was higher still (Figure 5.3C). Interestingly, the latter showed only a single lower 
band at 25 kDa, close to the predicted molecular weight of the protein backbone (27.7 kDa), 
while the wild-type and palmitoylation-deficient forms showed the typical doublet (Figure 
5.3C). This suggests that the lower band represents non-glycosylated Tspan18 at a relatively 
early stage in the biosynthetic pathway. Taken together, these results demonstrate that neither  
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Figure 5.2 Transfected Tspan18, CD9 and Tspan9 do not localize to HEK-293T cell lipid 
rafts. HEK-293T cells were transfected with control vector (A.), FLAG-tagged Tspan18 
isoform 2 (B.), FLAG-Tspan9 (C) or FLAG-CD9 (D). Two days after the transfection, cells 
were lysed in 1% Triton X-100 lysis buffer and lysates were ultracentrifuged at 200,000 xg 
for 16 hours. Samples were divided into 12 fractions and analysed by dot-blot with the -
cholera toxin, which detects the lipid raft-specific lipid GM1 (upper panels). An aliquot of 
each fraction was analyzed by western blotting with the FLAG antibody (lower panels). Data 
are representative of five independent experiments. 
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Figure 5.3 Neither glycosylation nor palmitoylation are essential for Tspan18-induced 
NFAT/AP-1 activation. DT40 cells were transfected with the NFAT/AP-1-luciferase and -
gal constructs, together with control vector, 20 g of wild-type FLAG-Tspan18, 20 g of 
glycosylation-deficient FLAG-Tspan18 with two mutated N-linked glycosylation sites 
(Tspan18gly), or 20 g of palmitoylation-deficient FLAG-Tspan18 with six cysteine residues 
replaced with serine residues (Tspan18CS). Transfected cells were left unstimulated (A.) or 
were stimulated with PMA and ionomycin (B.). Data were normalized for the relative -gal 
values and adjusted such that Tspan18 signalling in unstimulated cells was 100. Error bars 
represent the standard error of three independent experiments. Aliquots of transfected cells 
were separated by SDS-PAGE and blotted with the FLAG antibody (C.).
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glycosylation nor palmitoylation are essential for Tspan18 signalling, but palmitoylation 
appears to be important for maximal signalling. 
 
5.3.3 Biochemical analysis of Tspan18 isoform 1  
The bioinformatic characterization of Tspan18 conducted in Chapter 4 identified two 
alternatively spliced forms of the gene, in primates but not in other mammals, which differed 
in their carboxy-terminal regions. Isoform 2 showed the classical four-transmembrane 
topology that is typical of tetraspanins, but the analysis conducted on the carboxy tail of 
Tspan18 isoform 1 demonstrated that is is lickely this region might contain fourth 
transmemrbane domain, but this was predicted with a lower confidence level that the other 
three transmembrane domains (Figure 4.3).  
In order to biochemically test whether Tspan18 isoform 1 has three or four transmembranes, 
or in other words an extracellular or intracellular carboxy-terminus, a Tspan18 isoform 1 
expression construct was generated with a FLAG tag at the amino terminus and a MYC tag at 
the carboxy-terminus (Figure 5.4A). Tspan18 isoform 1 was then transfected into DT40 cells 
and analyzed by flow cytometry and western blotting. In these experiments, extracellular 
MYC tagged G6f was used as a positive control, since this platelet membrane protein is 
known to be surface-expressed (Craig Hughes, unpublished data). In flow cytometry using the 
anti-MYC antibody, the Tspan18 isoform 1-transfected cells were comparable to mock-
transfected cells and thus were negative (Figure 5.3B). This was in contrast to the G6f 
transfectants, in which a proportion was positive for MYC staining (Figure 5.3B). This failure 
to detect surface isoform 1 was not due to a lack of expression, since the protein was readily 
detected in whole cell lysates by anti-MYC blotting (Figure 5.4C). These finding confirm the  
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Figure 5.4 Two distinct topologies for a Tspan18 isoform 1 protein tagged with FLAG 
and MYC epitopes. The Tspan18 isoform 1 construct was cloned into the pEF6 vector with a 
FLAG tag at the amino-terminus and a MYC tag at the carboxy-terminus (A.). DT40 cells 
were transfected with empty vector (mock), the Tspan18 isoform 1 construct or a G6f positive 
control with an extracellular MYC tag. Twenty-four hours post transfection, cells were 
stained with mouse anti-MYC primary antibody, followed by anti-mouse FITC-conjugated 
secondary antibody. Cells were analyzed by flow cytometry (B.). Aliquots of samples were 
lysed in 1% Triton X-100 lysis buffer, separated by SDS-PAGE electrophoresis and western 
blotted with the MYC antibody, to evaluate Tspan18 isoform 1 and G6f expression (C.).  
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bioinformaitc finding that Tspan18 isoform 1 present four transmembrane domains. Despite 
this result, in theory this protein could possess only three transmembrane regions but be 
expressed on only intracellular membranes. Future surface biotinylation and 
immunofluorescence experiments could be used to address this issue. Nevertheless, the 
western blotting results have proved that isoform 1 can be expressed as a stable protein. 
 
5.3.4 Tspan18 isoform1 capability of activating NFAT/AP-1  
To determine whether Tspan18 isoform 1 could activate NFAT/AP-1, in common with 
isoform 2, DT40 cells were transfected with the NFAT/AP-1 luciferase construct and either 
Tspan18 isoform 1, Tspan18 isoform 2, or a combination of both isoforms. In contrast to 
isoform 2, which activated NFAT/AP-1 by approximately ten-fold over basal, isoform 1 only 
induced two-fold activation, showing a significant reduction in capability of NFAT/AP-1 
activation (Figure 5.5A). Moreover, when the two Tspan18 isoforms were co-transfected in 
the same sample, the combined NFAT/AP-1 activation was only four-fold over basal, again 
showing a significant reduction in signalling (Figure 5.5A). All of the transfectants were able 
to respond robustly to the PMA and ionomycin stimulation, used as a positive control, albeit 
to slightly different degrees (Figure 5.5B). An aliquot of each sample was analyzed by SDS-
PAGE and blotted with the FLAG antibody, to monitor the expression level of the different 
transfected constructs. Isoform 1 appeared to migrate at a lower molecular weight than 
isoform 2, but was expressed at a much lower level, despite the fact that four times more 
DNA was used in the transfections (Figure 5.5C; see legend). However, isoform 1 expression 
was greater in the presence of isoform 2 (Figure 5.5C). Several experiments were conducted 
in an attempt to achieve similar expression levels of the two isoforms, by varying the amount  
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Figure 5.5 Analysis of Tspan18 isoform 1 capability of activating NFAT/AP-1. DT40 
cells were transfected with NFAT/AP-1-luciferase and -gal constructs, together with either 5 
g of FLAG-Tspan18 isoform 2, 20 g of FLAG-Tspan18 isoform 1, or a combination of 5 
g of FLAG-Tspan18 isoform 2 and 20 g of FLAG-Tspan18 isoform 1. Cells were left 
unstimulated (A.) or were stimulated with PMA and ionomycin (B.). An aliquot of whole cell 
lysate was separated by SDS-PAGE and blotted with the FLAG antibody, in order to check 
Tspan18 expression levels (C.). Data were normalized for -gal values and analyzed by 
ANOVA. Statistical significance is indicated by Tukey’s test (* P < 0.05). Error bars 
represent the standard deviation of three independent experiments. 
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of transfected DNA, but these were not successful (data not shown). However, in agreement 
with Figure 5.5C, it was clear that DT40 cells expressed Tspan18 isoform 1 with more 
difficulty, but the reason for this remains unclear at present. In conclusion, isoform 1 did not 
induce substantial NFAT/AP-1 activation, but this could be due to a relatively low expression 
level. In addition, isoform 1 appeared to impair isoform 2-induced NFAT/AP-1 activation, 
although again this could be because of an effect on isoform 2 expression level. 
 
5.3.5 The Tspan18 extracellular loops in a chimeric protein are 
sufficient to induce NFAT/AP-1 signalling 
In order to begin to understand which region of Tspan18 is crucial in inducing NFAT/AP-1 
signalling, a CD9/Tspan18 chimeric construct was generated in which the transmembrane and 
intracellular regions of human Tspan18 were replaced with those of CD9 (Figure 5.6A), a 
tetraspanin that was unable to induce NFAT/AP-1 activation (Figure 3.2). 
In order to assess whether the CD9/Tspan18 chimera could induce NFAT/AP-1 activation, 
DT40 cells were transfected with the NFAT/AP-1-luciferase reporter in combination with 20 
g FLAG-Tspan18 (isoform 2), 20 g FLAG-CD9 or 20 g FLAG-chimera constructs. The 
CD9/Tspan18 chimera significantly induced NFAT/AP-1 activation to a level that was 70% 
of that induced by Tspan18 (Figure 5.6B). In contrast the CD9 control did not induce 
significant NFAT/AP-1 activation (Figure 5.6B). All samples responded robustly to the PMA 
and ionomycin stimulation, used as a positive control, although with somewhat different 
degrees of activation (Figure 5.6C.). Finally, the expression level of each construct was 
assessed by anti-FLAG western blotting, and the result confirmed expression of each 
construct (Figure 5.6D). A slightly lower expression of the chimera, relative to Tspan18, 
might explain the partial reduction in signalling response observed in Figure 5.6B. In  
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Figure 5.6 The Tspan18 extracellular loops are sufficient to induce NFAT/AP-1 
signalling in the context of a chimeric protein. Diagrammatic representation of the human 
CD9/Tspan18 chimeric construct (A.). DT40 cells were transfected with vector control, 20 g 
of FLAG-Tspan18, 20 g of FLAG-CD9 or 20 g of the FLAG-CD9/Tspan18 chimera. Cells 
were left unstimulated (B.) or stimulated with PMA and ionomycin (C.). Data were 
normalized for -gal values and analyzed by ANOVA test. Statistical significance is indicated 
by Tukey’s test (*P<0.05). Error bars represent the standard deviation of three independent 
experiments. An aliquot of whole cell lysate was separated by SDS-PAGE and blotted with 
the FLAG antibody, in order to check expression levels of the different constructs (of a 
Tspan18 antibody, which has yet to be made, or transfected GFP- and FLAG-tagged Tspan18 
constructs. 
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conclusion these data show that the extracellular regions of Tspan18, in the context of a 
chimeric protein, are sufficient to promote NFAT/AP-1 activation and conversely that the 
transmembrane and cytoplasmic regions are not essential. 
 
5.4 DISCUSSION 
In this chapter, a number of experiments have been performed to address the subcellular 
localisation and structure/function of Tspan18. The key findings are as follows: (1) Tspan18 
is localised to the cell surface and/or a cytoplasmic region close to the cell surface; (2) 
Tspan18, like other tetraspanins such as CD9 and Tspan9, is not localised to lipid raft 
membrane microdomains; (3) the two N-glycosylation and six putative palmitoylation sites 
are not essential for Tspan18-induced NFAT/AP-1 activation; (4) isoform 1, the atypical form 
of Tspan18 described in the previous chapter, transfects relatively poorly and does not induce 
substantial NFAT/AP-1 activation; and (5) the extracellular region of Tspan18 is sufficient to 
induce NFAT/AP-1 activation in the context of a Tspan18/CD9 chimera.  
In order to study the Tspan18 subcellular localization, an amino-terminal GFP-tagged 
Tspan18 construct was generated and transfected into DT40, HEK-293T and C2C12 cells. 
Confocal microscopy showed Tspan18 localisation to be similar to that of a GFP-tagged form 
of GPVI, a known plasma membrane protein, and distinct from GFP-tagged Btk, a 
cytoplasmic tyrosine kinase. However, the experiment conducted in HEK-293T cells is 
inconclusive, and cells observed in transmitted light appeared to have a round shape (data not 
shown). In C2C12 Tspan18 appeared to be distributed similary to the GFP, which present a 
cytoplasmic distribution. Form the esperiments here presented, it is not possible to conclude 
that Tspan18 is expressed only at the plasma membrane. It is also possible that Tspan18 is 
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expressed on intracellular membranes that lie close to the plasma membrane. Consistent with 
the idea that at least some Tspan18 is localised to the plasma membrane, FLAG-Tspan18 
stably expressed in Jurkat T cells was found to be plasma membrane localised because of its 
capacity to be detected by streptavidin blotting following cell surface biotinylation (M.G. 
Tomlinson, unpublished data). To resolve this, future experiments will utilise a cell type such 
as HUVEC, in which Tspan18 is normally expressed and which has a relatively large 
cytoplasm, thus more clearly allowing the distinction between plasma membrane and 
cytoplasmic staining. Such experiments would ideally involve the use of a Tspan18 antibody, 
which has yet to be made, or transfected GFP- and FLAG-tagged Tspan18 constructs.  
Since the lipid raft concept was introduced in 1997 (Simons and Ikonen 1997), several 
research groups have attempted to biochemically and functionally characterize these 
membrane microdomains and their associated proteins. Despite this extensive research work, 
the notion of lipid rafts has always been controversial. Some major topics of controversy 
include the necessity to perform the separation at low temperatures (4oC) and the critical 
choice of the optimal detergent and its concentration (Jacobson and Dietrich 1999). The 
Israels research group investigated the possible localisation of the tetraspanins CD9 and CD63 
in lipid rafts of resting human platelets. This group used the detergents Triton X-100 or Brij 
35 (at 1%) and showed that neither of these two tetraspanins was lipid raft-associated (Israels 
and McMillan-Ward 2007). In this chapter, only a minimal fraction of transfected Tspan18 
was present in the lipid raft fractions of HEK-293T cells, in either the relatively strong Triton 
X-100 or the weaker Brij 58 detergents. These data suggest that the unique signalling capacity 
of over-expressed Tspan18 is unlikely to be due to a specific association with lipid raft 
microdomains and their associated signalling machinery. However, future experiments should 
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repeat these experiments in transfected DT40 cells, because these were the cells in which the 
signalling phenomenon has been observed. 
In this chapter, the effects of glycosylation and palmitoylation on Tspan18 signalling have 
been preliminarily evaluated employing glycosylation and palmitoylation mutants. 
Palmitoylation has been shown to reduce secondary tetraspanin associations, resulting in 
impaired cell signalling and altered cell morphology (Hemler 2008), while the precise 
molecular role of tetraspanin glycosylation has not been clarified yet (Tarrant, Robb et al. 
2003). Neither the prevention of glycosylation or palmitoylation prevented Tspan18 
signalling, although the latter reduced the magnitude by 50%. It is possible to speculate that 
the reduction in signalling is a result of a reduced ability for Tspan18 to assemble into 
tetraspanin complexes and, consequently, reducing the interaction with its molecular partners. 
From the comparative analysis of the the western blot films presented so far, it seems 
Tspan18 isoform 1 presents only one western blot band, while Tspan18 isoform 2 presents 
three western blot bands (Figure 5.3, Figure 5.4 or Figure 3.8). It is possible to speculate that 
the diffent Tspan18 bands might be different Tspan18 glycosilation forms, as suggested from 
the analysis of the Figure 5.3. In this figure, a Tspan18 mutant form lacking of the 
glycosilation site was generated, and this was displayed as a single band. Despite this 
hypothesis, this does not explain why Tspan18 isoform 1, which contain a glycosilation site, 
does not present multiple western blotting bands. The second hyoithesis might be that the 
observed bands are different Tspan18 breackdown products, despite this is unlikely, as they 
seem to be recurrent. In conclusion, the specific reason behind this observation is at present 
not known. The second non-consitency that needs to be addressed regards Tspan18 western 
blotting molecular weight. Tspan18 isoform 2 has a molecular weight of 27.7KDa (aminoacid 
sequence only). In the presented western blotting, Tspan18 isoform 2 present its major bands 
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in the range of 32.5-25 KDa. This minor difference might be given by the fact that the 
western blotting separation time might not be consistant among experiment. The other 
possibility might be an error in reporting the markers from the gel to the film. In anycase, this 
registered variablility is minor, as the western blots appear to be clear and almost free from 
background noise or unspecific bands, confirming the visualized proiten is Tspan18, which is 
FLAG tagged.  
In the previous chapter, an alternative isoform of Tspan18 (isoform 1) was identified in 
human, chimp and monkey, whereas the more typical isoform 2 was present in mammals and 
lower vertebrates. Quantitative PCR demonstrated that isoform 1 was expressed at relatively 
low levels, or was absent, from the human cell types analysed. Consistent with this, the 
present chapter found that transfected isoform 1 was expressed at substantially lower levels 
than isoform 2, suggesting that the former may be a relatively unstable protein. This could in 
part be due to the lack of the fourth transmembrane in isoform 1, although the flow cytometry 
experiments used in this chapter could not conclusively prove this; they merely demonstrated 
that isoform 1 was not a plasma membrane ‘trispanin’ in transfected cells. Future experiments 
should use flow cytometry experiments in combination with confocal microscopy to address 
this issue. Consistent with the low levels of expression of isoform 1, there was no substantial 
activation of NFAT/AP-1. Interestingly, isoform 1 appeared to be stabilised by the co-
expression of isoform 2, which again complicated the interpretation of the NFAT/AP-1 data. 
In summary, it was not possible to conclusively conclude whether isoform 1 could induce 
signalling or, if not, whether it could inhibit isoform 2. Future experiments could be directed 
at raising an isoform 1-specific antibody to address these issues. However, addressing the role 
of the more typical isoform 2, for which mRNA clearly exists in cells such as endothelial cells 
(Chapter 4), should be a higher priority. 
 -141-
Chapter 5 
Finally, in this chapter, the role of Tspan18 extracellular loops have been evaluated, 
employing a chimeric construct composed of Tspan18 small and large extracellular loops and 
CD9 cytoplasmic and transmembrane domains. The construct has been raised on the basis that 
CD9 was not able to induce NFAT-AP1 signalling (Chapter 3). The result demonstrated that 
the chimera retains 70% of Tspan18 signalling capability. If the Tspan18 signalling 
mechanism involves an interaction with a signalling partner protein, these data suggest that 
the interaction is mediated by the extracellular region of the tetraspanin. This would be 
similar to the interaction of tetraspanin CD151 with the laminin-binding integrin 31, for 
which the large extracellular loop of CD151 mediates the interaction (Yauch, Kazarov et al. 
2000). 
 
5.5 SUMMARY 
In the present Chapter it has been demonstrated that: 
 Tspan18 is localised to the plasma membrane and/or cytoplasm in transfected DT40 
cells 
 Tspan18 is not present in lipid rafts of transfected HEK-293T cells 
 Tspan18-induced NFAT/AP-1 activation does not require N-glycosylation or 
palmitoylation of Tspan18, although the latter has a partial effect 
 Transfected Tspan18 isoform 1 is expressed poorly and does not induce substantial 
NFAT/AP-1 activation 
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 Tspan18 large and small extracellular loops are sufficient for NFAT/AP-1 activation 
in the context of a chimeric form of Tspan18 
Chapter 6 
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6.1 INTRODUCTION  
Earlier chapters of this thesis have shown that over-expression of Tspan18, but not other 
tetraspanins, could induce NFAT/AP-1 activation. Since tetraspanins lack intrinsic enzymatic 
activity, it is possible that Tspan18 signals indirectly, through a specific interaction with a 
signalling receptor. For Tspan18 this could be a calcium channel or a protein that regulates 
calcium channels, such as a STIM1. A platelet receptor that could be regulated by other 
tetraspanins is the collagen receptor GPVI. Indeed, before the start of this thesis, our group 
identified GPVI as a component of platelet tetraspanin microdomains, a finding that was 
recently published (Protty, Watkins et al. 2009). GPVI was found to associate with CD9 and 
CD151 in the weak detergent 1% Brij97, but its interaction was lost in the more stringent 1% 
Triton X-100 detergent. This suggests that GPVI might specifically interact with one of the 
several other platelet tetraspanins, and might be regulated within tetraspanin microdomains. 
This would not be without precedent for an ITAM-containing receptor, because T cells from 
several tetraspanin-deficient mice hyperproliferate in response to TCR cross-linking (Tarrant, 
Groom et al. 2002; Tarrant, Robb et al. 2003; van Spriel, Puls et al. 2004), suggesting 
negative regulation of this receptor by tetraspanin microdomains. This chapter will take 
advantage of the DT40 cell line model, used to study Tspan18 signalling earlier in this thesis, 
to address the hypothesis that one or more platelet tetraspanins regulates GPVI signalling. 
 
6.2 AIM 
The aim of this chapter was to determine whether over-expression of a panel of platelet 
tetraspanins affects GPVI/FcR-induced NFAT/AP-1 activation in the DT40 B cell line 
model.  
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6.3 RESULTS 
6.1 GPVI/FcR can induce NFAT/AP-1 signalling in the DT40 B 
cell line 
In order to establish the NFAT/AP-1 luciferase reporter assay to study collagen-induced 
GPVI/FcR signalling, DT40 cells were transfected with constructs encoding GPVI/FcR and 
the NFAT/AP-1 reporter. Cells were unstimulated, stimulated with 10 g/ml of collagen, or 
stimulated with PMA and ionomycin as a positive control (Figure 6.1A). The result 
demonstrated that GPVI/FcR was able to activate the NFAT/AP-1 promoter upon collagen 
stimulation inducing a statistically significant response of approximately 100-fold over basal. 
In addition, the PMA and ionomycin positive control induced similar robust NFAT/AP-1 
activation in both control and GPVI/FcR transfections, despite the presence of Tspan18 is 
not statistically significant (Figure 6.1A). In order to monitor the expression level of GPVI at 
the cell surface, an aliquot of each sample was analyzed by flow cytometry, after staining 
with the monoclonal GPVI antibody. The result showed that GPVI was expressed at the cell 
surface of approximately 18% of the cells (Figure 6.1B), a value that is typical for transient 
transfection of this cell line. 
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Figure 6.1: GPVI/FcR can induce NFAT/AP-1 activation in DT40 cells. (A.) DT40 cells 
were transfected with 20 g of the NFAT/AP-1-luciferase reporter construct, 2 g each of 
GPVI, FcR and -galactosidase expression constructs, the latter as a control for transfection 
efficiency. Cells were unstimulated (unstim) or stimulated with 10 g/ml of collagen or PMA 
(50 ng/ml) and ionomycin (1 M) as a positive control. Data were divided for the relative -
gal value and analyzed by ANOVA followed by a Tukey’s test. Error bars represent the 
standard deviation of eight independent experiments (B.) GPVI surface expression level was 
measured by FACS analysis and representative dot plots are shown. 
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6.2 The effect of tetraspanin over-expression on GPVI/FcR 
signalling 
To determine if some of the known platelet tetraspanins have an effect on GPVI/FcR 
signalling, the panel of FLAG-tagged tetraspanin proteins, used in Figure 3.2, was 
individually co-transfected with constructs for GPVI, FcRand the NFAT/AP-1 reporter in 
DT40 cells, and left unstimulated (Figure 6.2A), or stimulated with collagen (Figure 6.2B) or 
PMA and ionomycin (Figure 6.2C) The result demonstrated that, among the tested tetraspanin 
proteins, only Tspan18 can significally enhance basal GPVI/FcRsignalling. Interestingly, 
despite from the Figure 6.2A might appear that CD9 and Tspan9 might have an effect on 
GPVI/FcR signalling, this did not appeared to be statistically significative. Of all the tested 
tetraspanin proteins, none appeared to enhance GPVI/FcR collagen signalling (Figure 6.3B). 
PMA and ionomycin stimulation was performed to check cell response (Figure 6.3C), 
showing all samples responded to this positive control, despite with a different degree of 
activation. Despte Tspan18 and CD9 and Tspan18 PMA and ionomcin response appeared to 
be statistically significative, this is not believed to be of relevance in this context, as this 
positive control showed sample variation. 
 
6.3 Tspan18 synergises with GPVI/FcR to activate NFAT/AP-1  
The remaining experiments in this chapter were designed to address the basal signal in 
unstimulated cells transfected with GPVI/FcR and Tspan18 (Figure 6.3A). GPVI/FcR basal 
signalling in this model has been observed before (Mori, Pearce et al. 2008), but the current 
data does not distinguish between the two possibilities that either Tspan18 alone, or Tspan18 
in synergy with GPVI/FcR is responsible for the NFAT/AP-1 activation. Therefore DT40 
-148- 
Chapter 6 
cells were transfected with Tspan18 in the presence or absence of the GPVI/FcR complex. In 
unstimulated cells, Tspan18 alone induced an 11-fold NFAT/AP-1 activation, 
GPVI/FcRalone induced a 7-fold activation, whereas the combination of GPVI/FcR and 
Tspan18 produced a synergistic response of 62-fold activation (Figure 6.3A). Such synergy 
suggests that Tspan18 and GPVI/FcR activate the NFAT/AP-1 promoter through at least 
partially different mechanisms.  
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Figure 6.2: Tetraspanin over-expression does not affect collagen-induced GPVI/FcR 
activation of NFAT/AP-1. DT40 cells were transfected with 20 g of the NFAT/AP-1-
luciferase reporter construct, 2g each of GPVI, FcR and -galactosidase expression 
constructs and 5 g of the indicated tetraspanin proteins. Cells were unstimulated (A), 
stimulated with collagen (B) or stimulated with PMA and ionomycin as a positive control (C). 
Data were divided for the relative -gal value and moltiplied for 100. Error bars represent the 
standard deviation of two independent experiments. Data were analyzed by ANOVA and 
Tukey’s test. Significantdifference among samples has been indicated (P<0.05).  
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Figure 6.3: Tspan18 over-expression is sufficient to activate NFAT/AP-1. DT40 cells 
were transfected with the NFAT/AP-1-luciferase reporter, a -galactosidase construct and 
either a control vector, 5g of Tspan18, 2g each of GPVI and FcR or with the GPVI/FcR 
complex in conjunction with Tspan18. Samples were left unstimulated (A.), stimulated with 
collagen (B.) or with PMA and ionomycin (C.). Data were divided for the relative -
galactosidase value. Error bars represent the standard deviation of three independent 
experiments. Data were analyzed by ANOVA and Tukey’s test. Significant difference among 
samples has been indicated (P<0.05). Aliquots of whole cell lysates were separated by SDS-
PAGE and western blotted with a FLAG antibody, to evaluate Tspan18 expression (D.). Cells 
were stained with the GPVI monoclonal antibody and analyzed by flow cytometry (E.). The 
percentage of GPVI-expressing cells in the presence or absence of Tspan18 was calculated 
from three experiments and the error bars represent standard errors. Data were analysed by 
Student T-test and did not presented a significant difference (F). 
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In contrast to unstimulated cells, Tspan18 did not significantly affect NFAT/AP-1 activation 
in response to collagen stimulation of GPVI/FcRor the PMA and ionomycin positive control 
(Figure 6.3C and Figure 6.3D, respectively), as observed previously. Different doses of 
collagen and expression constructs were tested, but in all cases Tspan18 did not affect 
collagen-induced GPVI/FcR signalling (data not shown). 
Two additional controls were performed, to verify that the GPVI/FcR expression did not 
affect Tspan18 expression (and vice versa). As the Tspan18 construct has an intracellular 
FLAG tag, Tspan18 expression was evaluated by SDS-PAGE followed by western blotting 
using a FLAG antibody. The result showed that Tspan18 expression was not affected by the 
presence of GPVI (Figure 6.3D). GPVI surface expression was analyzed by flow cyotometry, 
using a GPVI monoclonal antibody, and expression was similar in the presence or absence of 
Tspan18, suggesting that the tetraspanin did not affect GPVI expression (Figures 6.3E-F). 
These data show that Tspan18 synergises with GPVI/FcR to activate NFAT/AP-1 in resting 
cells, but does not affect collagen-induced GPVI/FcRsignalling. 
 
6.4 DISCUSSION 
In this chapter it was demonstrated that in the DT40 model B cell line, using the NFAT/AP-1 
transcriptional reporter, a potent readout for combined calcium and MAPK signalling, over-
expression of a panel of tetraspanin proteins did not affect GPVI/FcR signalling in response 
to collagen. However, Tspan18 was found to synergize with GPVI/FcR to activate 
NFAT/AP-1 under unstimulated conditions.  
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The aim of this chapter was to determine whether tetraspanins affect GPVI/FcR signalling, 
because of our finding before the start of this thesis that these proteins can be co-
immunoprecipitated from human platelet lysates (Protty, Watkins et al. 2009), and because 
other ITAM-containing receptors are known to be regulated by tetraspanins (Tarrant, Groom 
et al. 2002; van Spriel, Puls et al. 2004). The first hypothesis was that a platelet tetraspanin 
might specifically interact with GPVI and/or FcR, and might enhance GPVI/FcR signalling 
by promoting its sustained localisation in lipid rafts, in a manner similar to that reported for 
the tetraspanin CD81 and the CD19/CD21/B cell receptor complex (Cherukuri, Shoham et al. 
2004), although this finding has recently been questioned (Sanyal, Fernandez et al. 2009). 
However, none of the six platelet tetraspanins affected collagen-induced GPVI signalling 
when over-expressed in DT40 B cells. Moreover, of the six platelet tetraspanins, only 
Tsoan18 could significantly enhance basal GPVI/FcR signalling. From the analysis of the 
Figure 6.2A, it seemed that CD9 and Tspan9 could slightly enhance basal GPVI/FcR 
signalling, but this difference did not appeared to be significant at a Tukey’s test analysis.  It 
is possible that GPVI/FcR signalling is regulated by some other platelet tetraspanin protein 
that was not included in the tested panel. Indeed, several other platelet tetraspanins have 
recently been identified by proteomics (Lewandrowski, Wortelkamp et al. 2009). It is also 
possible that tetraspanin over-expression is not the best technique to determine whether these 
proteins affect GPVI/FcR signalling. An alternative approach would be to use RNA 
interference (RNAi) to study GPVI/FcR signalling in cells lacking one or more tetraspanins.  
At present, it is still unclear whether tetraspanins functionally regulate GPVI/FcR or indeed 
whether a substantial proportion of platelet GPVI/FcR is localised within tetraspanin 
microdomains. The signalling studies performed by the Jackson group using tetraspanin 
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knockout mice demonstrated that GPVI/FcR signalling is not affected by the absence of 
CD151 or Tspan32 (Lau, Wee et al. 2004; Goschnick, Lau et al. 2006). Taking together these 
findings and the data in this chapter, it is possible to speculate that GPVI/FcR association 
with tetraspanin proteins might be a way of regulating other GPVI/FcR functions distinct 
from signalling. For example, since the platelet laminin-binding integrin 61 is recruited to 
tetraspanin microdomains via a well-characterised interaction with CD151 (Sterk, Geuijen et 
al. 2002), and since GPVI is also a laminin receptor (Inoue, Suzuki-Inoue et al. 2006), it is 
possible that platelet tetraspanin microdomains act as a platform for efficient binding to 
laminin, a major component of the sub-endothelial matrix. Indeed, the close proximity of the 
two laminin receptors within the microdomains would allow ‘inside-out’ signals, generated by 
GPVI/FcR engagement, to rapidly activate the integrin to induce strong adhesion and enable 
the platelets to plug the wound. A second possibility is that tetraspanin microdomains regulate 
GPVI shedding by the metalloprotease ADAM10, which can cleave off the GPVI 
extracellular region so rendering the platelet non-responsive to collagen (Gardiner, 
Karunakaran et al. 2007), and which is strongly associated with tetraspanin microdomains 
(Arduise, Abache et al. 2008).  
 
6.5 SUMMARY 
In the present chapter it has been demonstrated that: 
 Tspan18, but not the other platelet tetraspanins tested, synergizes with GPVI/FcRto 
induce NFAT/AP-1 activation in unstimulated cells 
 Of the tested platelet tetraspanins, none appear to affect collagen-induced GPVI/FcR 
signalling when over-expressed 
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7.1 SUMMARY OF MAJOR FINDINGS 
The signalling experiments performed in this thesis utilised a highly sensitive NFAT/AP-1 
luciferase transcriptional reporter assay in model cell lines. This assay was previously used by 
our group to study the platelet collagen receptor GPVI (Tomlinson, Calaminus et al. 2007), 
and allowed an investigation of the effects of tetraspanin proteins on NFAT/AP-1 activation. 
Indeed, the first chapter of this thesis addressed the question as to whether over-expression of 
platelet-expressed tetraspanin proteins could induce NFAT/AP-1 signalling. The result 
demonstrated that one of the six tested tetraspanins could affect NFAT/AP-1 signalling: 
Tspan18. This suggested a unique signalling role for Tspan18, and its signalling mechanism 
was studied using mutant cell lines and specific signalling inhibitors. The results 
demonstrated that Tspan18 signalling was independent of Syk, Lyn, PLC IP3Rs and STIM1. 
However, Tspan18 signalling was calcineurin- and calcium-dependent, strongly indicating 
this tetraspanin protein might be involved in calcium signalling. This was supported by 
studies that showed Tspan18 signalling to mimic the calcium ionophore ionomycin. In 
conclusion, it was proposed that Tspan18 might interact with and regulate a calcium channel 
or a protein involved in calcium entry. 
 
7.2 MODELS FOR TSPAN18 REGULATION OF NFAT 
ACTIVATION 
The mechanistic studies in Chapter 3 showed that Tspan18-induced NFAT/AP-1 activation 
did not require IP3 receptors, which release calcium from intracellular stores to initiate store-
operated calcium entry into the cell (Taylor, Rahman et al. 2009). In contrast, Tspan18 
signalling was dependent on calcineurin, the phosphatase which dephosphorylates NFAT 
proteins, allowing their translocation to the nucleus where they can activate target genes 
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(Macian 2005). These key findings suggest that Tspan18 exerts its effect at a point on the 
NFAT signalling pathway between IP3 receptors and calcineurin. Possible Tspan18-regulated 
proteins will be discussed later in this section, but how could Tspan18 over-expression induce 
their activation? Given that tetraspanins are thought to organise other transmembrane and 
signalling proteins in cell membranes, through specific tetraspanin-partner protein interactions 
(Hemler 2008; Charrin, le Naour et al. 2009), it seems likely that Tspan18 over-expression 
induces signalling by clustering or conformationally activating a signalling partner. However, 
although the data in this thesis suggest that Tspan18 is a positive regulator of NFAT 
activation, this may not necessarily be the case. For example, relatively low level, endogenous 
Tspan18 might normally negatively regulate a component of the NFAT signalling pathway, 
but over-expression might perturb the system to induce artefactual pathway activation. Such 
‘informative artefacts’ are a feature of previous over-expression studies on cytoplasmic 
adapters, for example (Burack and Shaw 2000).  
A number of possible models involving different candidate Tspan18 partner proteins can be 
proposed to explain the Tspan18 signalling phenomenon. Firstly, Since STIM1-induced Orai1 
opening represents the major mechanism for store-operated calcium entry in lymphocytes 
(Wang, Deng et al. 2009), it is possible that Tspan18 interacts with either of these proteins. 
The proposed working model, which illustrates this scenario, is presented in Figure 7.1. The 
figure, also takes into consideration all the other players considered in this thesis, and other 
possible working hypotheses. 
ER-resident STIM1 senses depletion of calcium stores and then reorganises itself in the 
membrane to form plasma membrane-proximal clusters, which then induce Orai1 
tetramerisation and calcium channel opening (Wang, Deng et al. 2009). It is not difficult to 
imagine that a tetraspanin might be involved in such a process. For example, tetraspanins are 
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known to regulate ICAM-1 and VCAM-1 endothelial cell adhesion molecules by promoting 
their clustering (Barreiro, Zamai et al. 2008). A possible interaction of Tspan18 with STIM1 
and Orai1 could be tested in future by co-immunoprecipitation in cells transfected with 
epitope-tagged proteins. The cells could be first stimulated with thapsigargin, an inhibitor of 
the sarco/endoplasmic reticulum calcium ATPase (SERCA) pumps in the ER, to activate 
store-operated calcium channel entry and induce STIM1/Orai1 clustering (Park, Hoover et al. 
2009). The cells could also be treated with a membrane-permeable cross-linker such as DSP 
(Dithiobis[succinimidyl propionate]), which captures potentially low affinity interactions and 
is the ‘gold standard’ method in the field for confirming direct tetraspanin-partner protein 
interactions (Charrin, le Naour et al. 2009). 
An involvement of STIM1 and Orai1 in Tspan18 signalling could also be tested functionally, 
through NFAT/AP-1 reporter assays either in combination with inhibitors of store-operated 
calcium entry, or RNAi to knock down STIM1 and/or Orai1, or DT40 mutants. Possible 
pharmacological inhibitors include 50 M 2-aminoethoxydiphenyl borate (2-APB) or 0.3 M 
lanthanum (La3+), which both completely inhibit store-operated calcium entry in DT40 cells 
at these concentrations (Broad, Braun et al. 2001; Prakriya and Lewis 2001; Morita, Tanimura 
et al. 2009) The 2-APB could also be used at 5 M, because at low concentration this drug 
enhances store-operated calcium entry by coupling STIM and Orai proteins (Wang, Deng et 
al. 2009) and thus may mimic the Tspan18 effect. RNAi knockdown of STIM1 and Orai1 and 
would best be used in human Jurkat T cells (in combination with PMA to yield a robust 
NFAT/AP-1 response, as shown in Figure 3.6), because knockdown of these proteins is well 
established in human cells but has not been done in chicken. Finally, in the current absence of 
Orai1-deficient DT40 cells, Tspan18-induced NFAT/AP-1 activation could be measured in 
DT40 cells doubly deficient in STIM1 and STIM2 (Wang, Deng et al. 2009). This would be 
useful because residual BCR- and Tspan18-induced NFAT/AP-1 activation was observed in 
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STIM1-deficient cells (Figure 3.8). This is possibly due to compensation by STIM2 and made 
it impossible to determine whether STIM proteins are essential for Tspan18 signalling. 
The above discussion has focussed on STIM1 and Orai1, because of their major role in 
lymphocyte calcium entry (Park, Hoover et al. 2009). However, it is certainly impossible to 
rule out other possibilities. Indeed, Tspan18 might interact with and regulate a calcium 
channel that does not involve Orai1. Examples include the two DT40 ryanodine receptors 
(RyRs), RyR1 and RyR3 (Kiselyov, Shin et al. 2001), which are calcium release channels in 
the ER, distinct from IP3 receptors, and which can be inhibited with the pharmacological 
inhibitor Ruthenium Red at 100 M in these cells (Kiselyov, Shin et al. 2001) (Figure 7.1). 
Another possibility is the ER-resident SERCA pump which, if inhibited by Tspan18 over-
expression, would be predicted to activate NFAT signalling in a manner that is IP3 receptor-
independent (Sugawara, Kurosaki et al. 1997), but calcineurin-dependent, consistent with the 
Tspan18 mechanistic data. Finally, Tspan18 could interact with and regulate lymphocyte-
expressed store-operated calcium channels on the plasma membrane such as TRPC1 or 
TRPC3 (Philipp, Strauss et al. 2003), or the non-store-operated plasma membrane TRPV or 
TRPM calcium channels. Investigation of the non-store-operated channels would be 
complicated by the large number of family members, namely six and eight, respectively 
(Inada, Iida et al. 2006). Nevertheless, each possibility in this section could be studied by the 
co-immunoprecipitation or RNAi studies outlined for STIM1 and Orai1 in the previous 
paragraph (Figure 7.1). 
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Figure 7.1: Working hypotheses of Tspan18 mechanism of function in DT40 cells. 
Tspan18 (in red) might inderact and regulate the IP3 receptor, or STIM1, or might interact 
with and regulate the rynodine receptors. Tspan18 might interact with and regulate the ORAI1 
plasma membrane calcium channel, or the TRP calcium channels. In green are indicated 
stimulatory or blockage agents.  
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7.3 DO TETRASPANINS REGULATE GPVI? 
We have recently reported that the platelet collagen receptor GPVI is a component of 
tetraspanin membrane microdomains on human platelets (Protty, Watkins et al. 2009). The 
evidence for this was initially derived from immunoprecipitation experiments using surface-
biotinylated human platelets lysed in the relatively weak detergent 1% Brij97, which 
maintains tetraspanin-tetraspanin interactions and the integrity of tetraspanin microdomains 
(Hemler 2008). The pattern of co-immunoprecipitated surface proteins, as detected following 
SDS-PAGE and streptavidin blotting, was very similar for GPVI and CD151 
immunoprecipitations. Moreover, CD9 and CD151 were detected in GPVI 
immunoprecipitations. As controls for specificity, the platelet von Willebrand receptor GPIb 
and the integrins IIb3 and 21, each of which are generally expressed at much higher 
levels than GPVI, were not found to be tetraspanin-associated (Protty, Watkins et al. 2008).  
These findings were the starting point for the final GPVI chapter of this thesis, which aimed 
to test the effect of tetraspanin over-expression on collagen-induced GPVI signalling using a 
newly-developed cell line model (Tomlinson, Calaminus et al. 2007). No evidence was 
obtained to suggest that GPVI collagen signalling was regulated by tetraspanins. However, 
recent developments suggest that the possibility of GPVI regulation by tetraspanins should be 
re-visited. Firstly, a proteomic analysis of the platelet surface has identified ten tetraspanins 
that are likely to be expressed on platelets (Lewandrowski, Wortelkamp et al. 2009). These 
are, in estimated order of abundance, CD9, Tspan9, Tspan33, CD151, CD63, Tspan14, 
Tspan32, Tspan15, Tspan2 and Tspan18 (Tomlinson 2009). Our lab has human and mouse 
FLAG-tagged expression constructs for each of these. In a relatively simple experiment, each 
could be co-transfected with GPVI/FcR constructs in an easily-transfectable cell line such as 
DT40 or HEK293T. The cells could be surface-cross-linked with a membrane impermeable 
chemical cross-linker such as BS3, considered as the ‘gold standard’ in the field for 
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covalently capturing potentially low affinity tetraspanin interactions with partner proteins. 
FLAG immunoprecipitations in highly-stringent conditions would then be followed by SDS-
PAGE and GPVI blotting to determine whether any platelet tetraspanin specifically interacts 
with the collagen receptor. Identification of a GPVI-binding tetraspanin would prompt further 
GPVI functional experiments using tetraspanin RNAi knockdown in GPVI-expressing 
megakaryocyte-like cell lines and potentially tetraspanin-deficient platelets; our lab has 
recently generated Tspan9-knockout mice (unpublished) and has obtained Tspan33-knockouts 
from the Tsai group (Heikens, Cao et al. 2007). 
Additional recent developments that suggest re-visiting the potential tetraspanin regulation of 
GPVI are the capacity for this collagen receptor to also bind laminin (Inoue, Suzuki-Inoue et 
al. 2006), the identification of ADAM10 as the ectodomain sheddase responsible for cleaving 
off the extracellular domain of GPVI following activation (Gardiner, Karunakaran et al. 
2007), and the finding that ADAM10 is a major component of tetraspanin microdomains on 
various cell types (Arduise, Abache et al. 2008) including platelets (Tomlinson MG, 
unpublished). These developments direct future experiments aimed at determining how 
tetraspanins might regulate GPVI. For example, both platelet laminin receptors, GPVI and the 
integrin 61, are components of tetraspanin microdomains (Sterk, Geuijen et al. 2002; 
Protty, Watkins et al. 2008). Could tetraspanin microdomains act as platforms for the optimal 
regulation of binding to laminin, a major component of the subendothelial matrix 
(Lammerding, Kazarov et al. 2003)? In addition could tetraspanin microdomains be platforms 
for the positive or negative regulation of ADAM10-induced GPVI shedding? Answers to 
these questions await further experiments. 
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7.4 FUTURE DIRECTIONS 
The work in this thesis represents the first characterisation of the tetraspanin protein Tspan18. 
The preliminary sub-cellular localisation and expression profiling performed in Chapters 4 
and 5, together with the functional data in Chapter 3, has raised a number of issues for future 
work. These include (1) the generation of Tspan18 antibodies, (2) studies to determine the 
expression profile and sub-cellular localisation of Tspan18, (3) over-expression and RNAi 
knockdown in a more relevant cell type such as endothelial cells, (4) experiments to 
determine whether Tspan18 induces calcium mobilisation, and (5) identification of a Tspan18 
partner protein or proteins.   
An anti-Tspan18 antibody would be of great use to characterise the Tspan18 expression 
profile, subcellular localisation and associated proteins. However, the generation of anti-
tetraspanin antibodies is a major problem in the field and such reagents do not exist for most 
tetraspanins, including Tspan18. Despite this, we have recently made the first antibodies to 
the tetraspanin Tspan9 using an anti-peptide approach in chicken and rabbit, by targeting the 
12 amino acid carboxy-terminal cytoplasmic tail (Protty, Watkins et al. 2009). The equivalent 
approach for Tspan18 is not possible because the carboxy-terminal tail is predicted to have 
only four amino acid residues. In addition, the amino-terminus is not considered to be a good 
immunogen (Eurogentec, personal communication to Tomlinson MG). Therefore a peptide 
corresponding to the carboxy-terminal region of the major extracellular region could be used, 
because this was successful for the generation of antibodies to Tspan2 by the Brophy group 
(Birling, Tait et al. 1999). Based on the Brophy Tspan2 antibody, the Tspan18 antibody might 
only recognise denatured protein, and thus may only be useful for western blotting. An 
alternative immunogen could be a recombinant GST fusion protein for the major extracellular 
region of Tspan18. However, such an approach is not favoured because it was not successful 
for tetraspanins CD37 and CD53 (Tomlinson MG, 1995, unpublished data). 
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In parallel with the polyclonal approach described above, monoclonal anti-Tspan18 
antibodies could be generated using recombinant full-length human Tspan18 as an 
immunogen. This material would be generated in the yeast Pichia pastoris, as has proved 
successful for tetraspanin CD81 (Jamshad, Rajesh et al. 2008). More importantly, Prof Jane 
McKeating’s group has recently generated seventeen monoclonal antibodies to CD81 using 
this methodology (McKeating JA personal communication to Tomlinson MG). An alternative 
immunogen for monoclonal antibody generation in mice is a mouse cell line expressing 
human Tspan18. Indeed, immunisation with cells was the method that generated most of the 
antibodies to tetraspanins such as CD9, CD37, CD53, CD63, CD81, CD82 and CD151 in the 
1980s. However, this method is not efficient (Tomlinson MG, personal communication), most 
likely because of the high degree of sequence conservation between tetraspanins, and their 
small size and tendency to associate with larger proteins, which together may impair their 
visibility to the immune system. A novel approach which was initiated, but not completed, in 
Chapter 5 of this thesis, was to generate a non-palmitoylated chimeric construct of the CD9 
cytoplasmic and intracellular regions and the Tspan18 extracellular loops. In transfected cells 
this construct might fail to interact efficiently with other tetraspanins or CD9/Tspan18 partner 
proteins, and might be more immunogenic, but this has not been tested. In summary, one of 
these approaches is likely to generate monoclonal antibodies for flow cytometry, 
immunoprecipitation and potentially western blotting and immunohistochemistry. The 
antibodies could also be tested in functional studies to examine the effect of Tspan18 cross-
linking on intracellular calcium or NFAT activation, for example. 
The experiments in Chapter 5 identified Tspan18 mRNA in endothelial cells and peripheral 
blood leukocytes using qRT-PCR. If a Tspan18 antibody can be generated in future, the 
expression profile could be extensively studied by immunostaining of tissue sections, an ideal 
method to examine Tspan18 expression on different endothelial cell types. Alternatively, flow 
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cytometry could be performed for sub-populations of leukocytes. The sub-cellular localisation 
could also be investigated by confocal fluorescence microscopy, following labelling of 
endogenous Tspan18 in an endothelial cell type such as HUVEC. In the present absence of an 
antibody, endothelial expression could best be studied by in situ hybridisation of day 9.5 
mouse embryos, at which stage the vasculature has just developed and the mice are small 
enough to allow full penetration of the labelled RNA probe. The sub-cellular localisation of 
Tspan18 could be examined by confocal fluorescence microscopy in HUVEC transfected 
with GFP- or FLAG-tagged Tspan18, the latter of which could avoid potential mis-
loacalisation due to the relatively large GFP tag. 
The NFAT activation experiments could also be extended to HUVEC, to examine the 
consequence of Tspan18 over-expression in a cell that has endogenous Tspan18. Although 
some publications have used NFAT/AP-1-luciferase assays in HUVEC (Qin, Zhao et al. 
2006), this has not proved successful in our group because of low transfection efficiencies and 
the need to serum-starve the cells to prevent constitutive growth factor-induced NFAT 
activation during the assay (Tomlinson MG, unpublished data). To overcome this problem, 
several groups have employed a construct encoding a GFP-tagged NFAT protein, which is 
localised to the cytoplasm in resting cells but rapidly translocates to the nucleus upon 
activation (Schabbauer, Schweighofer et al. 2007). This construct has been recently obtained 
by our group and could be used to determine whether Tspan18 over-expression can activate 
NFAT in HUVEC by fluorescence microscopy on a single cell level. Such experiments would 
be facilitated by a red-fluorescent version of Tspan18, which has recently been generated in 
our group (Yang J and Tomlinson MG, unpublished). Transfection of this red-Tspan18 into 
HUVEC or DT40 cells could also be used to determine whether Tspan18 induces elevated 
levels of intracellular calcium, using a green fluorescent calcium indicator and single cell 
imaging. This could be done in both resting cells and upon thapsigargin induction of store-
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operated calcium entry. Similar experiments were attempted in this thesis using fluorimetry to 
detect calcium elevation in populations of transfected cells, but none was detected, perhaps 
due to relatively low transfection efficiencies (data not shown). 
An additional type of experiment that would be ideally suited to HUVEC is knockdown of 
Tspan18 using RNAi duplexes. Indeed, our group has recently achieved 95-100% knockdown 
of tetraspanins CD81 and CD151 in these cells, as detected by flow cytometry (Tomlinson 
MG, unpublished). Moreover, we have achieved over 90% knockdown of Tspan18 mRNA, as 
detected by qRT-PCR (Figure Appendix 3). Single cell calcium imaging or fluorimetry could 
be performed on the knockdown cells, using growth factor agonists or thapsigargin, to 
determine whether Tspan18 is necessary for normal calcium mobilisation in HUVEC. In 
addition, a variety of functional assays could be performed to determine whether Tspan18 is 
necessary for processes such as HUVEC tube formation on the basement membrane extract 
Matrigel, migration in a scratch-wound assay, chemotaxis, proliferation and survival. If these 
experiments indicated an important role for Tspan18 in endothelial cells, an important next 
step would be to address whether this is true in vivo. To answer this question in a relatively 
quick and inexpensive way, Tspan18 could be studied in the widely-used zebrafish model of 
endothelial cell angiogenesis (Staton, Reed et al. 2009). Firstly, in situ hybridisations would 
be performed on zebrafish embryos to determine whether either of the two zebrafish Tspan18 
homologues is expressed in the vasculature. Secondly, antisense morpholinos would be used 
to knock down Tspan18 expression in embryos, to determine whether this tetraspanin is 
necessary for blood vessel development through angiogenesis. Ultimately, Tspan18 function 
could be addressed in mammals through the generation of knockout mice. 
Finally, a key future experiment will be to identify a Tspan18-interacting protein, or proteins, 
that could explain the mechanism by which Tspan18 over-expression induces NFAT 
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activation. Our group has previously used tetraspanin immunoprecipitations from biotinylated 
cells, followed by streptavidin western blotting, to visualise tetraspanin-associated proteins 
(Varga-Szabo, Braun et al. 2008; Protty, Watkins et al. 2009). Similar experiments could be 
performed for endothelial cell Tspan18, using specific antibodies to immunoprecipitate 
endogenous Tspan18, or FLAG antibody to immunoprecipitate transfected FLAG-tagged 
Tspan18. Immunoprecipitations would be performed in 1% Brij97 lysis buffer, which 
maintains tetraspanin microdomains, or the more stringent 1% Triton X-100 lysis buffer, 
which disrupts tetraspanin microdomains but not relatively strong tetraspanin-partner protein 
interactions (Hemler 2005). If candidate Tspan18-associated proteins are visualised in Triton, 
immunoprecipitations would be scaled up to visualise the band on coomassie gels, and the 
bands excised to obtain peptide sequence by mass spectrometry. Candidate Tspan18 binding 
partners would be tested by co-immunoprecipitation from cells treated with a chemical cross-
linker. An alternative approach would be to target candidate Tspan18-interacting proteins, 
such as STIM1 or Orai1, in direct co-immunoprecipitation experiments. 
 
7.5 SPECULATIONS ON THE ROLE OF TSPAN18 ON 
PLATELETS, ENDOTHELIAL CELLS AND 
LEUKOCYTES 
Tspan18 protein was recently shown to be expressed on human platelets using proteomics 
(Lewandrowski, Wortelkamp et al. 2009; Tomlinson 2009), and the data in Chapter 5 of this 
thesis has demonstrated mRNA expression in endothelial cells and peripheral blood 
leukocytes. It is possible that Tspan18 regulates calcium entry in each of these cell types, 
either through regulation of store-operated calcium entry involving STIM and Orai proteins, 
or through an alternative mechanism such as regulation of a plasma membrane calcium 
channel or channel regulator. Importantly, and as discussed earlier, it is not possible from the 
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current data to determine whether this regulation is positive or negative, although the NFAT 
activation data suggests that an activatory role is more likely.  
An increase in intracellular calcium following platelet activation is essential for integrin 
activation, secretion of positive feedback mediators such as ADP and thromboxane A2, and 
pro-coagulant activity (Bergmeier and Stefanini 2009). Studies in STIM1- and Orai1-deficient 
mice have shown these two proteins to be essential for store-operated calcium entry in 
platelets (Varga-Szabo, Braun et al. 2008; Braun, Varga-Szabo et al. 2009). Mutant platelets 
exhibited defective aggregation in vitro, which was most clearly seen in response to collagen 
through GPVI, and defective thrombus formation in vivo (Varga-Szabo, Braun et al. 2008; 
Braun, Varga-Szabo et al. 2009). It is possible that Tspan18 regulates such platelet functions 
through regulation of store-operated calcium entry. 
Endothelial cells are also thought to utilise STIM1 and Orai1 as the primary means of store-
operated calcium entry, which is essential for important processes such as cell proliferation 
(Abdullaev, Bisaillon et al. 2008). Calcium, through activation of calmodulin and protein 
kinase C, activates several intracellular enzymes including myosin light chain kinase, which 
results in cytoskeletal re-organisation and increased endothelial cell permeability. 
Calcium/calmodulin also activates endothelial nitric oxide synthase, which produces the nitric 
oxide signalling molecule. Nitric oxide is a potent vasodilator and is atheroprotective through 
inhibition of platelet activation and smooth muscle cell proliferation (Rudolph and Freeman 
2009). Unlike platelets, endothelial cells are nucleated and are regulated by NFAT-induced 
transcriptional responses. Indeed, vascular development and angiogenesis are dependent on 
NFAT transcription factors (Kulkarni, Greenberg et al. 2009). Tspan18 could regulate these 
processes through regulation of calcium and/or NFAT signalling. 
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Calcium/calcineurin/NFAT signalling is essential for normal leukocyte activation, as 
evidenced by the widespread clinical use of the immunosuppressive drug cyclosporin A, 
which inhibits calcineurin, to prevent rejection following organ transplants (Schulz and 
Yutzey 2004). Indeed, NFAT was first identified as the nuclear factor of activated T cells 
which activates the transcription of a number of genes involved in immunity, including 
interleukin-2 (Liu, Masuda et al. 1999). It is possible that Tspan18 plays a regulatory role in 
the immune response via regulation of NFAT activation. However, since Tspan18 mRNA 
was detected in peripheral blood leukocytes, it is currently unclear precisely which type of 
leukocyte expresses this tetraspanin. Interestingly, our group recently reported relatively 
strong Tspan18 mRNA expression on CD4-positive helper T cells (Protty, Watkins et al. 
2008) , suggesting a role for Tspan18 on this cell type that is central to the immune response. 
In summary, this thesis has characterised Tspan18, a novel tetraspanin expressed on platelets, 
endothelial cells and leukocytes with a potential role in calcium and NFAT signalling. Future 
knockdown and knockout studies are now required to determine whether Tspan18 is essential 
for key processes such as haemostasis and thrombosis, blood vessel development and 
function, and immunity. 
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Appendix 1 ClustalW sequence alignment of all human 
tetraspanin proteins 
Tspan9   ------MARGCLC--------CLKYMMFLFNLIFWLCGCGLLGVGIWLSVSQGNFATFSP 46 
Tspan4   ------------------------------------------------------------ 
CD53     ------MGMSSLK--------LLKYVLFFFNLLFWICGCCILGFGIYLLIHN-NFGVLFH 45 
CD9      ----MP-VKGGTK--------CIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQTKSIFEQ 47 
Tspan2   ----MGRFRGGLR--------CIKYLLLGFNLLFWLAGSAVIAFGLWFRFGGAIKELSSE 48 
CD81     ----MG-VEGCTK--------CIKYLLFVFNFVFWLAGGVILGVALWLRHDPQTTNLLYL 47 
Tspan8   -------MAGVSA--------CIKYSMFTFNFLFWLCGILILALAIWVRVSNDSQAIFGS 45 
CD82     ------MGSACIK--------VTKYFLFLFNLIFFILGAVILGFGVWILADKSSFISVLQ 46 
CD37     ----MSAQESCLS--------LIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVG 48 
Tspan7   -MAS--RRMETKP-----VITCLKTLLIIYSFVFWITGVILLAVGVWGKLTLGTYISLIA 52 
Tspan6   -MASPSRRLQTKP-----VITCFKSVLLIYTFIFWITGVILLAVGIWGKVSLENYFSLLN 54 
CD151    --MGEFNEKKTTC-----GTVCLKYLLFTYNCCFWLAGLAVMAVGIWTLALKSDYISLLA 53 
Tspan11  ------------------------------------------------LVEKSGYLSVLA 12 
Tspan5   -MSGK--HYKGPE-----VSCCIKYFIFGFNVIFWFLGITFLGIGLWAWNEKGVLSNISS 52 
Tspan17  -MPGKHQHFQEPE-----VGCCGKYFLFGFNIVFWVLGALFLAIGLWAWGEKGVLSNISA 54 
Tspan14  -MHYY--RYSNAK-----VSCWYKYLLFSYNIIFWLAGVVFLGVGLWAWSEKGVLSDLTK 52 
Tspan33  -MARRPRAPAASGEEFSFVSPLVKYLLFFFNMLFWVISMVMVAVGVYARLMKHAEAALAC 59 
Tspan15  -MPRG--DSEQVRYCARFSYLWLKFSLIIYSTVFWLIGALVLSVGIYAEVERQKYKTLES 57 
ROM1     MAPVLPLVLPLQP------RIRLAQGLWLLSWLLALAGGVILLCSGHLLVQLRHLGTFLA 54 
RDS      -MALLKVKFDQKK------RVKLAQGLWLMNWFSVLAGIIIFSLGLFLKIELRKRSDVMN 53 
Tspan18  ---MEGDCLS-----------CMKYLMFVFNFFIFLGGACLLAIGIWVMVDPTGFREIVA 46 
Tspan1   -----MQCFS-----------FIKTMMILFNLLIFLCGAALLAVGIWVSIDGASFLKIFG 44 
UP1A     -MASAAAAEAEKG------SPVVVGLLVVGNIIILLSGLSLFAETIWVTADQYRVYPLMG 53 
UP1B     -MAKDNSTVR-----------CFQGLLIFGNVIIGCCGIALTAECIFFVSDQHSLYPLLE 48 
Tspan31  ------MVCGGFA--------CSKNALCALNVVYMLVSLLLIGVAAWGKGLGLVSSIHII 46 
Tspan13  ------MVCGGFA--------CSKNCLCALNLLYTLVSLLLIGIAAWGIGFGLISSLRVV 46 
Tspan3   -----MGQCGITS---------SKTVLVFLNLIFWGAAGILCYVGAYVFITYDDYDHFFE 46 
Tspan19  -------MLRNNK------TIIIKYFLNLINGAFLVLGLLFMGFGAWLLLDRNNFLTAFD 47 
CD63     -----MAVEGGMK--------CVKFLLYVLLLAFCACAVGLIAVGVGAQLVLSQTIIQGA 47 
Tspan12  -----MAREDSVK--------CLRCLLYALNLLFWLMSISVLAVSAWMRDYLNNVLTLTA 47 
Tspan16  ----MAEIHTPYS--------SLKKLLSLLNGFVAVSGIILVGLGIGGKCGGASLTNVLG 48 
Tspan10  ------MEEGERS-------PLLSQETAGQKPLSVHRPPTSGCLGPVPREDQAEAWGCSC 47 
Tspan32  -MGPWSRVRVAKB--------CQMLVTCFFILLLGLSVATMVTLTYFGAHFAVIRRASLE 51 
                                                                             
 
Tspan9   SFP---------SLSAANLVIAIGTIVMVTGFLGCLGAIKENKCLLLSFFIVLLVILLAE 97 
Tspan4   ---------------------------MAIGFVGCLGAIKENKCLLLTFFLLLLLVFLLE 33 
CD53     NLP---------SLTLGNVFVIVGSIIMVVAFLGCMGSIKENKCLLMSFFILLLIILLAE 96 
CD9      ET--NN--NNSSFYTGVYILIGAGALMMLVGFLGCCGAVQESQCMLGLFFGFLLVIFAIE 103 
Tspan2   DK--SP--E--YFYVGLYVLVGAGALMMAVGFFGCCGAMRESQCVLG------------- 89 
CD81     ELGDKP--APNTFYVGIYILIAVGAVMMFVGFLGCYGAIQESQCLLGTFFTCLVILFACE 105 
Tspan8   ED------VGSSSYVAVDILIAVGAIIMILGFLGCCGAIKESRCMLLLFFIGLLLILLLQ 99 
CD82     TSS-------SSLRMGAYVFIGVGAVTMLMGFLGCIGAVNEVRCLLGLYFAFLLLILIAQ 99 
CD37     LAF-------VPLQIWSKVLAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQ 101 
Tspan7   ENS---------TNAP-YVLIGTGTTIVVFGLFGCFATCRGSPWMLKLYAMFLSLVFLAE 102 
Tspan6   EKA---------TNVP-FVLIATGTVIILLGTFGCFATCRASAWMLKLYAMFLTLVFLVE 104 
CD151    SGT---------YLATAYILVVAGTVVMVTGVLGCCATFKERRNLLRLYFILLLIIFLLE 104 
Tspan11  SST---------FAASAYILIFAGVLVMVTGFLGFGAILWERKGCLSTYFCLLLVIFLVE 63 
Tspan5   ITDLG-------GFDPVWLFLVVGGVMFILGFAGCIGALRENTFLLKFFSVFLGIIFFLE 105 
Tspan17  LTDLG-------GLDPVWLFVVVGGVMSVLGFAGCIGALRENTFLLKFFSVFLGLIFFLE 107 
Tspan14  VTRMH-------GIDPVVLVLMVGVVMFTLGFAGCVGALRENICLLNFFCGTIVLIFFLE 105 
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Tspan33  LA-----------VDPAILLIVVGVLMFLLTFCGCIGSLRENICLLQTFSLCLTAVFLLQ 108 
Tspan15  AF-----------LAPAIILILLGVVMFMVSFIGVLASLRDNLYLLQAFMYILGICLIME 106 
ROM1     PSCQF-------PVLPQAALAAGAVALGTGLVGVGASRASLNAALYPPWRGVLGPLLVAG 107 
RDS      -NSES-------HFVPNSLIGMGVLSCVFNSLAGKICYDALDPAKYARWKPWLKPYLAIC 105 
Tspan18  ANP--------LLLTGAYILLAMGGLLFLLGFLGCCGAVRENKCLLLFFFLFILIIFLAE 98 
Tspan1   PLSSSA--M--QFVNVGYFLIAAGVVVFALGFLGCYGAKTESKCALVTFFFILLLIFIAE 100 
UP1A     VSGKD------DVFAGAWIAIFCGFSFFMVASFGVGAALCRRRSMVLTYLVLMLIVYIFE 107 
UP1B     ATDND------DIYGAAWIGIFVGICLFCLSVLGIVGIMKSSRKILLAYFILMFIVYAFE 102 
Tspan31  G-----------------GVIAVGVFLLLIAVAGLVGAVNHHQVLLFFYMIILGLVFIFQ 89 
Tspan13  G-----------------VVIAVGIFLFLIALVGLIGAVKHHQVLLFFYMIILLLVFIVQ 89 
Tspan3   DVY---------TLIPAVVIIAVGALLFIIGLIGCCATIRESRCGLAT------------ 85 
Tspan19  ENN-------HFIVPISQILIGMGSSTVLFCLLGYIGIHNEIRWLLIVYAVLITWTFAVQ 100 
CD63     TPG----------SLLPVVIIAVGVFLFLVAFVGCCGACKENYCLMITFAIFLSLIMLVE 97 
Tspan12  ETRVEEAVILTYFPVVHPVMIAVCCFLIIVGMLGYCGTVKRNLLLLAWYFGTLLVIFCVE 107 
Tspan16  LSS-------AYLLHVGNLCLVMGCITVLLGCAGWYGATKESRGTLLFCILSMVIVLIME 101 
Tspan10  CPP----------ETKHQALSGTPKKGPAPSLSPGSSCVKYLIFLSNFPFSLLGLLALAI 97 
Tspan32  KNP-----YQAVHQWAFSAGLSLVGLLTLGAVLSAAATVREAQGLMAGGFLCFSLAFCAQ 106 
                                                                             
 
Tspan9   LILL--------ILFFVYMDKVNENAKKDLKEGLLLYHT--ENNVG-------LKNAWNI 140 
Tspan4   ATIA--------ILFFAYTDKIDRYAQQDLKKGLHLYGT--QGNVG-------LTNAWSI 76 
CD53     VTLA--------ILLFVYEQKLNEYVAKGLTDSIHRYHS--DNST---------KAAWDS 137 
CD9      IAAA--------IWGYSHKDEVIKEV-QEFYKDTYNKLKTKDEPQ---------RETLKA 145 
Tspan2   --------------------SAIRHV-QTMYEEAYNDYLKDRGKG---------NGTLIT 119 
CD81     VAAG--------IWGFVNKDQIAKDV-KQFYDQALQQAVVDDDANN-------AKAVVKT 149 
Tspan8   VATG--------ILGAVFKSKSDRIVNETLYENTKLLSATGESEKQ-------FQEAIIV 144 
CD82     VTAG--------ALFYFNMGKLKQEMGGIVTELIRDYNS-SRED-S-------LQDAWDY 142 
CD37     ITLG--------ILISTQRAQLERSLRDVVEKTIQKYGT-NPEETA-------AEESWDY 145 
Tspan7   LVAG--------ISGFVFRHEIKDTFLRTYTDAMQTYNGN-----------DERSRAVDH 143 
Tspan6   LVAA--------IVGFVFRHEIKNSFKNNYEKALKQYNSTG----------DYRSHAVDK 146 
CD151    IIAG--------ILAYAYYQQLNTELKENLKDTMTKRYHQPGH--------EAVTSAVDQ 148 
Tspan11  LVAG--------VLAHVYYQRLSDELKQHLNRTLAENYGQPGA--------TQITASVDR 107 
Tspan5   LTAG--------VLAFVFKDWIKDQLYFFINNNIRAYRDDID-----------LQNLIDF 146 
Tspan17  LATG--------ILAFVFKDWIRDQLNLFINNNVKAYRDDID-----------LQNLIDF 148 
Tspan14  LAVA--------VLAFLFQDWVRDRFREFFESNIKSYRDDID-----------LQNLIDS 146 
Tspan33  LAAG--------ILGFVFSDKARGKVSEIINNAIVHYRDDLD-----------LQNLIDF 149 
Tspan15  LIGG--------VVALTFRNQTIDFLNDNIRRGIENYYDDLD-----------FKNIMDF 147 
ROM1     TAGGGGLLVVALGLALALPGSLDEALEEGLVTALAHYKDTEVPGHCQ------AKRLVDE 161 
RDS      VLFNIILFLVAL-CCFLLRGSLENTLGQGLKNGMKYYRDTDTPGRCF------MKKTIDM 158 
Tspan18  LSAA--------ILAFIFRENLTRE---FFTKELTKHYQGNNDTDI-------FSATWNS 140 
Tspan1   VAAA--------VVALVYTTMAEHF---LTLLVVPAIKKDYGSQED-------FTQVWNT 142 
UP1A     CASC--------ITSYTHRDYMVSNPSLITKQMLTFYSADTDQGQE-------LTRLWDR 152 
UP1B     VASC--------ITAATQQDFFTPN--LFLKQMLERYQNNSPPNNDDQWKNNGVTKTWDR 152 
Tspan31  FVIS-----------CSCLAINRSKQTDVINASWWVMSNK----------------TRDE 122 
Tspan13  FSVS-----------CACLALNQEQQGQLLEVGWNNTAS-----------------ARND 121 
Tspan3   ---------------------VENEVDRSIQKVYKTYNGTNPDAAS---------RAIDY 115 
Tspan19  VVLS--------AFIITKKEEVQQLWHDKIDFVISEYGSKDKPEDIT------KWTILNA 146 
CD63     VAAA--------IAGYVFRDKVMSEFNNNFRQQMENYPKNNHT-----------ASILDR 138 
Tspan12  LACG----------VWTYEQEVMVPVQWSDMVTLKARMTNYGLPRYR-----WLTHAWNY 152 
Tspan16  VTAA------------------------------------------------------TV 107 
Tspan10  GLWG-----------LAVKGSLGSDLGGPLPADPMLGLALGG----------LVVSAVSL 136 
Tspan32  VQVV--------FWRLHSPTQVEDAMLDTYDLVYEQAMKGTSHVR---------RQELAA 149 
                                                                             
 
 
Tspan9   IQAEMRCCGVTDYTDWY-------------------------------PVLGENTVPDRC 169 
Tspan4   IQTDFRCCGVSNYTDWF-------------------------------EVYNATRVPDSC 105 
CD53     IQSFLQCCGINGTSDW-------------------------------------TSGPPAS 160 
CD9      IHYALNCCG--------------------------------------------LAGGVEQ 161 
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Tspan2   FHSTFQCCG--------------------------------------------KES--SE 133 
CD81     FHETLDCCGSST----------------------------------------LTALTTSV 169 
Tspan8   FQEEFKCCGLVNGAADW-------------------------------GNNFQHYPELCA 173 
CD82     VQAQVKCCGWVSFYNWT-------------------------------DNAELMNRPEVT 171 
CD37     VQFQLRCCGWHYPQDWF-------------------------------QVLILRGNGSEA 174 
Tspan7   VQRSLSCCGVQNYTNWS-----TSPYFL------------------------EHGIPPSC 174 
Tspan6   IQNTLHCCGVTDYRDWT-----DTNYYS------------------------EKGFPKSC 177 
CD151    LQQEFHCCGSNNSQDWR-----DSEWIRS-------------------QEAGGRVVPDSC 184 
Tspan11  LQQDFKCCGSNSSADWQ-----HSTYILL-------------------REAEGRQVPDSC 143 
Tspan5   TQEYWQCCGAFGADDWN-----LNIYFN---------------CTDSNASRERCGVPFSC 186 
Tspan17  AQEYWSCCGARGPNDWN-----LNIYFN---------------CTDLNPSRERCGVPFSC 188 
Tspan14  LQKANQCCGAYGPEDWD-----LNVYFN---------------CSGASYSREKCGVPFSC 186 
Tspan33  GQKKFSCCGGISYKDWS-----QNMYFN---------------CSEDNPSRERCSVPYSC 189 
Tspan15  VQKKFKCCGGEDYRDWS-----KNQYHD---------------CSAPGP--LACGVPYTC 185 
ROM1     LQLRYHCCGRHGYKDWF-----GVQWVSSRYLDPGDRDVADRIQSNVEGLYLTDGVPFSC 216 
RDS      LQIEFKCCGNNGFRDWF-----EIQWISNRYLDFSSKEVKDRIKSNVDGRYLVDGVPFSC 213 
Tspan18  VMITFGCCGVNGPEDFK-FASVFRL----------------------LTL-DSEEVPEAC 176 
Tspan1   TMKGLKCCGFTNYTDFE-DSPYFK---------------------------ENSAFPPFC 174 
UP1A     VMIEQECCGTSGPMDWVNFTSAFRA----------------------ATPEVVFPWPPLC 190 
UP1B     LMLQDNCCGVNGPSDWQKYTSAFRT----------------------ENNDADYPWPRQC 190 
Tspan31  LERSFDCCGLFNLTTLY-------------------------------------QQDYDF 145 
Tspan13  IQRNLNCCGFRSVN------------------------------------------PNDT 139 
Tspan3   VQRQLHCCGIHNYSDWEN--------------------------TDWFKETKNQSVPLSC 149 
Tspan19  LQKTLQCCGQHNYTDWIK----------------------------NKNKENSGQVPCSC 178 
CD63     MQADFKCCGAANYTDWEK-----------------------------IPSMSKNRVPDSC 169 
Tspan12  FQREFKCCGVVYFTDWL-------------------------------EMTEMDWPPDSC 181 
Tspan16  VLLFFPIVG--------------------------------------------------- 116 
Tspan10  AGYLGALCENTCLLRGFS-----------------------------------GGILAFL 161 
Tspan32  IQDVFLCCGKKSPFSRLG--------------------------STEADLCQGEEAARED 183 
                                                                             
 
Tspan9   CMENSQGCGR-----------------------------------NATTPLWRTGCYEKV 194 
Tspan4   CLEFSESCGL-----------------------------------HAPGTWWKAPCYETV 130 
CD53     CPSDRK----------------------------------------------VEGCYAKA 174 
CD9      FISDICPKK------------------------------------DVLETFTVKSCPDAI 185 
Tspan2   QVQPTCPK----------------------------------------ELLGHKNCIDEI 153 
CD81     LKNNLCPSGS-----------------------------------NIISNLFKEDCHQKI 194 
Tspan8   CLDKQRPCQS-----------------------------------YNGKQVYKETCISFI 198 
CD82     Y--PCSCEVKGEEDNSLSVRKGFCEAP---GNRTQSGN------HPEDWPVYQEGCMEKV 220 
CD37     HRVPCSCYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGL 234 
Tspan7   CMNETDCNPQD-----------------------------LHNLTVAATKVNQKGCYDLV 205 
Tspan6   CKLE-DCTPQ-----------------------------------RDADKVNNEGCFIKV 201 
CD151    CKTVVALCGQ-------------------------------RDHASNIYKVEG-GCITKL 212 
Tspan11  CKTVVARCGQ-------------------------------RAHPSNIYKVEG-GCLTKL 171 
Tspan5   CTKDPAEDVINTQCG---------------------YDARQKPEVDQQIVIYTKGCVPQF 225 
Tspan17  CVRDPAEDVLNTQCG---------------------YDVRLKLELEQQGFIHTKGCVGQF 227 
Tspan14  CVPDPAQKVVNTQCG---------------------YDVRIQLKSKWDESIFTKGCIQAL 225 
Tspan33  CLPTPDQAVINTMCG---------------------QGMQAFDYLEASKVIYTNGCIDKL 228 
Tspan15  CIRN-TTEVVNTMCG---------------------YKTIDKERFSVQDVIYVRGCTNAV 223 
ROM1     CNPHSPRPCLQNRLSD-------------------SYAHPLFDPRQPNQNLWAQGCHEVL 257 
RDS      CNPSSPRPCIQYQITN-------------------NSAHYSYDHQTEELNLWVRGCRAAL 254 
Tspan18  CRREPQSRDG-------------------------VLLSREECLLGRSLFLNKQGCYTVI 211 
Tspan1   CNDNVTN------------------------------TANETCTKQKAHDQKVEGCFNQL 204 
UP1A     CRRTGNFIP----------------------------LNEEGCRLGHMDYLFTKGCFEHI 222 
UP1B     CVMNNLKEP----------------------------LNLEACKLGVPGFYHNQGCYELI 222 
Tspan31  CTAICKSQSP-----------------------------------------TCQMCGEKF 164 
Tspan13  CLASCVKSDH-----------------------------------------SCSPCAPII 158 
Tspan3   CRETASNCNG---------------------------------SLAHPSDLYAEGCEALV 176 
Tspan19  TKSTLRKWFCD----------------------------------EPLNATYLEGCENKI 204 
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CD63     CINVTVGCGIN----------------------------------FNEKAIHKEGCVEKI 195 
Tspan12  CVREFPGCSK-------------------------------QAHQEDLSDLYQEGCGKKM 210 
Tspan16  -------------------------------------------------DVALEHTFVTL 127 
Tspan10  VLEAVAGALVVALWG-------------------------------PLQDSLEHTLRVAI 190 
Tspan32  CLQGIRSFLR--------------------------------THQQVASSLTSIGLALTL 211 
                                                                             
 
Tspan9   KMWFD--DNKHVLGTVGMCILIMQILGMAFSMTLFQHIHRTGKKYDA------------- 239 
Tspan4   KVWLQ--ENLLAVGIFGLCTALVQILGLTFAMTMYCQVVKA-DTYCA------------- 174 
CD53     RLWFH--SNFLYIGIITICVCVIEVLGMSFALTLNCQIDKTSQTIGL------------- 219 
CD9      KEVFD--NKFHIIGAVGIGIAVVMIFGMIFSMILCCAIRRNREMV--------------- 228 
Tspan2   ETIIS--VKLQLIGIVGIGIAGLTIFGMIFSMVLCCAIRNSRDVI--------------- 196 
CD81     DDLFS--GKLYLIGIAAIVVAVIMIFEMILSMVLCCGIRNSSVY---------------- 236 
Tspan8   KDFLA--KNLIIVIGISFGLAVIEILGLVFSMVLYCQIGNK------------------- 237 
CD82     QAWLQ--ENLGIILGVGVGVAIIELLGMVLSICLCRHVHSEDYSKVPKY----------- 267 
CD37     QKWLH--NNLISIVGICLGVGLLELGFMTLSIFLCRNLD-HVYNRLARYR---------- 281 
Tspan7   TSFME--TNMGIIAGVAFGIAFSQLIGMLLACCLSRFITANQYEMV-------------- 249 
Tspan6   MTIIE--SEMGVVAGISFGVACFQLIGIFLAYCLSRAITNNQYEIV-------------- 245 
CD151    ETFIQ--EHLRVIGAVGIGIACVQVFGMIFTCCLYRSLKLEHY----------------- 253 
Tspan11  EQFLA--DHLLLMGAVGIGVACLQICGMVLTCCLHQRLQRHFY----------------- 212 
Tspan5   EKWLQ--DNLTIVAGIFIGIALLQIFGICLAQNLVSDIEAVRASW--------------- 268 
Tspan17  EKWLQ--DNLIVVAGVFMGIALLQIFGICLAQNLEQ-ME--------------------- 263 
Tspan14  ESWLP--RNIYIVAGVFIAISLLQIFGIFLARTLISDIEAVKAGHHF------------- 270 
Tspan33  VNWIH--SNLFLLGGVALGLAIPQLVGILLSQILVNQIKDQIKLQLYNQQHRADPWY--- 283 
Tspan15  IIWFM--DNYTIMAGILLGILLPQFLGVLLTLLYITRVEDIIMEHSVTDGLLGPGAKPSV 281 
ROM1     LEHLQ--DLAGTLGSMLAVTFLLQALVLLGLRYLQTALEGLGGVIDAGGETQGYLFPSGL 315 
RDS      LSYYS--SLMNSMGVVTLLIWLFEVTITIGLRYLQTSLDGVSNPEESESESQGWLLERSV 312 
Tspan18  LNTFE--TYVYLAGALAIGVLAIELFAMIFAMCLFRGIQ--------------------- 248 
Tspan1   LYDIR--TNAVTVGGVAAGIGGLELAAMIVSMYLYCNLQ--------------------- 241 
UP1A     GHAID--SYTWGISWFGFAILMWTLPVMLIAMYFYTML---------------------- 258 
UP1B     SGPMN--RHAWGVAWFGFAILCWTFWVLLGTMFYWSRIEY-------------------- 260 
Tspan31  LKHSD--EALKILGGVGLFFSFTEILGVWLAMRFRNQKDPRANPSAFL------------ 210 
Tspan13  GEYAG--EVLRFVGGIGLFFSFTEILGVWLTYRYRNQKDPRANPSAFL------------ 204 
Tspan3   VKKLQ--EIMMHVIWAALAFAAIQLLGMLCACIVLCRRSRDPAYELLITGGTYA------ 228 
Tspan19  SAWYN--VNVLTLIGINFGLLTSEVFQVSLTVCFFKNIKNIIHAEM-------------- 248 
CD63     GGWLR--KNVLVVAAAALGIAFVEVLGIVFACCLVKSIRSGYEVM--------------- 238 
Tspan12  YSFLRGTKQLQVLRFLGISIGVTQILAMILTITLLWALYYDRREPGTDQMLSLKNDTSQH 270 
Tspan16  RKNYR-----GYNEPDDYSTQWNLVMEKGLSKYFFSSL---------------------- 160 
Tspan10  AHYQDDPDLRFLLDQVQLGLRCCGAASYQDWQQNLYCLSSPCSSQ--------------- 235 
Tspan32  GPQGQIHPDPTSMWPPAPGAQPLEMLPGWTHTLSPLRSSCYWSKRMLG------------ 259 
                                                                             
 
Tspan9   ------------------------------------ 
Tspan4   ------------------------------------ 
CD53     ------------------------------------ 
CD9      ------------------------------------ 
Tspan2   ------------------------------------ 
CD81     ------------------------------------ 
Tspan8   ------------------------------------ 
CD82     ------------------------------------ 
CD37     ------------------------------------ 
Tspan7   ------------------------------------ 
Tspan6   ------------------------------------ 
CD151    ------------------------------------ 
Tspan11  ------------------------------------ 
Tspan5   ------------------------------------ 
Tspan17  ------------------------------------ 
Tspan14  ------------------------------------ 
Tspan33  ------------------------------------ 
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Tspan15  EAAGTGCCLCYPN----------------------- 294 
ROM1     KDMLKTAWLQGGVACRPAPEEAPPGEAPPKEDLSEA 351 
RDS      PETWKAFLESVKKLGKGNQVEAEGADAGQAPEAG-- 346 
Tspan18  ------------------------------------ 
Tspan1   ------------------------------------ 
UP1A     ------------------------------------ 
UP1B     ------------------------------------ 
Tspan31  ------------------------------------ 
Tspan13  ------------------------------------ 
Tspan3   ------------------------------------ 
Tspan19  ------------------------------------ 
CD63     ------------------------------------ 
Tspan12  LSCHSVELLKPSLSRIFEHTSMANSFNTHFEMEEL- 305 
Tspan16  ------------------------------------ 
Tspan10  ------------------------------------ 
Tspan32  ------------------------------------ 
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Appendix 2 Tspan18 signalling is not affected by DMSO 
                   
Figure Appendix 2: DT40 cells were transfected with 20 g of Tspan18 (or control vector), 
and 20 g of NFAT/AP-1 promoter. Cells were left unstimulated, or were treated with 0.31 
M DMSO or stimulated with PMA and ionomycin. Data were normalized for the relative -
gal value. Error bars represent the standard deviation of three independent experiments. 
Unstimulated and DMSO samples (both transfected with empty vector or Tspan18) were 
analysed by ANOVA and Tukey’s test, which revealed no significant differences. This 
experiment was important because certain inhibitors in this thesis were dissolved in DMSO to 
yield a 0.31 M final concentration of DMSO. 
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Appendix 3 siRNA Tspan18 knockdown in HUVEC cells 
 
 
Figure Appendix 3: DAMI, HEL, RAJI and HUVEC cells were tested by qRT-PCR for 
Tspan18 isoform1 and Tspan18 isoform 2 expression. Three days prior to qRT-PCR analysis, 
HUVEC cells were transfected with two different Tspan18 siRNA Stealth duplexes from 
Invitrogen (RNA1 and RNA3), using RNAiMAX transfection reagent (Invitrogen). One 
tested siRNA duplex successfully inhibited Tspan18 isoform 2 expression by 90% (HUVEC 
RNA1).  This figure is courtesy of Dr Mike Tomlinson, who performed this work. 
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Appendix 4 Tspan18 isoform 1 is not detected by PCR from 
HUVEC cDNA 
 
 
Figure Appendix 4: cDNA from three different donors was tested for the presence of 
Tspan18 isofom 1 and isoform 2 by PCR. The positive control lanes represent PCR reactions 
from isoform 1 and 2 cDNA constructs. This experiment is important because it includes a 
positive control for isoform 1, which was not included in Figure 4.5B. This figure is courtesy 
of Dr Mike Tomlinson, who performed this work. 
.  
 
 
Appendices 
Appendix 5 Identification of Tspan9 as a novel platelet 
tetraspanin and the collagen receptor GPVI as a component of 
tetraspanin microdomains 
Reproduced with permission, from Authors, 2009, Biochemical Journal, Volume 417, 
391-400,© the Biochemical Society (http://www.biochemj.org) 
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